plan prepare perform 201617 annual report table content turnover 0117 corporate overview 01 17 plan prepare perform corporate information 2000 cr 1862 statutory report 18 management discussion analysis 22 director report 45 report corporate governance profit 56 business responsibility report 63174 financial statement 64 consolidated 120 standalone 500 cr 175180 notice entered league indian company detail please visit wwwajantapharmacom planning planning preparing performing ajanta pharma represent continuous sequence initiative global mindset deliver differentiated product global market fine tune scientific strategy line changing focus specific requirement global customer market year continued move towards building meaningful longterm value threepronged strategy plan prepare perform result encouraging player enhanced presence usa driven product launch superior execution preparing reinforced therapy specific strategy drive growth india business deliver strengthened effort regain growth momentum effective solution emerging market matter build healthy product pipeline focused market global healthcare enhanced rd spend robust product landscape development successful u fda inspection 2 manufacturing facility performing commissioned new manufacturing facility future build sustainable growth requirement business creates value stakeholder annual report 201617 serving healthcare need worldwide ajanta pharma specialty pharmaceutical company engaged development manufacturing marketing quality finished dosage business includes branded generic india rest asia africa generic usa mission serve global healthcare need empathy innovation technology scale robust service operational leadership delivery excellence global footprint leadership global marketing network singleminded focus quality segment field force geography excellence stateoftheart rd facility customercentric approach ingenious use science innovative 1st market solution technology provide advanced large manufacturing facility solution approved leading regulatory proactive efficient execution agency ensure timely launch optimum utilisation resource distribution deliver superior return resilient leadership proven track record delivering committed inspired team sustained growth adding value stakeholder manufacturing operational highlight facility filed additional 8 andas u fda taking total count 34 5 formulation 1 api manufacturing facility india commissioned 1st phase manufacturing facility guwahati 1 formulation facility mauritius u fda completes inspection dahej paithan manufacturing facility enhanced rd spend 8 revenue 6 revenue last year 2 business segment india emerging market usa specialty segment customised product portfolio focus oral solid ophthalmology dermatology market mix para ii iii iv cardiology pain management many firsttomarket product 17 final andas approved leadership product amongst leading player many segment 12 product commercialised market 250 product shelf 2 tentative anda approval presence 30 country across 3000 medical representative asia africa 15 andas review launched many first institutional sale amongst 6 8 andas filed fy 2017 market global supplier antimalarial drug global fund strength employee team rd scientist 6500 28 800 year ended year ended 31st march 2017 different nationality 31st march 2017 3 annual report 201617 financial performance total income cr 2026 revenue 1771 2026 cr 1230 1502 942 21 5year cagr fy 2017 fy 2015 fy 2016 fy 2013 fy 2014 ebitda 35 ebitda cr 701 587 505 369 net profit 224 33 5year cagr fy 2017 fy 2015 fy 2016 fy 2013 fy 2014 25 net profit cr 507 free cash flow 416 568 cr 310 234 112 46 5year cagr fy 2017 fy 2015 fy 2016 fy 2013 fy 2014 4 plan prepare perform corporate overview financial highlight cash profit cr dividend payout 568 25 460 18 19 18 362 278 15 146 40 5year cagr fy 2017 fy 2017 fy 2015 fy 2016 fy 2015 fy 2016 fy 2013 fy 2014 fy 2013 fy 2014 ebitda margin ronw 34 34 35 47 31 43 40 37 24 32 fy 2017 fy 2017 fy 2015 fy 2016 fy 2015 fy 2016 fy 2013 fy 2014 fy 2013 fy 2014 net margin roce 24 25 50 45 44 21 41 19 37 12 fy 2017 fy 2017 fy 2015 fy 2016 fy 2015 fy 2016 fy 2013 fy 2014 fy 2013 fy 2014 5 annual report 201617 management speak strategy present right market differentiated difficulttoproduce product designed create impact optimise opportunity across geography dear stakeholder continue plan revival infrastructure timely expansion growth emerging market rd facility commencement steady growth year implementing sustainable business guwahati plant year characterised strategy expansion outcome foresight ability plan prepare perform emerging market team futureoriented action taken two line market opportunity fy 2017 part preparation year ago dynamic ajanta pharma reviving growth market achievement fy 2017 similarly strengthened outcome philosophy usa success current year grew rd team accelerating demonstrated meticulous planning instance outcome product filing different market proactive preparedness across plan laid fy 2010 detailed preparation operation resulting meaningful player market recent u fda inspection satisfactory performance introduced seven new product manufacturing plant helped u sail including two successful day one inspection without strategy present right launch usa fy 2017 major concern comment market differentiated difficultto launch planned fy 2018 produce product designed precise preparation allowed u file industry largely knowledge create impact optimise eight andas u fda driven therefore importance opportunity across geography ready 1215 filing innovation important ensures consistent growth u ensuing year demonstrates preparedness cannot year strong product pipeline overemphasised consequently monetised approval steadily augmenting india market plan validation rd effort rd investment help doctor leader subtherapeutic treat difficult disease segment supported order fulfil global patient grapple many innovative firsttomarket aspiration also worked investment growing product launch better customer meticulous plan augment absolute term also experience enhance manufacturing rd percentage turnover signifying 6 rajesh agrawal yogesh agrawal joint managing director managing director timely expansion rd facility commencement guwahati plant year outcome foresight futureoriented action taken two year ago immense importance place headwind challenge also reinforce footprint innovation rd investment remain relevant emerging chosen market strengthen fy 2017 rose 153 cr 8 market manner value balance sheet enhance revenue 106 cr 6 accretive capability talent pool revenue fy 2016 continue create value financial performance reflective stakeholder core investment ambition ability grow performance belief despite challenge fy 2017 achieved many milestone sustainable growth possible achieved consolidated net profit backed threepronged strategy achieve notwithstanding dynamic 507 cr 22 growth compared plan prepare perform business environment 416 cr last year consolidated believe approach shall evolving regulatory scenario total income also touched 2026 cr continue work compared 1771 cr rise 14 confident delivering even better planning preparedness across previous year performance future every aspect business best yet come borne fruit performance core objective augment outcome fy 2017 delivered differentiated product portfolio regard outstanding result usa offer impactful solution backed yogesh agrawal rajesh agrawal continued grow india intensive extensive research effectively managed currency specialty therapeutic segment 7 annual report 201617 opportunity landscape rising income increased government healthcare expenditure higher life expectancy growing chronic illness augmenting demand pharmaceutical product service globally ajanta pharma uniquely positioned pharmaceutical opportunity landscape vision led u follow unconventional path believe offer sustainable revenue competitive advantage enable u grow consistently coming year strategic priority fy 2018 reinforcing reviving building operational india emerging usa excellence market market market continue innovation deploy additional quick launch strengthen process resource approved product strengthen leadership enhance rd plant subtherapeutic launch new product enhance customer productivity segment supply chain experience increase market share scaling operation enhance sale force file 1215 andas new plant productivity create strong pipeline 8 put place multiple growth catalyst believe greatest competitive advantage passion deliver outcome presence country planning marketspecific global strategy 10 plan prepare perform corporate overview plan prepare perform ajanta pharma follow continue launch product countryspecific therapeutic strengthen marketing team requirement specific model invigorate market coming year approach focus select country measure stability wider product portfolio economic scenario expect resulted sustainable regain growth momentum profitable business branded generic business medium term strengthening presence india year developed entered philippine six year propensity launching number ago recognised inherent first market focus growth potential market new drug delivery system ndds insight allowed u cater specific around 250 actively marketed therapeutic area anti brand 150 brand india first infectives dermatology orthopaedics focus specialty therapy ophthalmic cardiovascular ajanta pharma niche product led u post gastro intestinal among strategy always strong cagr 256 branded top 25 pharma company generic business fy 201317 demonstrated one fastest present growth graph philippine right market plan remain focused market delivered cagr highgrowth specialty 32 five year driven plan entry therapeutic segment india new product launch increased new geographical enhance leadership cardiology traction existing product dermatology ophthalmology pain market based management aggressive launch creating sound usa strategy clear understanding improving research productivity growth aspiration inspired led superior growth fy presence large complex opportunity 2017 launched 25 product marketplace provide profitable ability india propel opportunity focused growth coming year strong creating presence usa place specialty pipeline product offing world largest pharmaceutical differentiated line strategy plan prepare marketplace selecting niche perform complex product oral solid complex product space filed 34 abbreviated market invigorating asia africa new drug application andas established strong received 17 meticulous planning presence rest asia africa final approval two tentative resulted greater branded generic business approval awaiting approval major segment antimalaria anti 15 andas plan file 1215 scale enhanced bacterial cardiovascular orthopaedic andas fy 2018 u fda product portfolio gynaecology paediatric fy 2017 accomplished 2 among others 700 medical day one launch confirms higher penetration representative field strategy plan prepare perform across global market formidable presence market 11 preparing emerging opportunity challenge 12 plan prepare perform corporate overview plan prepare perform strengthening rd core quality framework assurance rd remains critical differentiator procedure team focus strategic positioning multiple strategy reduce cost important element brand obtaining regulatory conformity image supremely important reinforcing market leadership regularly upgrade rd initiative driven market process line evolving demand implementation regulatory scenario advanced technology play key role context quality control quality assurance standard significant expertise benchmarked best ajanta pharma develop manufacture complex industry strive enhance formulation various dosage form consistently future readiness including tablet capsule powder dependent ophthalmic sterile eye drop continuously review ointment injectables upgrade standard research performance match development rd agenda best industry support growth strategy rd capability developing new product follow standard operating worldclass process enrich procedure ensure best enhance portfolio manufacturing process manufacturing facility strive constant process improvement attain year manufacturing cost competency proactively focus developing complex steadily enhanced product high entry barrier investment initiative expected area service enhance product registration filing changing need broaden product basket key market presence patient healthcare professional manufacturing facility along expansion existing society facility building new facility equipped address pursue growth objective coming year global healthcare need quality key survival growth global pharmaceutical empathy innovation landscape manufacturing technology facility conform rigorous 13 consolidated total income profit tax 10year trend cr consolidated total income cagr 23 pat cagr 42 2500 700 2026 600 2000 1771 500 1502 507 1500 400 1230 416 1000 942 300 310 692 513 234 200 500 317 413 112 355 77 51 100 22 25 34 0 317 fy 2009 fy 2008 fy 2017 fy 201 1 fy 2010 fy 2015 fy 2016 fy 2012 fy 2013 total operating income fy 2014 profit tax performing set industry benchmark 14 plan prepare perform corporate overview plan prepare perform ajanta pharma built strong countryspecific product foundation entrepreneurial specific model business energy professional integrity augmenting well enhance market commitment board director share international market leadership team consistently 1400 product registration provide guidance create hand equal number nurture sustainable value approval thus investment stakeholder operate facility rd new product business highest ethical fuelling future growth plan standard remain committed achieving sustainable part professional ethos profitable growth focus improving operational efficiency hr practice customer effectiveness consolidated total income cr investment give u chance strengthen industry standing 21 cagr 1771 2026 thought leadership 1502 ajanta pharma 1230 flexible risk 942 focused business model enables u fy 2017 fy 2015 fy 2016 fy 2013 fy 2014 deliver effective solution customer generate healthy return monitor operating margin prudently manage operating cost shareholder ensure business cost build sustainable effective leverage scale flexible delivery model effective business vision procurement value added commitment service deliver client stakeholder exercising rigorous fiscal discipline enabled u grow strengthening transparency developing risk matrix adhere revenue highest standard corporate 942 cr fy 2013 governance time ensuring accuracy financial 2026 cr fy 2017 reporting effective internal 21 cagr control 15 annual report 201617 supporting community sustainability strategy embedded approach community service work realm healthcare education general community wellbeing summary total direct beneficiary health activity fy 2017 95000 patient benefitted free eye checkup 750 camp organised different part country education education brings awareness awareness brings confidence healthcare ajanta pharma focus bringing meaningful transformation confidence brings change associated various school rural tribal area 58000 cataract surgery performed giving vision life lack resource provide educational infrastructure poor people opportunity less privileged one form renovating school rural tribal india provide building science laboratory needy patient best health library computer lab area cataract operation emphasis promoting family planning programme plastic surgery year education girl child besides provide vocational training 2500 also added prisoner maharashtra many girl student area family planning surgery performed jail healthcare initiative sewing embroidery singing additionally longterm benefit computer training among others poor patient provided assistance enhances girl child employability upgradation charitable hospital right formal education subsidised food facility patient relative near also process settingup independent technical institute 1700 government hospital benefitted vocational training rural provided skin treatment plastic surgery large section unemployed treatment 16 plan prepare perform corporate overview corporate information corporate information board director auditor mannalal b agrawal kapoor parekh associate chairman cost auditor purushottam b agrawal sevekari khare associate vice chairman internal auditor madhusudan b agrawal mahajan aibara vice chairman chief financial officer yogesh agrawal arvind agrawal managing director company secretary rajesh agrawal gaurang shah joint managing director cin chandrakant khetan l24230mh1979plc022059 director registered office dr anil kumar ajanta house charkop director kandivli west mumbai 400 067 tel 91 22 6606 1000 k h vishwanathan fax 91 22 6606 1200 1300 director website wwwajantapharmacom email infoajantapharmacom prabhakar r dalal director dr anjana grewal director 17 annual report 201617 management discussion analysis economic overview outlook factor underpenetration rising healthcare spends international monetary fund imf expects global household greater prevalence chronic disease drive economy grow 34 fy 2017 36 fy 2018 growth domestic market time generic drug versus 31 growth fy 2016 outlook emerging developed market foray growing emerging market economy expected broadly improve though market drive performance internationally volatility capital flow remain challenge fy 2020 india likely among top three according economic survey 201617 india real pharmaceutical market incremental growth sixth gdp growth projected 71 fy 2017 could reach largest market globally absolute size overall market 67575 fy 2018 project india one size expected grow 100 billion fy 2025 primarily fastest growing country landscape uncertain due rising consumer spending rapid urbanisation global economy increasing healthcare insurance awareness industry poised grow driven increasing affordability shifting pharmaceutical sector overview disease pattern healthcare reform however recent global policy shift increased government control factor pharmaceutical industry one world fastest growing create uncertainty market growth industry remains one biggest contributor world economy unprecedented expansion global healthcare access past year seen fy 2020 india likely hundred million people low middle income among top three pharmaceutical group benefiting governmental programme rising income market incremental growth sixth largest market globally usa continue world largest pharmaceutical market emerging market make 9 top 20 market absolute size developed market spending growth driven original brand emerging market continue driven emerging market nonoriginal product make average 91 huge potential growth spending emerging emerging market volume 78 spending market increase per caput volume monetary allocation towards medicine suggests conscious desire emerging market longterm economic growth increasing government private insurance market emerging expectation healthcare provision changing diet country increase bandwidth healthcare volume lifestyle increasing demand healthcare product medicine use projected increase compound annual across life stage primarily treat chronic condition growth rate 3 globally next five year 6 including respiratory cardiovascular disease demand fy 200611 3 fy 201116 expected grow significantly faster market coming year mature economy pharmaceutical market africa expected reach 45 time downward pressure pricing government focus billion fy 2020 tropical climate africa make prevention treatment high cost rd pose major continent largest reservoir infectious disease particularly challenge industry globally malaria tuberculosis tb acquired immune deficiency syndrome aid noncommunicable disease india cardiovascular diabetes projected rise 60 india pharma industry placed third global ranking term illness africa fy 2020 key challenge volume 14th value industry grown cagr market volatile local currency internal disturbance 1746 fy 200516 expected grow transfer restriction keep player 6 billion fy 2005 367 billion fy 2016 source ibef toe indian pharma company welldiversified business usa market model optimal business mix across primary medicine spending growth usa market slowing geography india emerging market usa steadily since fy 2001 bounced back sharply fy 2014 fy 2015 generic medicine continue larger industry commendable growth path share prescription medicine market usa poised stepup trajectory combination coming five year market grow 462 billion 18 plan prepare perform statutory report management discussion analysis 645675 billion fy 2021 invoice price basis segment performance growth 318 billion 405435 billion fy 2021 net basis 22 global demand generic drug continue grow consumer pursue avenue reduce cost usa 16 16 16 generic drug comprise 70 pharma market volume around 100 billion worth patent expiry next five year generic business significant growth 11 11 10 potential however issue compliance fast erosion 9 8 8 price along clear strategy new administration remain key challenge market around 100 billion worth pharma market dermatology cardiology ophthalmology pain mgt patent expiry next five ipm ajanta pharma year generic business export significant growth potential export grew 12 fy 2017 driven strong growth usa market year company company overview received 9 anda approval launched 7 product ajanta pharma speciality pharmaceutical company usa market 2 product day 1 launch engaged development manufacture marketing strategy company diversifying different market quality finished dosage domestic international helped maintain growth momentum even market business includes branded generic emerging subdued growth africa negative growth asia market asia africa generic developed market emerging market got impacted due currency usa institution sale employ nearly 7000 people devaluation restriction across asia africa worldwide product sold 30 country export detail cr operational highlight 12 entered elite club fortune 500 indian company turnover crossed 2000 cr 1319 profit crossed 500 cr 1178 commissioned 1st phase guwahati manufacturing plant 3 u fda completes inspection paithan dahej plant 10 without major observation 692 712 enhanced rd spend fuel growth 1179 461 417 performance highlight 185 india 14 india branded generic business continued perform well per ims mat march 2017 company grew 16 total export africa asia usa indian pharmaceutical market ipm growth 9 even fy 2016 fy 2017 within speciality segment company operates growth higher industry except dermatology research development company continues launch new product many research development rd represents cornerstone 1st market pipeline innovation ajanta pharma rd played vital role launch coming year company sustained growth last decade team 800 well qualified experienced professional india institution business degrown 40 specialised across value chain pharmaceutical previous year company decided defocus research responsible creating strong product business due low margin pipeline different market rd facility comply international standard well equipped excellent infrastructure supported bestinclass manpower 19 annual report 201617 800 32 geographywise sale fy 2017 territory sale cr sale rd scientist new product launched fy 2017 india 614 32 africa 712 37 asia 417 21 company rd initiative support activity usa 185 10 various business new product process others 5 0 development engagement technology establishing technology commercial scale analysis consolidated financial statement year follows ajanta pharma designed scientifically driven successful rd continues ensure delivery profit loss statement sustainable pipeline highvalue drug product revenue operation company rd strategy centred improving speed revenue operation increased 14 1749 cr yield generic product financial year fy 2016 2002 cr fy 2017 increase driven company invested 8 total operating income growth volume along niche new launch rd continues build support infrastructure product rd spend total oper income excluding capex material cost cr material cost declined 21 fy 2017 24 8 fy 2016 reduction account growth quality business niche first time product launch 153 employee expense 6 peoplerelated expense increased 257 cr fy 2016 295 cr fy 2017 increase due 106 5 additional manpower recruited marketing rd 4 4 support function 70 expense 50 expense include marketing distribution rd fy 2013 37 administrative expense stood 603 cr fy 2017 fy 2015 fy 2016 fy 2014 fy 2017 492 cr fy 2016 revenue expense gone 30 28 last year higher spend rd loss foreign currency fluctuation major reason increase financial review company healthy financial performance margin year contributed strong product portfolio ebidta net margin stood 35 25 respectively differentiated approach focus execution fy 2017 compared 34 24 respectively strategy improving product mix gaining presence fy 2016 result quality product mix higher market going forward company shall strive efficiency sustain performance continuation approval expansion manufacturing capacity vertical balance sheet add value ajanta pharma stakeholder shareholder fund shareholder fund increased 1191 cr fy 2016 snapshot 1568 cr fy 2017 increase primarily due increase net margin earnings per share stood 58 cr fy 2017 47 fy 2016 year fy 2017 fy 2016 growth income operation 2002 1749 14 noncurrent liability ebidta 701 587 19 balance head declined 37 cr pbt 648 559 16 fy 2016 32 cr fy 2017 largely due repayment pat 507 416 22 longterm borrowing 20 plan prepare perform statutory report management discussion analysis current liability following table highlight key risk along mitigating balance head reduced 260 cr fy plan place manage risk 2016 223 cr fy 2017 decrease due reduction shortterm borrowing sr risk statement mitigation plan noncurrent asset 1 competition risk innovation per customer need noncurrent asset increased 251 cr fy 2017 customisation product primarily due addition property plant equipment ground presence every market guwahati dahej facility 2 regulatory risk robust quality assurance framework regular training update current asset 3 global economic well dispersed geographic presence balance head increased 763 cr fy volatility risk regular monitoring local presence 2016 847 cr fy 2017 increase largely due 4 foreign disciplined hedging policy increase investment surplus fund exchange risk systematic monitoring human asset internal control system adequacy company take pride dynamic knowledgedriven talent pool employee base consistently contributed internal control framework governing operation towards growth sustainability year ensures effectiveness automated internal business efficiency control operation company belief open translucent culture reliability financial centralised global process welldefined robust leadership competency framework reporting framework instils strengthens common leadership approach compliance law integrated key support across organisation leadership capability regulation function integral talent management philosophy leadership monitor ensures quarterly tracking development initiative development programme process designed prepare company leader adjust prudent financial annual quality objective fastpaced change industry manage growth control accountability us qms quality management consistently encourages culture integrity management system employee recognition motivation achieved software built company automated control company welldesigned policy procedure process recognise reward contribution report formation team various employee benefit scheme internal auditor different location ajanta pharma work environment motivates submit report people achieve best encourages ecosystem update teamwork continuous learning worklife balance audit committee company promotes innovation rewarding idea board review make real difference key facet business provides direction company total employee strength stood 7000 31st march 2017 cautionary statement certain statement management discussion risk management analysis describing company objective prediction ajanta pharma institutionalised strong risk may forwardlooking statement within meaning management structure enables regular meticulous applicable law regulation actual result may vary examination business activity identification significantly forward looking statement contained evaluation mitigation potential internal external document due various risk uncertainty risk company established robust process risk uncertainty include effect economic guideline along strong overview monitoring political condition india volatility interest rate system board senior management level new regulation government policy may impact laid procedure inform board member company business well ability implement risk assessment risk minimisation measure strategy company undertake update organisation ajanta pharma operates framework statement strong ethical value high level integrity activity strategy considerably mitigates risk 21 annual report 201617 director report dear shareholder director take pleasure presenting thirtyeighth annual report audited financial statement year ended 31st march 2017 1 financial result cr except eps standalone consolidated year ended 31 march 2017 2016 growth 2017 2016 growth total revenue 1823 1574 16 2002 1749 14 ebitda 645 523 23 701 587 19 profit tax 500 422 18 507 416 22 dividend paid equity share including tax 129 135 129 135 transfer general reserve nil 330 nil 321 earnings per share eps 5679 4795 5759 4723 2 dividend 5 share capital year company declared paid two year 3750 share issued interim dividend totaling 13 650 per equity esos 2011 consequent thereto total paid equity share 2 director recommend interim share capital company 31st march 2017 dividend considered final stood 1760 cr divided 88005000 equity share 2 particular employee stock 3 performance review option grantedvestedexercised year company posted remarkable performance given annexure report year review continued grow different parameter domestic business contributed 32 whereas 6 credit rating export contributed 68 total revenue company company bank facility rated credit analysis continues launch new product first market product research limited care company continues gain market share therapeutic segment rating a1 working capital facility geography operates denotes strong degree safety regarding timely payment financial obligation long term company continues operate one segment borrowing company rating aa indicates ie pharmaceutical change high degree safety regarding timely servicing nature business company financial obligation material change commitment 7 subsidiary associate affecting financial position company company continues six subsidiary occurred end financial year overseas including one step subsidiary date report change year financials subsidiary disclosed significant material order passed consolidated financial statement form part company regulator court annual report tribunal impact going concern status company operation future statement containing salient feature financial statement subsidiary pursuant section 129 4 management discussion analysis company act 2013 act read rule 5 management discussion analysis mda form company account rule 2014 annexed part annual report given elsewhere report prescribed form aoci report annexure b financial statement subsidiary 22 plan prepare perform statutory report director report company available inspection aspect would enable effectively shareholder registered office company discharge responsibility function conferred company laid policy material program undertaken subsidiary none subsidiary material year include subsidiary per policy policy placed website company httpwwwajantapharma overview business operation comadmindatapolicycodesc2ea3c56332b4e83 a771f1a8934ec008policyonmaterialsubsidiariespdf ii tax regulatory update compliance indas company invested jv turkmenderman ajanta pharma limited tdapl two decade back iii nvestor relation employee development management control however later etc company surrendered management control favour local partner since control role responsibility function iv significant influence tdapl independent director corporate law operates severe restriction significantly impairs ability transfer fund hence company v visit dahej manufacturing facility impaired entire investment tdapl considered unrelated party associate vi business operation subsidiary account consolidated vii rd operation way forward 8 director change director detail familiarization programme key managerial personnel year imparted placed company independent director given declaration website wwwajantapharmacom meet criterion independence admindatadirectorfamiliarizationprogram laid section 1496 act directorsfamilarisationprogramme2017pdf security exchange board india listing obligation disclosure requirement e evaluation board committee director regulation 2015 listing regulation based pursuant provision act disclosure provided director none listing regulation board carried disqualified appointed director performance evaluation board section 164 act committee independent director independent director separate b retirement rotation meeting evaluated performance non mr madhusudan b agrawal mr rajesh independent director board whole agrawal retire rotation ensuing chairman board manner annual general meeting eligible offer evaluation carried detailed reappointment board recommends corporate governance report reappointment approval member f policy appointment remuneration c board meeting director year five board meeting held detail criterion laid appointment detail given corporate director policy remuneration director governance report given corporate governance report independent director familiarization 9 audit committee programme detail pertaining composition audit company continued independent committee included corporate governance director familiarization program familiarizing report form part report company operation critical 23 annual report 201617 10 new project c cost auditor company commenced commercial company appointed m sevekari khare production new manufacturing facility associate practicing cost accountant audit guwahati phase dahej construction phase cost record company financial ii guwahati underway addition company year 201718 subject ratification proactively assesses requirement infrastructure remuneration member ensuing agm future growth continuously invests 12 internal control system risk management 11 auditor compliance framework statutory auditor company place well defined adequate auditor report year review internal financial control framework year contain qualification adverse control tested material weakness remark auditor also reported design operation observed risk fraud committed company management system followed company officer employee detailed mda statutory auditor m kapoor parekh 13 vigil mechanism associate chartered accountant mumbai hold company set vigil mechanism viz whistle office till conclusion ensuing annual general blower policy enable employee director meeting agm eligible report audit committee chairman genuine appointment term section 139 2 act concern unethical behaviour irregularity noticed company could basis recommendation audit adversely affect company operation posted committee board appointed m b r intranet company reviewed co llp new auditor subject approval audit committee time time concern member ensuing annual general meeting irregularity reported employee company received consent certificate director till date eligibility m b r co llp accordance section 139 141 applicable 14 related party transaction policy provision act rule issued thereunder related party transaction rpts entered confirmed hold valid financial year arm length basis certificate issued peer review board ordinary course business particular institute chartered accountant india icai contract arrangement furnished required listing regulation r pt foreseen repetitive nature omnibus board recommends approval member approval audit committee obtained beginning appointment period 5 five year financial year rpts affected year conclusion 38th agm till conclusion disclosed note financial statement 43rd agm subject ratification member agm board approved adopted policy related party transaction uploaded b secretarial auditor company website httpwwwajantapharmacom pursuant provision section 204 admindatapolicycodesec6023bc420f438c94f9 act company appointment 506925ee2cf4policyonrelatedpartytransactionspdf remuneration managerial personnel rule 2014 company appointed m alwyn 15 managerial remuneration particular dsouza co company secretary practice employee undertake secretarial audit company information pursuant rule 51 company secretarial audit report annexed appointment remuneration managerial report annexure c personnel rule 2014 annexed report qualification reservation adverse remark annexure also given elsewhere report report 24 plan prepare perform statutory report director report information pursuant rule 52 53 company accounting standard followed along appointment remuneration managerial proper explanation relating material personnel rule 2014 pertaining top ten name departure particular employee also form part report however information sent along b director selected accounting report pursuant proviso section 1361 policy applied consistently made act shareholder interested obtaining judgment estimate reasonable copy may write company secretary prudent give true fair view compliance officer registered office address state affair company end company financial year ended 31st march 2017 profit company year 16 loan guarantee investment detail loan guarantee investment covered c proper sufficient care taken provision section 186 act given maintenance adequate accounting note financial statement record accordance provision act safeguarding asset company 17 corporate social responsibility csr preventing detecting fraud company csr policy primarily rest three irregularity broad tenet healthcare education community development within ambit annual accountsfinancial statement schedule vii act year company prepared going concern basis continued several initiative csr program directly well agency permitted e proper internal financial control place act detail csr policy csr activity financial control adequate undertaken year annexed report operating effectively annexure e also given elsewhere report f director devised proper system ensure compliance provision 18 deposit applicable law place adequate company accepted deposit operating effectively public falling within purview section 73 act read company acceptance deposit 22 conservation energy technology rule 2014 absorption foreign exchange earnings outgo 19 unclaimed dividend unclaimed share information relating conservation energy pursuance regulation 39 read schedule vi technology absorption foreign exchange earnings listing regulation company outgo pursuant section 134 act read year transferred unclaimed share unclaimed company account rule 2014 annexed suspense account opened purpose report annexure g following due process 23 corporate governance 20 extract annual return report corporate governance annexed extract annual return form mgt 9 form integral part annual report certificate annexed report annexure f auditor regarding compliance condition corporate governance stipulated listing 21 director responsibility statement regulation also appended report best knowledge belief according corporate governance information explanation obtained director confirm 24 business responsibility reporting business responsibility report company preparation annual account year ended 31st march 2017 form part year ended 31st march 2017 applicable annual report given elsewhere report 25 annual report 201617 25 human resource process followed complainant keeping company firm belief human icc whilst dealing issue related sexual resource play pivotal role success harassment work place woman employee organization company continued organise permanent temporary contractual trainee various inbound outbound training programes covered policy company recreational team building activity enhance received complaint year employee skill motivation also foster team spirit company also conducted various workshop 27 gratitude acknowledgement event grooming upgrading vocational director place record sincere gratitude skill talent pool order meet future talent staunch dedication highly motivated requirement industrial relation cordial performance employee across globe throughout year contributed greatly persistent performance company director also sincerely thank 26 policy sexual harassment woman stakeholder medical professional business work place partner government statutory body bank company place policy prevention financial institution analyst shareholder prohibition redressal sexual harassment continued assistance cooperation support woman workplace accordance requirement sexual harassment woman behalf board director workplace prevention prohibition redressal act 2013 internal complaint committee icc set per statutory requirement mannalal b agrawal redress complaint regarding sexual harassment chairman policy set guideline redressal enquiry mumbai 3rd may 2017 26 plan prepare perform statutory report director report annexure director report employee stock option scheme description detail option total option granted 172000 b pricing formula exercise price 2 per option c option vested 147500 option exercised 127500 e total number share arising result exercise option 127500 f option lapsed year none g variation term option exercise price reduced 835 2 option h money realized exercise option 255000 total option force 24500 j employeewise detail option granted senior managerial personnel 149500 option granted employee company 22500 employee overseas subsidiary ii employee option granted amounting 5 none total option granted year iii employee option equal exceeding 1 issued none capital granted year k diluted earnings per share eps calculated accordance 5758 accounting standard 20 eps l company calculated employee compensation cost using applicable intrinsic value stock option difference employee compensation cost computed employee compensation cost shall recognized used fair value option shall disclosed impact difference profit eps company weighted average exercise price weighted average fair value weighted average exercise price 2 24500 option option outstanding disclosed separately option whose exercise price either equal exceeds less market price stock weighted average fair value 3000 option 1207 6000 option 145691 15500 option 1681 n description method significant assumption used year estimate fair value option including following weighted average information variable weighted average information plan esos 2011 3000 option 6000 option 15500 option grant date 8th may 26th july 26th july 2015 2016 2016 last date acceptance 8th june 26th august 26th august 2015 2016 2016 risk free rate 800 730 730 expected life year 1 3 year 3 4 year 1 3 year volatility 3170 2023 2023 dividend yield 150 053 053 price underlying share market time option grant 1264 1478 170160 original grant date 13th august 2015 however grant date revised variation exercise price note fair value calculated using blackscholes option pricing formula stock price closing price nse date grant considered valuing option granted volatility historical volatility stock till date grant considered calculate fair value option risk free rate return risk free interest rate date grant considered calculation interest rate applicable maturity equal expected life option based zero coupon yield curve government security time maturity time maturity expected life option period company expects option live minimum life stock option minimum period option cannot exercised maximum life period option cannot exercised expected dividend yield expected dividend yield calculated average dividend yield four financial year preceding date grant 27 annual report 201617 annexure b director report form aoc 1 statement containing salient feature financial statement subsidiariesassociate companiesjoint venture pursuant first proviso subsection 3 section 129 read rule 5 company account rule 2014 part subsidiary cr 1 sl 1 2 3 4 ajanta pharma ajanta pharma ajanta pharma ajanta pharma 2 name subsidiary mauritius limited philippine inc usa inc nigeria ltd consolidated 3 reporting period subsidiary concerned different 31mar17 31mar17 31mar17 31mar17 holding company reporting period 4 reporting currency subsidiary mur php usd nn 5 reporting exchange rate last date 178 129 6486 021 relevant financial year case foreign subsidiary rupee equivalent 1 unit foreign currency 31st march 2017 6 share capital 810 138 607 036 7 reserve surplus 7464 4251 435 136 8 total asset 8781 7095 17040 990 9 total liability excluding share capital reserve 507 2706 15998 1090 surplus 10 investment 11 turnover 20798 12182 16818 801 12 profit taxation 3981 2830 1597 195 13 provision taxation 087 879 668 052 14 profit taxation 3894 1951 929 143 15 proposed dividend 16 shareholding 100 100 100 100 note 1 ajanta pharma mauritius ltd consolidated figure includes wholly owned subsidiary ajanta pharma mauritius intl ltd 2 detail ajanta pharma uk ltd given equity contribution made yet started business operation per report even date attached kapoor parekh associate behalf board director chartered accountant nilesh parekh mannalal b agrawal partner chairman purushottam b agrawal yogesh agrawal arvind agrawal vice chairman managing director chief financial officer madhusudan b agrawal rajesh agrawal gaurang shah mumbai 3rd may 2017 vice chairman joint managing director company secretary 28 plan prepare perform statutory report director report annexure c director report secretarial audit report financial year ended 31st march 2017 pursuant section 2041 company act 2013 rule no9 company appointment remuneration managerial personnel rule 2014 security exchange board india member listing obligation disclosure requirement ajanta pharma limited regulation 2015 conducted secretarial audit compliance security exchange board india b applicable statutory provision adherence substantial acquisition share takeover good corporate practice ajanta pharma limited regulation 2011 hereinafter called company security exchange board india c secretarial audit conducted manner provided prohibition insider trading regulation 2015 u reasonable basis evaluating corporate conduct statutory compliance expressing opinion security exchange board india issue capital disclosure requirement based verification company statutory regulation 2009 register book paper minute book form return filed record maintained company e security exchange board india share information provided company officer based employee benefit regulation 2014 agent authorized representative conduct secretarial audit hereby report opinion security exchange board india f company audit period covering registrar issue share transfer agent financial year ended 31st march 2017 complied regulation 1993 regarding company act statutory provision listed hereunder also dealing client company followed proper boardprocesses required compliance mechanism place extent security exchange board india g manner subject reporting made hereinafter delisting equity share regulation 2009 applicable company examined book paper minute book form return filed record maintained security exchange board india h company financial year ended 31st march 2017 buyback security regulation 1998 according provision applicable company bought back proposed buyback security company act 2013 act rule made financial year review thereunder vi specific businessindustry related law applicable ii security contract regulation act 1956 scra company company complied rule made thereunder specific applicable law rule regulation guideline viz drug cosmetic act 1940 iii depository act 1996 regulation pharmacy act 1948 food drug administration byelaws framed thereunder licensing term condition applicable general law rule regulation guideline foreign exchange management act 1999 iv rule regulation made thereunder extent also examined compliance applicable foreign direct investment overseas direct investment clause following external commercial borrowing applicable secretarial standard regard meeting v following regulation guideline prescribed board director ss1 general meeting security exchange board india act ss2 issued institute company 1992 sebi act secretary india 29 annual report 201617 ii listing regulation entered operation monitor ensure compliance company bse limited national stock applicable law rule regulation guideline exchange india limited informed company responded appropriately communication received various statutory regulatory period review company complied authority including initiating action corrective provision act rule regulation guideline measure wherever found necessary standard etc mentioned material noncompliance come knowledge report audit period following eventsactions taken place major bearing report board director company affair pursuance referred company duly constituted proper balance law rule regulation guideline standard executive director nonexecutive director independent director change composition board company meeting held 18th march 2017 board director took place period considered approved amalgamation gab review investment private limited gab company proposed amalgamation would carried vide adequate notice given director schedule scheme amalgamation arrangement gab board meeting agenda detailed note agenda company respective shareholder sent least seven day advance system section 230232 read section 52 section 66 exists seeking obtaining information act applicable provision act clarification agenda item meeting meaningful participation meeting minute board meeting identified alwyn dsouza co dissent member board hence company secretary reason believe decision board approved director present alwyn p dsouza report adequate system place mumbai fcs 5559 process company commensurate size date 3rd may 2017 c p no5137 30 plan prepare perform statutory report director report annexure director report detail pursuant rule 51 company appointment remuneration managerial personnel rule 2014 1 name designation director kmp ratio remuneration increase decrease remuneration director median remuneration fy 201617 employee company fy 201617 mannalal agrawal 491 1 ii purushottam agrawal 821 10 iii madhusudan agrawal 821 10 iv yogesh agrawal 821 10 v rajesh agrawal 821 10 vi chandrakant khetan 31 62 vii dr anil kumar 31 181 viii k h viswanathan 21 64 ix prabhakar dalal 21 91 x dr anjana grewal 21 82 xi arvind agrawal chief financial officer na 19 xii gaurang shah company secretary na 13 includes sitting fee paid nonexecutive director sitting fee increased 24000 30000 wef 1st april 2016 2 percentage increase median remuneration 1186 employee financial year 3 number permanent employee roll company 6316 4 average percentile increase already made salary average increase remuneration employee employee managerial personnel last financial year 201617 1115 increase financial year comparison percentile increase managerial remuneration 1002 percentile increase managerial remuneration justification thereof point median remuneration managerial personnel exceptional circumstance increase range need justification managerial remuneration 5 affirmation remuneration per remuneration yes policy company 31 annual report 201617 annexure e director report report csr pursuant section 1343o company act 2013 rule 9 company corporate social responsibility rule 2014 1 brief outline company csr policy including overview project programme proposed undertaken reference weblink csr policy project programme csr policy appended weblink httpwwwajantapharmacomadmindatapolicycodescsrpoilcypdf 2 composition csr committee mr mannalal b agrawal chairman mr chandrakant khetan member mr yogesh agrawal member dr anil kumar member 3 average profit tax company last three financial year 42113 cr 4 prescribed csr expenditure two per cent amount item 3 company required spend 842 cr towards csr 5 detail csr spent financial year total amount spent financial year 872 cr b amount unspent none c manner amount spent financial year detailed lac location state amount csr project activity sector budget direct agency dist spent 1 medical assistance eye care family maharashtra 180 170 agency planning hospital charge 2 subsidized food patient relative maharashtra 35 30 agency 3 facility gradation charitable hospital maharashtra 212 236 agency direct 4 educational assistance b india 65 84 agency 5 renovation facility school b india 60 53 agency 6 technical institute b maharashtra 200 211 agency 7 community development rural area c maharashtra 90 88 agency direct total 842 872 refers detail sector promoting health care including preventive health care b promoting education including special education c reducing inequality faced socially economically backward group note overhead included amount spent agency seth shri bhagwandasji agrawal charitable trust 6 corporate social responsibility committee company hereby confirms implementation monitoring csr policy compliance csr objective policy company ajanta pharma limited behalf csr committee ajanta pharma limited yogesh agrawal mannalal b agrawal managing director chairman csr committee mumbai 3rd may 2017 32 plan prepare perform statutory report director report csr policy amended board director 26th october 2016 background drinking water community hall park welfare corporate social responsibility ajanta pharma stem victim natural calamity amenity government ideology providing sustainable value hospital subsidized meal needy patient society company operates meeting relative initiative interest stakeholder recognize importance contributing towards development underprivileged 4 maintaining balance ecosystem support section society committed execute initiate program continual improvement responsibly small contribution aspire environment health safety standard improve quality life weaker section society making available basic necessity selective basis contribute government 5 easily accessible andor available voluntary organization academic institute working cause listed schedule vii csr policy company act 2013 rule framed program ajantas csr policy primarily rest 4 broad category healthcare education community 6 surplus arising csr project program development ecology program aimed activity shall form part business profit longterm sustainability inclusive development company special emphasis area around company operational location program designed implemented budget taking consideration specific need area minimum 2 average net profit tax preceding three year allocated every financial year 1 healthcare aim provide medical assistance csr activity expenditure incurred capacity rural underprivileged living remote village area building program training workshop seminar initiative like conference etc corporate communication strategy engagement stakeholder whether free medical camp health eye cataract internal external implement csr company surgery family welfare related area accounted csr expenditure unspent csr budget company financial year allowed b developing basic infrastructure around lapse carried forward next year government hospital people visiting remote area like shelter subsidized food monitoring review similar facility company board formed csr committee oversee policy execution prepare monitoring education effort concentrate providing 2 mechanism ensure implementation project quality learning affordable cost rural area aiding programme activity proposed undertaken school vocational skill center related institution company per policy 3 community development advocate support csr policy shall periodically reviewed sustainability rural area giving assistance safe appropriately revised csr committee 33 annual report 201617 annexure f director report form mgt 9 extract annual return financial year ended 31st march 2017 pursuant section 92 3 company act 2013 rule 121 company management administration rule 2014 registration detail 1 cin l24230mh1979plc022059 2 registration date 31121979 3 name company ajanta pharma limited 4 categorysubcategory company company share capital 5 address registered office contact detail ajanta house 98 govt industrial area charkop kandivali west mumbai 400 067 tel 022 66061000 fax 022 66061200 website wwwajantapharmacom email investorgrievanceajantapharmacom 6 whether listed company yes 7 name address contact detail registrar transfer agent link intime india pvt ltd c 101 247 park l b marg vikhroli west mumbai 400 083 tel 022 49186000 fax 022 49186060 email rnthelpdesklinkintimecoin ii principal business activity company business activity contributing 10 total turnover company shall stated sr name description main product nic code product total turnover service service company 1 pharmaceutical product 21002 21005 100 iii particular holding subsidiary associate company sr name address company cin gln holdingsubsidiary share applicable associate held section 1 ajanta pharma usa inc na subsidiary 100 287 600 1st ave raritan nj 08869 2 ajanta pharma philippine inc na subsidiary 100 287 unit 710 axa life bldg 1286 sen gil puyat ave makati city phillipines 3 ajanta pharma mauritius limited na subsidiary 100 287 medium building goodlands mauritius 4 ajanta pharma mauritius international limited na subsidiary step 287 abax corporate administrator ltd 6th floor tower subsidiary 1 cyber city ebene mauritius 5 ajanta pharma nigeria limited na subsidiary 100 287 block 6 house 6b houson wright estate oregun lagos 6 ajanta pharma uk ltd na subsidiary 100 287 2 cabot house compass point business park st ives 34 plan prepare perform statutory report director report iv share holding pattern equity share capital breakup percentage total equity categorywise shareholding shareholding beginning year 2016 shareholding end year 2017 change sn category shareholder total total demat physical total demat physical total share share year shareholding promoter promoter group 1 indian individual hindu undivided family 56537497 56537497 6424 56537497 56537497 6424 b central government state government c financial institution bank specify body corporate 8392262 8392262 954 8392262 8392262 954 sub total a1 64929759 64929759 7378 64929759 64929759 7378 2 foreign individual nonresident individual foreign individual b government c institution foreign portfolio investor e specify sub total a2 total shareholding promoter promoter groupaa1a2 64929759 64929759 7378 64929759 64929759 7378 b public shareholding 1 institution mutual fund uti 1660642 1660642 189 1732747 1732747 197 008 b venture capital fund c alternate investment fund foreign venture capital investor e foreign portfolio investor 8587032 8587032 976 9615446 9615446 1093 117 f financial institution bank 19906 19906 002 152780 152780 017 015 g insurance company h provident fund pension fund specify sub total b1 10267580 10267580 1167 11500973 11500973 1307 140 2 central government state government president india sub total b2 3 noninstitutions individual individual shareholder holding nominal 7471822 487943 7959765 905 7513973 409693 7923666 900 005 share capital upto 2 lakh ii individual shareholder holding nominal 3246744 3246744 369 2271816 2271816 258 111 share capital excess 2 lakh b nbfcs registered rbi c employee trust overseas depositoriesholding drs balancing figure e specify trust 8114 8114 001 7770 7770 001 foreign national 8500 7500 16000 002 8500 11250 19750 002 hindu undivided family 214771 214771 024 198313 198313 023 001 non resident indian non repat 183510 183510 021 108644 108644 012 009 non resident indian repat 251726 11625 263351 030 192677 4125 196802 022 008 clearing member 124951 124951 014 114175 114175 013 001 market maker 8984 8984 001 181 181 000 001 body corporate 776971 750 777721 088 732401 750 733151 083 005 sub total b3 12296093 507818 12803911 1455 11148450 425818 11574268 1315 140 total public shareholding 22563673 507818 23071491 2622 22649423 425818 23075241 2622 000 bb1b 2b3 total ab 87493432 507818 88001250 10000 87579182 425818 88005000 10000 000 c non promoter non public 1 custodiandr holder 2 employee benefit trust sebi share based employee benefit regulation 2014 total abc 87493432 507818 88001250 10000 87579182 425818 88005000 10000 35 annual report 201617 b shareholding promoter sn shareholder name shareholding beginning year shareholding end year change total share share total share shareholding share share pledged share pledged company encumbered company encumbered year total total share share 1 gab investment pvt ltd 8392262 954 372 8392262 954 0 000 2 mr rajesh agrawal 6411102 729 0 100000 011 100 718 3 mr yogesh agrawal 6383560 725 0 100000 011 100 714 4 mr mannalal b agrawal 5406720 614 0 0 0 0 614 5 mr purushottam b agrawal 5389425 612 0 0 0 0 612 6 mr madhusudan b agrawal 5388750 612 0 0 0 0 612 7 m ganga export represented 5137500 584 0 na na na na mr manisha agrawal mr aayush agrawal mr richa r agrawal m ganga export represented na na na 5137500 584 9917 000 mr yogesh agrawal mr rajesh agrawal mr ravi p agrawal mr aayush agrawal 8 mr madhusudan b agrawal huf 3075000 350 0 0 0 0 350 9 mr mannalal b agrawal huf 3060652 348 0 0 0 0 348 10 mr purushottam b agrawal huf 3036015 345 0 0 0 0 345 11 mr ravi p agrawal 2767060 314 0 190000 021 100 293 12 mr aayush agrawal 2577317 293 0 190000 021 7895 272 13 mr mamta agrawal 1808932 206 0 0 0 0 206 14 mr manisha agrawal 1678912 191 0 0 0 0 191 15 mr richa r agrawal 1657500 188 0 0 0 0 188 16 mr smriti r agrawal 1655302 188 0 0 0 0 188 17 mr vimal agrawal 1103750 125 0 0 0 0 125 18 mr yogesh agrawal trustee 0 0 0 12749999 1449 125 1449 yogesh agrawal trust 19 mr rajesh agrawal trustee 0 0 0 12749999 1449 125 1449 rajesh agrawal trust 20 mr ravi p agrawal trustee 0 0 0 12659999 1439 126 1439 ravi agrawal trust 21 mr aayush agrawal trustee 0 0 0 12660000 1439 126 1439 aayush agrawal trust note change promoter holding account interse transfer share amongst promoter year c change promoter shareholding please specify change sn particular shareholding beginning year cumulative shareholding year share total share share total share company company 1 mannalal b agrawal 5406720 614 5406720 614 less 18nov16 interse transfer 2703360 307 2703360 307 add 21mar17interse transfer 11398319 1295 14101679 1602 less 22mar17interse transfer 1351680 154 12749999 1449 less 22mar17interse transfer 12749999 1449 0 0 2 purushottam b agrawal 5389425 614 5389425 614 less 22sep16 interse transfer 2686064 305 2703361 307 36 plan prepare perform statutory report director report sn particular shareholding beginning year cumulative shareholding year share total share share total share company company add 24mar17interse transfer 7000000 795 9703361 1103 add 27mar17interse transfer 2956639 336 12660000 1439 less 27mar17interse transfer 12660000 1439 0 0 3 madhusudan b agrawal 5388750 612 5388750 612 less 22sep16 interse transfer 2685390 305 2703360 307 add 22mar17 interse transfer 2500000 284 5203360 591 add 23mar17 interse transfer 7456639 847 12659999 1439 less 24mar17 interse transfer 12659999 1439 0 0 4 yogesh agrawal 6383560 725 6383560 725 add 22sep16 interse transfer 3736079 427 10146639 1153 add 18nov16 interse transfer 1351680 154 11498319 1307 less 21mar17interse transfer 11398319 1295 100000 011 5 rajesh agrawal 6411102 729 6411102 729 add 22sep16 interse transfer 3735537 424 10146639 1153 add 18nov16 interse transfer 1351680 154 11498319 1307 less 21mar17interse transfer 7000000 795 4498319 511 less 22mar17interse transfer 4398319 500 100000 011 6 ganga export represented manisha 5137500 584 5137500 584 agrawal aayush agrawal richa agrawal ganga export represented yogesh 0 0 5137500 584 agrawal rajesh agrawal ravi agrawal aayush agrawal 7 mannalal b agrawal huf 3060652 348 3060652 348 less 22sep16 interse transfer 3060652 348 0 0 8 purushottam b agrawal huf 3036015 345 3036015 345 less 22sep16 interse transfer 3036015 345 0 0 9 madhusudan b agrawal huf 3075000 350 3075000 350 less 22sep16 interse transfer 3075000 350 0 0 10 ravi p agrawal 2767060 314 2767060 314 add 22sep16 interse transfer 7379579 839 10146639 1153 less 24mar17interse transfer 7000000 795 3146639 358 less 27mar17interse transfer 2956639 336 190000 021 11 aayush agrawal 2577317 293 2577317 293 add 22sep16 interse transfer 7569322 860 10146639 1153 less 22mar17 interse transfer 2500000 284 7646639 869 less 23mar17 interse transfer 7456639 847 190000 021 12 mamta agrawal 1808932 206 1808932 206 less 22sep16 interse transfer 1808932 206 0 0 13 manisha agrawal 1678912 191 1678912 191 less 22sep16 interse transfer 1678912 191 0 0 14 richa r agrawal 1657500 188 1657500 188 less 22sep16 interse transfer 1657500 188 0 0 15 smriti r agrawal 1655302 188 1655302 188 less 22sep16 interse transfer 1655302 188 0 0 16 vimal agrawal 1103750 125 1103750 125 less 22sep16 interse transfer 1103750 125 0 0 add 21mar17interse transfer 7000000 795 7000000 795 add 22mar17interse transfer 1351680 154 8351680 949 37 annual report 201617 sn particular shareholding beginning year cumulative shareholding year share total share share total share company company add 22mar17interse transfer 4398319 500 12749999 1449 less 23mar17interse transfer 12749999 1449 0 0 17 yogesh agrawal trustee yogesh 0 0 0 0 agrawal trust add 23mar17interse transfer 12749999 1449 12749999 1449 18 rajesh agrawal trustee rajesh 0 0 0 0 agrawal trust add 22mar17interse transfer 12749999 1449 12749999 1449 19 ravi p agrawal trustee ravi agrawal trust 0 0 0 0 add 24mar17interse transfer 12659999 1439 12659999 1439 20 aayush agrawal trustee aayush 0 0 0 0 agrawal trust add 27mar17interse transfer 12660000 1439 12660000 1439 change partner partnership firm m ganga export shareholding top ten shareholder director promoter holder gdrs adrs sn top 10 shareholder shareholding beginning cumulative shareholding year year share total share share total share company company 1 matthew india fund 2872072 326 2872072 326 less market sale 645842 073 2226230 253 2 motilal oswal focused multicap 35 fund 1398015 159 1398015 159 add market purchase 519925 059 1917940 218 less market sale 498810 057 1419130 161 3 narendra kumar agarwal 550000 063 550000 063 less market sale 550000 063 0 0 4 narendra kumar agarwal 550000 063 550000 063 less market sale 550000 063 0 0 5 kotak mahindra international limited 970573 110 970573 110 6 onkar singh kalra 507455 057 507455 057 add market purchase 1345 000 508800 057 7 prerna chaudhary 472074 053 472074 053 add market purchase 18101 002 490175 055 8 sushama chaudhary 461529 052 461529 052 add market purchase 10101 001 471630 053 9 orbimed partner master mauritius limited 220000 025 220000 025 add market purchase 217000 025 437000 050 10 orbimed partner ii mauritius limited 190000 021 190000 021 add market purchase 195200 023 385200 044 11 suresh kumar agarwal 550000 063 550000 063 less market sale 200000 023 350000 040 12 madhulika agrawal 550000 063 550000 063 less market sale 200000 023 350000 040 38 plan prepare perform statutory report director report e shareholding director key managerial personnel sn shareholding director key shareholding beginning cumulative shareholding managerial personnel year year share total share share total share company company 1 mannalal b agrawal chairman 5406720 614 5406720 614 less 18nov16 interse transfer 2703360 307 2703360 307 add 21mar17interse transfer 11398319 1295 14101679 1602 less 22mar17interse transfer 1351680 154 12749999 1449 less 22mar17interse transfer 12749999 1449 0 0 2 purushottam b agrawal vicechairman 5389425 614 5389425 614 less 22sep16 interse transfer 2686064 305 2703361 307 add 24mar17interse transfer 7000000 795 9703361 1103 add 27mar17interse transfer 2956639 336 12660000 1439 less 27mar17interse transfer 12660000 1439 0 0 3 madhusudan b agrawal vicechairman 5388750 612 5388750 612 less 22sep16 interse transfer 2685390 305 2703360 307 add 22mar17 interse transfer 2500000 284 5203360 591 add 23mar17 interse transfer 7456639 847 12659999 1439 less 24mar17 interse transfer 12659999 1439 0 0 4 yogesh agrawal managing director 6383560 725 6383560 725 add 22sep16 interse transfer 3736079 427 10146639 1153 add 18nov16 interse transfer 1351680 154 11498319 1307 less 21mar17interse transfer 11398319 1295 100000 011 5 rajesh agrawal joint managing director 6411102 729 6411102 729 add 22sep16 interse transfer 3735537 424 10146639 1153 add 18nov16 interse transfer 1351680 154 11498319 1307 less 21mar17interse transfer 7000000 795 4498319 511 less 22mar17interse transfer 4398319 500 100000 011 6 yogesh agrawal trustee yogesh agrawal 0 0 0 0 trust add 23mar17interse transfer 12749999 1449 12749999 1449 7 rajesh agrawal trustee rajesh 0 0 0 0 agrawal trust add 22mar17interse transfer 12749999 1449 12749999 1449 8 dr anil kumar independent director 9 chandrakant khetan independent director 10 kh viswanathan independent director 11 prabhakar dalal independent director 12 dr anjana grewal independent director 13 arvind agrawal chief financial officer 22500 003 22500 003 14 gaurang shah company secretary 500 000 500 000 change number share held promoter director due interse transfer share amongst promoter year 39 annual report 201617 v indebtedness indebtedness company including interest outstandingaccrued due payment cr secured loan unsecured deposit total excluding loan indebtedness deposit indebtedness beginning financial year principal amount 5813 995 6808 ii interest due paid iii interest accrued due 002 002 total iiiiii 5815 995 6810 change indebtedness financial year addition reduction 5262 995 6257 net change 5262 995 6257 indebtedness end financial year principal amount 553 553 ii interest due paid iii interest accrued due total iiiiii 553 553 vi remuneration director key managerial personnel remuneration managing director wholetime director andor manager sn particular remuneration name mdwtd manager total amount purushottam madhusudan yogesh rajesh b agrawal b agrawal agrawal agrawal 1 gross salary salary per provision contained 20736000 20736000 20736000 20736000 82944000 section 171 incometax act 1961 b value perquisite u 172 income tax act 1961 c profit lieu salary section 173 income tax act 1961 2 stock option na na na na na 3 sweat equity na na na na na 4 commission nil nil nil nil nil profit others specify 5 others please specify nil nil nil nil nil total 20736000 20736000 20736000 20736000 82944000 ceiling per act 679180565 10 net profit company calculated per section 198 company act 2013 40 plan prepare perform statutory report director report b remuneration director sn particular remuneration name director total mannalal chandrakant dr anil kh p r dalal dr anjana amount b agrawal khetan kumar viswanathan grewal 1 independent director fee attending board 500000 475000 350000 350000 325000 2000000 committee meeting commission 125000 125000 125000 125000 125000 625000 others please specify total 1 625000 600000 475000 475000 450000 2625000 2 nonexecutive director fee attending board 375000 375000 committee meeting commission 12000000 12000000 others please specify total 2 12375000 12375000 total b12 12375000 625000 600000 475000 475000 450000 15000000 ceiling per act 67918057 1 net profit company calculated per section 198 company act 2013 c remuneration key managerial personnel mdmanagerwtd sn particular remuneration key managerial personnel c cfo total amount 1 gross salary salary per provision contained section 171 3496570 7894200 11390770 incometax act 1961 b value perquisite u 172 incometax act 1961 32400 28800 61200 c profit lieu salary section 173 incometax act 1961 na na na 2 stock option na na na 3 sweat equity na na na 4 commission na na na profit others specify 5 others please specify na na na total 3528970 7923000 11451970 vii penalty punishment compounding offence type section brief detail penalty authority appeal made company description punishment compounding rd nclt give act fee imposed court detail company penalty punishment none compounding b director penalty punishment none compounding c officer default penalty punishment none compounding 41 annual report 201617 annexure g director report conservation energy 1 energy conservation measure taken year monitored power factor unity ii replacement cfl metal headlight lamp led light plant warehouse iii continuous monitoring hvac system ahu iv eliminated leakage utility system v installation solar heater one manufacturing facility vi installation motion sensor reduce electricity wastage vii fixed variable frequency heavy load machine viii ensured best possible automation reduce electricity wastage 2 impact measure reduction power consumption ii reduction fuel consumption iii reduction carbon footprint iv reduction fuel power cost v increase operational efficiency 3 total energy consumption energy consumption per unit production per detail form form year ended 31 march 2017 2016 power fuel consumption electricity purchased unit thousand kwh 1151446 1186871 total amount lac 79512 91118 rateunit kwh 663 768 b generation unit thousand kwh 14290 59804 unit per ltr diesel oil kwh 400 312 cost unit kwh 2001 1771 ii consumption per unit production company manufacture apis several drug formulation different pack size therefore impracticable apportion consumption cost utility product 4 step taken company utilizing alternate source energy taken step adopt green energy alternate invested significantly installation solar heater system one manufacturing facility 5 capital investment energy conservation equipment company invested significantly energy conservation equipment across unit b research development technology absorption continued fortify research foundation prudent investment place u frontline technology help u deliver complex product continued develop new product process enrich portfolio give impetus growth plan year added around 200 scientist strengthen team significant expertise develop manufacture complex formulation various dosage form including tablet capsule powder ophthalmic sterile eye drop ointment injectables year continued 42 plan prepare perform statutory report director report develop robust potent cost effective formulation introduced 80 1st time ophthalmic meet patient need bridge gap launch last 11 year special emphasis deployment new process synthesis active pharmaceutical ingredient launched world fastest acting india first development novel drug delivery system existing ocular antiallergic drug approved newer active drug substance use cutting usfda regulator technology making superior quality product analytical method development validation etc received approval 9 andas launched commercialized 7 product u market filed 1 specific area r carried 8 news product usfda anda approval development peroduo gel treatment acne first day launch omeprazole sodium development minocycline foam without bicarbonate capsule u market surfactant acne treatment 13 apis successfully developed charged development minocycline gel acne stability study fy17 7 api scaledup treatment plant commercialization domesticrow market development lotion fungal infection several apis development ready development double triple combination scale plant level product effective fast remedy 3 future plan action development low high power tablet coming year company plan treatment pulmonary arterial hypertension new platform technology development derma development tablet treatment product better stability rheumatoid arthritis development parenteral topical dosage u developed market company form made successful development formulation area development ophthalmic product row market immediaterelease solid oral dosage form including nanonized technology develop preservative free ophthalmic product powder oral solution suspension continue innovate apis specialty segment extendedrelease delayedrelease pellet focus formulation development patent based capsule dosage form challenge product oros osmotic release oral system based developlaunch annually 12 15 first time technology solid oral dosage form product product india file 12 15 andas various therapeutic segment continue quality upgradation existing product ophthalmic product various therapeutic newer technology segment filing regulated market continue develop costeffective formulation 2 benefit derived result rd expanding consumer base company launched 15 new product seven domestic market one row accelerate r activity support product market seven u market pipeline various market across globe 43 annual report 201617 4 effort brief made towards technology 5 expenditure rd absorption adaptation innovation company strives develop technologically advanced particular cr potent affordable product meet patient capital expenditure 4577 need focus continuous quality upgradation recurring expenditure 15015 existing product adopting new technology total 19592 developing new improved drug delivery system total rd expenditure percentage 1075 enhancing patient comfort total turnover company set separate stateofart r c foreign exchange earnings outgo facility meet need different geography 1 information activity relating export initiative segment top quality benchmark taken increase export etc covered r facility team develop formulation management discussion analysis annual apis meet stringent regulatory norm audit report enjoy consumer preference worldwide 2 total foreign exchange used earned company lay emphasis absorbing adapting earnings foreign currency 114770 cr latest technology find innovative solution previous year 104218 cr form novel drug delivery system double triple combination give multiple relief alternative outgo foreign currency 22058 cr previous efficient formulation visàvis traditional one etc year 16782 cr 44 plan prepare perform statutory report report corporate governance report corporate governance company philosophy corporate nonexecutive promoter director 5 independent governance director including 1 woman director director ajanta pharma belief sustained growth rich varied experience field business enhancing shareholder value sound corporate management medicine banking finance project governance must ensure fairness every management risk management international stakeholder customer investor vendor operation marketing hr corporate governance community operate transparency bring extensive knowledge expertise accountability two basic tenet corporate board board provides strategic guidance governance accordingly always seek company ensures effective monitoring ensure performance driven integrity management corporate governance practice value ethic proud responsible corporate citizen b board meeting attendance board meeting date finalized consultation company compliance mandatory director agenda paper detailed note requirement corporate governance laid background information circulated least 8 day new listing regulation also prior meeting thereby enabling board complying nonmandatory requirement effectively reasonably perform duty company guiding principle laid take informed decision arrangement made code business conduct duly adopted adhered participation board member board meeting director senior management personnel video conferencing requested posted website company detailed presentation made management apprise board important development ii board director industry business segment operation marketing composition category director product hr subsidiary etc year change board composition five board meeting held 29th april 2016 year board continues comprise 26th july 2016 26th october 2016 24th january 2017 10 director 4 executive promoter director 1 18th march 2017 composition director 31st march 2017 excluding directorship committee membership private limited company foreign company attendance board annual general meeting given committee membership audit committee stakeholder relationship committee name director category attendance committee membership board agm directorship member chairman mr mannalal b agrawal promoter nonexecutive 5 yes 3 3 0 mr purushottam b agrawal promoter executive 3 yes 3 0 0 mr madhusudan b agrawal promoter executive 5 yes 3 0 0 mr yogesh agrawal promoter executive 5 yes 1 0 0 mr rajesh agrawal promoter executive 5 yes 1 0 mr chandrakant khetan independent 5 yes 4 0 1 dr anil kumar independent 5 yes 0 1 mr k h viswanathan independent 5 yes 1 0 mr prabhakar dalal independent 5 yes 7 6 1 dr anjana grewal independent 5 yes 2 2 0 note mr mannalal b agrawal mr purushottam b agrawal mr madhusudan b agrawal brother mr yogesh agrawal mr rajesh agrawal son mr mannalal b agrawal b none nonexecutives director holding share company 45 annual report 201617 c reappointment director retiring rotation f independent director meeting detail director seeking appointmentreappointment year review one meeting forthcoming annual general meeting required independent director held 24th january 2017 regulation 36 security exchange independent director reviewed matter board india listing obligation disclosure per schedule iv company act 2013 act requirement regulation 2015 listing regulation annexed notice convening annual general independent director present meeting form part annual report meeting independent director familiarisation programme g code conduct detail familiarisation programme imparted board director laid code conduct independent director put website director senior management code company link accessed wwwajantapharma board member senior management comadmindatadirectorfamiliarizationprogram personnel director senior management directorsfamilarisationprogramme2017pdf affirmed compliance code conduct approved adopted board director e performance evaluation declaration effect signed managing board carried annual performance evaluation director annexed report code committee independent director conduct posted website year 2016 nomination remuneration committee company wwwajantapharmacom evaluated individual director performance separate meeting independent director evaluated performance h prevention insider trading executive director board whole chairman company devised adopted code conduct regulate monitor report trading performance evaluation done scale 1 company security person access 5 1 poor 5 good rating unpublished price sensitive information performance laid criterion like company company secretary compliance officer purpose code year board composition diversity governance due compliance code leadership direction strategic input etc company insider requisite disclosure made stock exchange time time ii executive director skill knowledge performance compliance ethical standard risk iii audit committee mitigation sustainability etc term reference audit committee cover matter prescribed regulation 18 listing regulation independent director objectivity bringing iii section 177 act interalia includes independent judgement time devotion domain knowledge contribution etc oversight company financial reporting process disclosure financial hairman guidance overall direction board iv c information ensure financial statement member participation governance conducting correct sufficient credible meeting impartially etc ii reviewing management quarterly committee effectiveness implementation v annual financial statement submission policy procedure plan adherence board approval term reference strategic input board etc evaluation internal financial control risk iii board expressed satisfaction process management system well performance director committee board whole iv recommendation appointment remuneration term appointment statutory auditor 46 plan prepare perform statutory report report corporate governance review monitor auditor independence v formulation criterion evaluation iii performance effectiveness audit process performance independent director board director approval subsequent modification vi transaction related party iv evaluate performance individual director vii scrutiny intercorporate loan investment v devise policy diversity board director viii discussion internal auditor significant vi identifying person qualified become finding follow director may appointed senior management recommend board discussion statutory auditor ix director appointment removal nature scope audit well postaudit discussion ascertain area concern committee comprises four independent director financial year 201617 two meeting x reviewing functioning whistle blower mechanism committee held 29th april 2016 24th january 2017 composition committee committee comprises 4 director member attendance meeting year three independent director member including chairman audit committee financially literate ability read understand financial statement financial year 201617 five meeting held 29th april 2016 26th july 2016 26th october 2016 24th january 2017 18th march name designation meeting attended 2017 composition committee 31st march 2017 member attendance meeting dr anil kumar chairman 2 year mr chandrakant khetan member 2 mr k h viswanathan member 2 name designation meeting mr prabhakar dalal member 2 attended mr chandrakant khetan chairman 5 company secretary act secretary mr k h viswanathan member 5 committee mr prabhakar dalal member 5 mr mannalal b agrawal member 5 v remuneration director nomination remuneration committee formulated company secretary act secretary policy remuneration director key managerial committee personnel kmp employee per policy remuneration nonexecutive director chief financial officer statutory auditor internal independent director includes fee attending auditor attend meeting meeting board well committee commission net profit travelling expense iv nomination remuneration committee remuneration executive director shall fair term reference committee comprise reasonable taking account level skill various matter provided regulation 19 knowledge core competence individual function listing regulation section 178 act duty responsibility company performance interalia include achievement compensation peer industry standard factor laid policy formulation criterion determining qualification positive attribute committee shall recommend board periodic independence director revision remuneration executive director board shall fix remuneration taking ii formulate recommend board policy consideration factor also ceiling limit relating remuneration director key prescribed act shall also managerial personnel employee approved shareholder required 47 annual report 201617 pecuniary relationship transaction nonexecutive director visàvis company year independent director paid sitting fee commission year stock option granted director remuneration paid executive nonexecutive director year ended 31st march 2017 lac remuneration director remuneration sitting fee commission total mr purushottam b agrawal 20736 20736 mr madhusudan b agrawal 20736 20736 mr yogesh agrawal 20736 20736 mr rajesh agrawal 20736 20736 mr mannalal b agrawal 375 12000 12375 mr chandrakant khetan 500 125 625 dr anil kumar 475 125 600 mr prabhakar dalal 350 125 475 mr k h viswanathan 350 125 475 dr anjana grewal 325 125 450 vi stakeholder relationship committee contributing towards development committee performs various function conferred underprivileged section society based listing regulation section 178 act recommendation csr committee company mainly cover ensuring resolution grievance laid csr policy displayed security holder company website company accessed http wwwajantapharmacomadmindatapolicycodes committee comprises three director csrpoilcypdf csr policy within ambit two independent financial year 2016 schedule vii act 17 four meeting committee held 29th april 2016 26th july 2016 26th october 2016 committee oversees implementation 24th january 2017 composition committee execution csr policy provides guidance member attendance meeting year various csr activity undertaken company committee comprises four director name designation meeting financial year 201617 four meeting committee attended held 29th april 2016 26th july 2016 dr anil kumar chairman 4 26th october 2016 24th january 2017 composition dr anjana grewal member 4 committee member attendance mr rajesh agrawal member 4 meeting year name designation meeting mr gaurang shah designated compliance attended officer company act secretary mr mannalal b agrawal chairman 4 committee mr yogesh agrawal member 4 mr chandrakant khetan member 4 company received 61 complaint year dr anil kumar member 4 redressedanswered satisfaction investor investor grievance remained unattendedpending company secretary act secretary committee vii corporate social responsibility committee csr viii compensation committee corporate social responsibility company committee constituted granting employee stem philosophy providing sustainable stock option eligible employee esop value society company operates scheme company financial year 48 plan prepare perform statutory report report corporate governance 201617 two meeting held 6th may 2016 result announces forthwith result 26th july 2016 detail composition stock exchange share committee member attendance meeting company listed together press release brief analysis result published meeting within 48 hour economic time english name designation daily newspaper maharashtra time marathi attended mr chandrakant khetan chairman 2 newspaper result simultaneously mr yogesh agrawal member 2 posted website company dr anjana grewal member 2 wwwajantapharmacom also uploaded dr anil kumar member 2 website national stock exchange india ltd bse limited official news company secretary act secretary release presentation made institutional committee investorsanalysts also posted website company ix executive committee board constituted executive committee dealing xii general shareholder information various urgent operational matter viz granting 1 38th annual general meeting held power attorney employee need basis opening wednesday 5th july 2017 1100 aspee operating bank account availing various banking auditorium laxminarayan mandir complex facility routine administrative matter eight marve road next nutan school malad west meeting executive committee held mumbai maharashtra 400064 year detail composition committee member attendance meeting 2 financial calendar financial year 1st april 2017 31st march 2018 name designation meeting quarterly result declared normally attended 4th week following month end mr yogesh agrawal chairman 8 financial quarter mr rajesh agrawal member 8 mr purushottam b agrawal member 6 3 date book closure mr madhusudan b agrawal member 8 wednesday 28th june 2017 wednesday 5th july 2017 day inclusive x general body meeting annual general meeting last 3 year held 4 dividend payment date agm date time venue interim dividend paid 10th november 2016 special 30th march 2017 proposed final dividend resolution additional dividend recommended passed 35th 5th august 1100 prabodhankar 3 5 listing stock exchange 2014 thackrey bse limited code ajantapharm 532331 natyagrah sodawala lane b national stock exchange india limited borivali west mumbai 400092 code ajantpharmeq 36th 4th july 2015 2 37th 5th july 2016 annual listing fee paid time stock exchange year company passed resolution postal ballot 6 isin number nsdl cdsl ine031b01049 xi mean communication board director approves take record 7 cin number unaudited quarterly result audited annual l24230mh1979plc022059 49 annual report 201617 8 stock market data bombay stock exchangebse national stock exchangense high low high low apr16 156100 135050 156400 134925 may16 164000 144600 161435 144510 jun16 159300 140005 159455 139930 jul16 178500 150005 179000 149200 aug16 200725 175200 200995 175235 sep16 209800 183770 209590 182500 oct16 215000 188440 212500 189025 nov16 205000 168600 205390 168305 dec16 192200 166500 192700 166555 jan17 183725 152745 184000 152665 feb17 183390 166530 183200 166500 mar17 187000 169800 185295 170010 9 performance apl share price comparison bse sensex stock performance 2500 30000 29000 2000 28000 1500 per share 27000 sensex 26000 1000 25000 500 24000 0 23000 apr16 may16 jun16 jul16 aug16 sep16 oct16 nov16 dec16 jan17 feb17 mar17 apl bse bse sensex 50 plan prepare perform statutory report report corporate governance 10 registrar transfer agent sr category 31st march 2017 link intime india private limited unit ajanta pharma total limited c 101 247 park l b marg vikhroli west share share mumbai 400 083 2 mutual fund 1732747 197 tel 91 22 49186000 fax 91 22 49186060 3 bank financial 152780 017 email rnthelpdesklinkintimecoin institution insurance company centralstate 11 share transfer system govt institutionsnon share physical form sent registering transfer government institution 4 private corporate body 733151 083 registrar share transfer agent m link 5 indian public 10401565 1182 intime india private limited registered returned 6 nrisocbsfiisforeign 9940642 1130 within statutory period 15 day date national receipt document order respect 7 clearance 114356 013 share transfer committee company meet total 88005000 10000 often required year 201617 total number share transferred physical form follows 14 dematerialisation share liquidity 9952 total equity capital held transfer request dematerialized form nsdl cdsl period processed effected share 31st march 2017 per guideline sebi trading day dispatched equity share company permitted 115 42 42625 9420 dematerialised form 1620 3 2625 580 2130 nil nil nil share company liquid traded 30 nil nil nil normal volume bse nse relevant data total 45 45250 100 average daily turnover financial year 201617 given 12 distribution equity shareholding 31st march 2017 bombay national bse nse stock stock share shareholder share exchange exchange held bse nse share 17310 153333 170643 upto 500 34352 9022 2236517 254 value term 30452078 270129788 300581866 501 1000 1992 523 1459840 166 10012000 914 240 1267011 144 15 outstanding gdradrwarrants 20013000 297 078 748293 085 convertible instrument conversion date 30014000 129 034 464887 053 likely impact equity 40015000 73 019 329761 037 company issued type security 500110000 144 038 1000147 114 10001 174 046 80498544 9147 16 commodity price risk foreign exchange risk total 38075 10000 88005000 10000 hedging activity company purchase active pharmaceutical 13 pattern shareholding ingredient api material used manufacturing operation foreign domestic sr category 31st march 2017 supplier material sourced total domestic market therefore significant share share foreign exchange fluctuation risk company 1 promoter holding risk management framework proactively promoter 64929759 7378 mitigate impact measure like cost based foreign promoter na na price increase cost reduction measure portfolio 51 annual report 201617 rationalization renegotiate procurement contract ii share held demat form etc company also develops ongoing basis concerned depository participant alternate supply source key product subject economic justification currency risk mainly arise iii detail compliance officer overseas operation financing activity exchange mr gaurang shah rate fluctuation could significantly impact earning avp legal company secretary net equity invoicing foreign currency ajanta house 98 govt ind area expenditure foreign currency translation charkop kandivali west financial statement overseas subsidiary mumbai 400067 indian rupee company defined exchange tel 022 6606 1000 fax 022 6606 12001300 risk management framework manage risk email investorgrievanceajantapharmacom excluding translation risk company hedge foreign exchange risk exposure way forward xiii subsidiary company exchange contract per decision forex company indian subsidiary management committee time time requirement appointment independent director company board material indian 17 employee stock option scheme 2011 esos 2011 subsidiary applicable audited annual financial year 2500 option exercised statement overseas subsidiary company employee subsidiary company also tabled audit committee board meeting granted bonus element 1250 option thus copy minute board meeting total 3750 option allotted listed subsidiary company individually given stock exchange year 15500 option director tabled subsequent granted employee including employee board meeting web link policy determining overseas subsidiary company 31st march 2017 material subsidiary httpwwwajantapharmacom option due vesting admindatapolicycodesc2ea3c56332b4e83a771f1 a8934ec008policyonmaterialsubsidiariespdf 18 plant location company 6 manufacturing plant xivother disclosure follows transaction material nature related party may potential b4 b5 b6 midc industrial area paithan dist conflict interest company large aurangabad transaction related party disclosed ii 31o midc industrial area chikalthana note 47 financial statement aurangabad iii gut 11121415 chitegaon paithan road dist b instance noncompliance aurangabad penaltiesstrictures imposed stock iv gut 378 plot 8 waluj aurangabad exchange sebi statutory authority v plot z103 dahej sez part ii dist bharuch matter related capital market vi mirza palashbari road mouza kamrup r dist last 3 financial year guwahati board director company c 19 r centre located charkop kandivali west adopted put place whistle blower policy mumbai personnel denied access 20 investor correspondence address audit committee detail vigil mechanism share held physical form whistle blower policy provided director link intime india pvt ltd report unit ajanta pharma limited c 101 247 park l b marg vikhroli west managing director cfo company mumbai 400 083 certified board regard tel 91 22 49186000 fax 91 22 49186060 compliance made term regulation email rnthelpdesklinkintimecoin 178 listing regulation part b schedule ii certificate form part annual report 52 plan prepare perform statutory report report corporate governance e noncompliance requirement h financial statement company corporate governance report prepared accordance indian required disclosure made stock exchange accounting standard indas notified regulatory body required company indian accounting standard rule 2015 amended company indian f risk management committee would formed accounting standard amendment rule 2016 deemed necessary period including year ended 31st march 2016 company prepared financial g company complies following non mandatory statement accordance accounting requirement regulation 271 specified part standard notified section 133 e schedule ii listing regulation act read company account rule 2014 previous gaap financial statement company appointed separate person prepared accrual basis post chairman managing director historical cost basis except certain asset liability measured fair value ii nonexecutive chairman provided revalued amount wherever applicable office company expense also allowed reimbursement expense incurred behalf board director performance duty mannalal b agrawal iii internal auditor report audit committee mumbai 3rd may 2017 chairman declaration pursuant schedule v listing regulation accordance schedule v listing regulation stock exchange hereby declare director senior management company affirmed compliance code conduct applicable year ended 31st march 2017 ajanta pharma limited yogesh agrawal managing director mumbai 3rd may 2017 53 annual report 201617 certificate pursuant regulation 178 listing regulation mr yogesh agrawal managing director mr arvind agrawal chief financial officer hereby certify financial year ended 31st march 2017 reviewed indas financial statement cash flow statement year best knowledge belief statement contain materially untrue statement omit material fact contain statement might misleading ii statement together present true fair view company affair compliance indas applicable law regulation b best knowledge belief transaction entered company year fraudulent illegal violative company code conduct c accept responsibility establishing maintaining internal control financial reporting evaluated effectiveness internal control system company pertaining financial reporting disclosed auditor audit committee deficiency design operation internal control aware step taken propose take rectify deficiency indicated auditor audit committee significant change internal control financial reporting year ii significant change accounting policy year iii instance significant fraud become aware ajanta pharma limited ajanta pharma limited yogesh agrawal arvind agrawal managing director chief financial officer mumbai 3rd may 2017 54 plan prepare perform statutory report report corporate governance auditor certificate corporate governance member ajanta pharma limited examined compliance condition corporate governance ajanta pharma limited company year ended 31st march 2017 prescribed regulation 17 27 462b para c e schedule v chapter iv sebi listing obligation disclosure requirement regulation 2015 listing regulation compliance condition corporate governance responsibility management examination limited review procedure implementation thereof adopted company ensuring compliance condition corporate governance neither audit expression opinion financial statement company opinion best information according explanation given u based representation made director management certify company complied condition corporate governance stipulated mentioned listing regulation state compliance neither assurance future viability company efficiency effectiveness management conducted affair company kapoor parekh associate chartered accountant icai frn 104803w nilesh parekh partner 33528 mumbai 3rd may 2017 55 annual report 201617 business responsibility report section general information company 1 corporate identity number cin company l24230mh1979plc022059 2 name company ajanta pharma limited 3 registered address ajanta house charkop kandivli west mumbai 400067 4 website wwwajantapharmacom 5 email id infoajantapharmacom 6 financial year reported 1st april 2016 31st march 2017 7 sector company engaged industrial manufacture pharmaceutical product code 21002 21005 activity codewise 8 list three key productsservices company artefan metxl softdrops manufacturesprovides balance sheet 9 total number location business activity number international location 6 undertaken company company six foreign subsidiary including one step subsidiary located usa nigeria philippine mauritius uk b number national location registered corporate office located kandivli mumbai ii six manufacturing plant situated paithan chikalthana waluj chitegaon maharashtra b dahej gujarat c guwahati assam iii rd centre situated kandivli mumbai iv two central warehouse situated zikarpur chandigarh aurangabad maharashtra v c f agent various location throughout country 10 market served company domestic global section b financial detail company 1 paid capital inr 1760 cr 2 total turnover inr 182271 cr standalone 3 total profit tax inr 49981 cr standalone 4 total spending corporate social responsibility csr company total spending csr year ended percentage profit tax 31st march 2017 872 cr 174 profit tax 5 list activity expenditure 4 incurred healthcare b education c community development section c detail 1 company subsidiary company company 31st march 2017 company 6 subsidiary including one step subsidiary 2 subsidiary companycompanies participate br subsidiary incorporated outside india comply initiative parent company yes indicate requirement respective country number subsidiary company independent business responsibility initiative 3 entityentities eg supplier distributor etc entity directly participate br initiative company business participate br company initiative company yes indicate percentage entityentities less 30 3060 60 56 plan prepare perform statutory report business responsibility report section br information b detail br head 1 detail directordirectors responsible br particular detail detail directordirector responsible 1 din number applicable na implementation br policypolicies 2 name mr arvind agrawal 3 designation cfo din number 00073673 4 telephone number 022 66061000 name mr yogesh agrawal 5 email id arvindagrawal designation managing director ajantapharmacom 2 principlewise per nvgs br policypolicies detail compliance reply yn 3 p1 p2 p3 p4 p5 p6 p7 p8 p9 1 policypolicies 3 3 3 3 3 3 x 3 3 2 policy formulated consultation 3 3 3 3 3 3 3 3 relevant stakeholder 3 policy conform national policy broadly based national voluntary guideline international standard yes specify 50 social environmental economical responsibility business issued word ministry corporate affair government india 4 policy approved board 3 3 3 3 3 3 3 3 yes signed mdownerceo appropriate board director 5 company specified committee 3 3 3 3 3 3 3 3 boarddirectorofficial oversee implementation policy 6 indicate link policy viewed online 7 policy formally communicated 3 3 3 3 3 3 3 3 relevant internal external stakeholder 8 company inhouse structure 3 3 3 3 3 3 3 3 implement policypolicies 9 company grievance redressal 3 3 3 3 3 3 3 3 mechanism related policypoliciesto address stakeholder grievance related policypolicies 10 company carried independent audit 1st year independent auditevaluation done taken evaluation working policy next year internal external agency policy placed intranet company except csr policy available httpwwwajantapharmacomadmindatapolicycodes csrpoilcypdf b answer question serial number 1 principle please explain tick 2 option question p7 1 company understood principle 2 company stage find position formulate implement need felt formulate policy specified principle specific policy public advocacy company engage directly 3 company financial manpower resource available task 4 planned done within next 6 month 5 planned done within next 1 year 6 reason please specify 57 annual report 201617 3 governance related br indicate frequency board director annually committee board ceo assess br performance company within 3 month 36 month annually 1 year b company publish br sustainability report company publish br sustainability report hyperlink viewing report frequently however detail relating corporate social responsibility published activity presented annual report section e principlewise performance principle 1 1 policy relating ethic bribery corruptionyes company put place code conduct director cover company yes extend senior management personnel extends group including groupjoint venturessupplierscontractorsngos employee director subsidiary company also put others place whistleblower policy order enable employee others bring notice board management wrongdoing unethical practice observed company 2 many stakeholder complaint received complaint received stakeholder past financial year percentage fy 2017 satisfactorily resolved management provide detail thereof 50 word principle 2 1 list 3 product service whose design tiban teneligliptin antidiabetic low cost drug incorporated social environmental concern risk andor b betoact bepotastine 2nd generation antiocular anti opportunity allergic product 1st time india c azutan azilsartan management diabetic hypertension 2 product provide following detail product consume major quantum energy respect resource use energy water raw material etc per water either production level consumer level unit product optional company taken several effective measure reduce reduction sourcingproduction distribution overall consumption energy water achieved since previous year throughout value chain b reduction usage consumer energy water achieved since previous year 3 company procedure place sustainable company established stringent process approve vendor sourcing including transportation material procured quality assurance team yes percentage input sourced conduct periodic audit vendor especially sustainably also provide detail thereof 50 supply key material ensure sustainability word company enters annual freight contract leading transporter ensuring sustainable seamless movement material good 4 company taken step procure good yes company procures lab reagent solvent service local small producer including community packing material local small producer vicinity surrounding place work manufacturing location periodically audit facility yes step taken improve guide quality front also service level capacity capability local small vendor improve quality standard adapt customer requirement 5 company mechanism recycle product 100 waste water generated plant recycled recovered waste yes percentage recycling reused thereby reducing consumption fresh water treated product waste separately 5 510 10 also waste water used gardening company premise provide detail thereof 50 word solvent recycled reused 58 plan prepare perform statutory report business responsibility report principle 3 1 please indicate total number employee 7720 2 please indicate total number employee hired temporarycontractualcasual basis 1275 3 please indicate number permanent woman employee 460 4 please indicate number permanent employee disability 5 5 employee association recognized management yes 2 manufacturing plant 6 percentage permanent employee member recognized employee 160 association 7 please indicate number complaint relating child labour forced labour involuntary labour sexual harassment last financial year pending end financial year category complaint filed complaint pending financial year end financial year 1 child labourforced labourinvoluntary labour nil nil 2 sexual harassment nil nil 3 discriminatory employment nil nil 8 percentage mentioned employee given safety skill upgradation training last year permanent employee 5735 b permanent woman employee permanent employee includes permanent woman employee c casualtemporarycontractual employee 4265 employee disability 0 principle 4 1 company mapped internal yes external stakeholder yesno 2 company identified yes disadvantaged vulnerable marginalized stakeholder 3 special initiative taken engage disadvantaged vulnerable marginalized stakeholder company engage disadvantaged enable educate empower focused initiative health vulnerable marginalized stakeholder education woman empowerment rural infrastructure provide detail thereof 50 word provide needy patient best health area cataract operation family planning program plastic surgery camp completely free cost including transport food medicine eye glass associated various school rural tribal area provide educational infrastructure form renovating school building science laboratory library computer lab scholarship deserving student etc provide vocational training girl student area sewing embroidery singing computer etc 5000 girl availed benefit facility different school rural india 59 annual report 201617 principle 5 policy company human right cover cover entire ajanta pharma limited group however company extend groupjoint venturessuppliers cover supplier contractor ngo others contractor ngosothers b many stakeholder complaint received none past financial year percent satisfactorily resolved management principle 6 1 policy related principle 6 cover policy cover company subsidiary alongwith company extends groupjoint venture contractor working within premise company supplierscontractors ngosothers 2 company strategy initiative address conservation optimum utilisation natural resource continues global environmental issue climate change topmost priority company environment health safety policy company stress conservation energy global warming etc yn yes please give hyperlink webpage etc eliminatingreducing waste company mechanism place recycling 100 waste water 3 company identify assess potential yes taking necessary stepsmeasures control environmental risk yn mitigate 4 company project related clean applicable development mechanism provide detail thereof 50 word also yes whether environmental compliance report filed 5 company undertaken initiative energy conservation measure taken year clean technology energy efficiency renewable energy monitored power factor unit etc yn yes please give hyperlink web page etc variable frequency drive fixed heavy load machine energy efficient led tube light fixed instead regular tube light plant 110 watt cfl light warehouse replaced led 90 watt monitored hvac system ahu required eliminated leakage utility system installed solar heater 6 emissionswaste generated company yes parameter within limit within permissible limit given cpcbspcb financial year reported 7 number show cause legal notice received none cpcbspcb pending ie resolved satisfaction end financial year principle 7 1 company member trade chamber association bombay chamber commerce industry yes name major one business deal b india association industriesaiai indomauritius chamber commerce industry c imcci indian drug manufacturer association b advocatedlobbied association advancement improvement public good yesno yes specify broad area drop box governance administration economic reform inclusive development policy energy security water food security sustainable business principle others 60 plan prepare perform statutory report business responsibility report principle 8 1 company specified yes company specified programmesinitiatives field healthcare programmesinitiativesprojects education community development health pursuit policy related principle 8 yes detail thereof constantly working eradicating cataract rural mass 200000 people regained vision living better life last 2 decade organised 3000 diagnostics eye camp screening 400000 villager tribal rural area last decade initiative family planning program remote rural tribal india 5000 family planning operation last 3 year conducted plastic surgery camp child rural tribal india physical deformity like cut nose lip mark squint eye white patch etc caused due burn accident injury birth defect treated 3000 needy poor patient last 2 decade education identified girl child education focus area working various school vidarbha marathwada region maharashtra undertaken renovation infrastructure school including classroom washroom computer lab music lab science lab library etc till 3850 student benefited program school identified upliftment developing girl prepare future help independent built successfully implemented wellplanned comprehensive woman empowerment program many school rural part india program imparts knowledge exposure life skill girl age group 1018 year created part school curriculum girl deprived section gain skill english singing computer tailoring skill personality enhancement would help career financially independent social development built maintained waiting shed government hospital campus providing proper sitting drinking water facility light fan etc make waiting patient relative comfortable relative getting treatment till date built 6 shelter renovated 3 dharmshalas benefited 1 million patient relative running subsidised canteen called annachatra poor patient relative rural india get hygienic food 3 meal snack every day nominal cost 2010 2016 200000 needy poor patient taken benefit facility 2 programmesprojects programme undertaken inhouse well charitable trust undertaken inhouse teamown ngo foundationexternal ngogovernment structuresany organization 3 done impact assessment yes initiative 4 company direct 872 cr contribution community development project amount inr detail detail project undertaken company mentioned annexure e project undertaken director report 5 taken step ensure ajanta pharma dedicated inhouse team visit inaccessible community development adopted remote area looking need based community development activity gap community please explain 50 identified ajanta undertakes complete execution maintenance csr activity word company majorly work field woman education empowerment cataract operation health solution social development infrastructure facility etc 61 annual report 201617 principle 9 1 percentage customer complaintsconsumer case company received total 22 complaint financial pending end financial year year 19 satisfactorily resolved 3 investigation two old consumer case pending consumer court end financial year 2 company display product information product pharmaceutical product company display statutory label mandated per local law yes information required respect product labelling nonaremarks additional information product information 3 case filed stakeholder company none regarding unfair trade practice irresponsible advertising andor anticompetitive behaviour last five year pending end financial year provide detail thereof 50 word 4 company carry consumer survey consumer consumer survey regularly carried company satisfaction trend doctor level behalf board director mannalal b agrawal mumbai 3rd may 2017 chairman 62 63174 financial statement 64 consolidated 120 standalone annual report 201617 independent auditor report auditor responsibility member responsibility express opinion consolidated ajanta pharma limited ind financial statement based audit conducting audit taken account provision report consolidated ind financial act accounting auditing standard matter statement required included audit report audited accompanying consolidated ind provision act rule made thereunder financial statement ajanta pharma limited holding company subsidiary collectively referred conducted audit accordance standard group comprising consolidated balance auditing specified section 14310 act sheet 31st march 2017 consolidated statement standard require comply ethical requirement profit loss including comprehensive income plan perform audit obtain reasonable assurance consolidated cash flow statement consolidated whether consolidated ind financial statement statement change equity year ended free material misstatement summary significant accounting policy explanatory information hereinafter referred audit involves performing procedure obtain audit consolidated ind financial statement evidence amount disclosure consolidated ind financial statement procedure management responsibility selected depend auditor judgment including consolidated ind financial statement assessment risk material misstatement holding company board director responsible consolidated ind financial statement whether due preparation presentation consolidated ind fraud error making risk assessment auditor financial statement term requirement considers internal financial control relevant holding company act 2013 act give true fair view company preparation consolidated ind financial consolidated state affair financial position consolidated statement give true fair view order design profit financial performance including comprehensive audit procedure appropriate circumstance income consolidated cash flow consolidated statement audit also includes evaluating appropriateness change equity group accordance accounting policy used reasonableness accounting principle generally accepted india including accounting estimate made holding company board accounting standard specified section 133 director well evaluating overall presentation act read relevant rule issued thereunder respective consolidated ind financial statement board director company included group responsible maintenance adequate accounting believe audit evidence obtained u sufficient record accordance provision act appropriate provide basis audit opinion safeguarding asset group preventing consolidated ind financial statement detecting fraud irregularity selection application appropriate accounting policy making opinion judgment estimate reasonable prudent opinion best information according design implementation maintenance adequate explanation given u aforesaid consolidated ind internal financial control operating effectively financial statement give information required ensuring accuracy completeness accounting act manner required give true fair view record relevant preparation presentation conformity accounting principle generally accepted consolidated ind financial statement give true india consolidated state affair financial position fair view free material misstatement whether group 31st march 2017 consolidated profit due fraud error used purpose financial performance including comprehensive income preparation consolidated ind financial statement group consolidated cash flow consolidated director holding company aforesaid change equity group year ended date 64 plan prepare perform financial statement consolidated matter holding company none director audit financial statement financial information holding company disqualified 31st march subsidiary whose financial statement financial information 2017 appointed director term reflect total asset 33907 cr 31st march 2017 total section 164 2 act revenue 50608 cr net cash inflow amounting 2519 cr year ended date considered f respect adequacy internal financial consolidated ind financial statement control financial reporting group operating effectiveness control refer financial statement financial information separate report annexure audited auditor whose report furnished u management opinion far relates g respect matter included amount disclosure included respect auditor report accordance rule 11 subsidiary based solely report auditor company audit auditor rule 2014 opinion best information opinion consolidated ind financial statement according explanation given u report legal regulatory requirement modified respect matter respect consolidated ind financial statement reliance work done report auditor disclose impact pending litigation 31st march 2017 financial position report legal regulatory refer note 48 consolidated financial requirement statement 1 required section143 3 act report extent applicable ii group entered longterm contract including derivative contract requiring sought obtained information provision applicable law accounting explanation best knowledge standard material foreseeable loss belief necessary purpose audit aforesaid consolidated financial statement delay transferring iii amount required transferred b opinion proper book account required investor education protection fund law relating preparation aforesaid holding company consolidated ind financial statement kept far appears examination company provided requisite iv book disclosure consolidated ind financial statement holding well dealing c consolidated balance sheet consolidated specified bank note period statement profit loss consolidated cash 8th november 2016 30th december 2016 flow statement consolidated statement accordance book change equity dealt report account maintained company refer agreement relevant book account note 52 consolidated ind financial maintained purpose preparation statement consolidated ind financial statement kapoor parekh associate opinion aforesaid consolidated ind chartered accountant financial statement comply indian icai frn 104803w accounting standard prescribed section 133 act read relevant rule issued thereunder nilesh parekh e basis written representation received partner director holding company 31st mno 33528 march 2017 taken record board director mumbai 3rd may 2017 65 annual report 201617 annexure independent auditor report annexure referred para 1 f heading audit involves performing procedure obtain audit report legal regulatory requirement evidence adequacy internal financial report even date member ajanta pharma control system financial reporting operating limited consolidated ind financial statement effectiveness audit internal financial control year ended 31st march 2017 financial reporting included obtaining understanding internal financial control financial reporting assessing report internal financial control risk material weakness exists testing financial reporting clause sub evaluating design operating effectiveness internal section 3 section 143 company act control based assessed risk procedure selected 2013 act depend auditor judgement including assessment conjunction audit consolidated ind risk material misstatement financial statement financial statement group year ended whether due fraud error 31st march 2017 audited internal financial control financial reporting holding company date believe audit evidence obtained sufficient appropriate provide basis audit management responsibility internal opinion holding company internal financial control financial control system financial reporting board director holding company responsible establishing maintaining internal financial control meaning internal financial control based internal control financial reporting criterion financial reporting established holding company considering essential company internal financial control financial reporting component internal control stated guidance process designed provide reasonable assurance note audit internal financial control financial regarding reliability financial reporting reporting issued institute chartered accountant preparation financial statement external purpose india icai responsibility include design accordance generally accepted accounting principle implementation maintenance adequate internal financial company internal financial control financial reporting control operating effectively ensuring orderly includes policy procedure 1 pertain efficient conduct business including adherence maintenance record reasonable detail accurately company policy safeguarding asset fairly reflect transaction disposition prevention detection fraud error accuracy asset company 2 provide reasonable assurance completeness accounting record timely transaction recorded necessary permit preparation preparation presentation reliable financial information financial statement accordance generally accepted required company act 2013 accounting principle receipt expenditure company made accordance auditor responsibility authorisation management director company responsibility express opinion holding 3 provide reasonable assurance regarding prevention company internal financial control financial reporting timely detection unauthorised acquisition use disposition based audit conducted audit accordance company asset could material effect guidance note audit internal financial control financial statement financial reporting issued icai standard auditing issued icai deemed prescribed inherent limitation internal financial section 14310 company act 2013 control financial reporting extent applicable audit internal financial control inherent limitation internal financial control standard mentioned guidance note financial reporting including possibility collusion require comply ethical requirement plan improper management override control material perform audit obtain reasonable assurance misstatement due error fraud may occur whether adequate internal financial control financial detected also projection evaluation internal reporting established maintained control financial control financial reporting future period operated effectively material respect subject risk internal financial control 66 plan prepare perform financial statement consolidated financial reporting may become inadequate matter change condition degree compliance aforesaid report section 1433i act policy procedure may deteriorate adequacy operating effectiveness internal financial control financial reporting restricted holding opinion company since subsidiary group foreign opinion holding company material subsidiary subject report internal respect adequate internal financial control system financial control financial reporting internal financial control financial reporting operating effectively 31st march kapoor parekh associate 2017 based internal control financial reporting chartered accountant criterion established holding company considering icai frn 104803w essential component internal control stated guidance note audit internal financial control financial nilesh parekh reporting issued icai partner mno 33528 mumbai 3rd may 2017 67 annual report 201617 consolidated balance sheet 31st march 2017 cr particular note 31 march 2017 31 march 2016 1 april 2015 asset 1 noncurrent asset property plant equipment 8 58316 44698 28378 b capital workinprogress 8 33803 23842 17020 c intangible asset 8 601 376 322 intangible asset development 8 123 138 e financial asset investment 9 4535 ii others 10 929 926 923 f deferred tax asset net 11 2445 858 506 g noncurrent asset 12 1393 1631 538 2 current asset inventory 13 21102 20458 15903 b financial asset investment 14 18156 7678 1989 ii trade receivables 15 32184 37235 25876 iii cash cash equivalent 16 5192 4142 4167 iv bank balance iii 17 412 195 8227 v financial asset 18 124 071 912 c current tax asset net 19 1123 1764 current asset 20 6368 4784 5046 total asset 182271 148796 114342 equity liability equity equity share capital 21 1769 1769 1768 b equity 154999 117317 88675 liability 1 noncurrent liability financial liability borrowing 22 104 1487 3325 ii financial liability 23 009 046 250 b provision 24 315 259 476 c deferred tax liability net 25 2734 1929 1378 2 current liability financial liability borrowing 26 553 4625 508 ii trade payable 27 13957 14557 10906 iii financial liability 28 2552 4051 4286 b current liability 29 3999 1621 1547 c provision 30 1280 1135 968 current tax liability net 31 256 total equity liability 182271 148796 114342 see accompanying note forming part financial statement per report even date attached kapoor parekh associate behalf board director chartered accountant nilesh parekh mannalal b agrawal partner chairman purushottam b agrawal yogesh agrawal arvind agrawal vice chairman managing director chief financial officer madhusudan b agrawal rajesh agrawal gaurang shah mumbai 3rd may 2017 vice chairman joint managing director company secretary 68 plan prepare perform financial statement consolidated statement consolidated profit loss year ended 31st march 2017 cr note 31 march 2017 31 march 2016 income revenue operation 32 200164 174937 income 33 2386 2115 total income 202550 177052 expense cost material consumed 34 37785 40009 purchase stockintrade 35 4736 6301 change inventory finished good workinprogress stockintrade 36 1062 4927 employee benefit expense 37 29542 25664 finance cost 38 349 489 depreciation amortisation expense 39 6121 4443 expense 40 60262 49184 total expense 137733 121164 profit tax 64817 55889 tax expense current tax 15749 14117 deferred tax 1615 211 profit year 50683 41561 comprehensive income comprehensive income reclassified profit loss subsequent year exchange difference translation foreign operation 242 558 income tax effect net comprehensive income reclassified profit loss 242 558 subsequent year comprehensive income reclassified profit loss subsequent year remeasurement gain loss defined benefit plan 017 035 income tax effect 006 012 net comprehensive income reclassified profit loss 011 023 subsequent year comprehensive income year net tax 253 535 total comprehensive income year net tax 50430 42096 exceptional item discontinuing operation earning per equity share face value 2 42 basic 5759 4723 diluted 5758 4723 see accompanying note forming part financial statement per report even date attached kapoor parekh associate behalf board director chartered accountant nilesh parekh mannalal b agrawal partner chairman purushottam b agrawal yogesh agrawal arvind agrawal vice chairman managing director chief financial officer madhusudan b agrawal rajesh agrawal gaurang shah mumbai 3rd may 2017 vice chairman joint managing director company secretary 69 annual report 201617 statement consolidated cash flow year ended 31st march 2017 cr 31 march 2017 31 march 2016 cash flow operating activity profit tax 64816 55890 adjustment reconcile profit tax net cash flow depreciation amortisation expense 6121 4443 provision expired good 133 122 loss sale discard property plant equipment 389 692 interest expense 349 489 gain financial instrument fvtpl 1683 545 income investment deposit 121 578 employee stock option expense 145 031 receivable written 2327 095 exchange fluctuation 242 558 operating profit working capital change 72234 61197 change working capital decrease increase trade receivables 3215 11454 decrease increase current financial asset 1584 262 decrease increase noncurrent asset 196 102 decrease increase current asset 227 245 decrease increase inventory 645 4555 increase decrease non current financial liability 037 204 increase decrease current liability 2859 105 increase decrease non current provision 056 216 increase decrease current provision 011 045 increase decrease trade payable 600 3651 cash generated operation 75086 48762 direct tax paid net refund 14277 16149 net cash generated operating activity 60809 32614 b cash flow investing activity capital expenditure property plant equipment including capital advance 30146 29792 proceeds sale property plant equipment 127 043 bank balance considered cash cash equivalent net 024 8145 purchase investment 35920 21900 proceeds investment 26778 21539 income investment deposit 101 1059 net cash generated used investing activity 39084 20907 70 plan prepare perform financial statement consolidated cr 31 march 2017 31 march 2016 c cash flow financing activity proceeds long term borrowing 473 repayment long term borrowing 3384 2410 proceeds repayment short term borrowing 4072 4117 proceeds issue equity share esop 001 interest paid 351 490 dividend paid 11419 12279 dividend distribution tax paid 1450 1144 net cash generated used financing activity 20675 11732 net increase decrease cash cash equivalent 1050 025 cash cash equivalent beginning year 4142 4167 cash cash equivalent end year refer note 16 5192 4142 figure bracket indicates outflow see accompanying note forming part financial statement per report even date attached kapoor parekh associate behalf board director chartered accountant nilesh parekh mannalal b agrawal partner chairman purushottam b agrawal yogesh agrawal arvind agrawal vice chairman managing director chief financial officer madhusudan b agrawal rajesh agrawal gaurang shah mumbai 3rd may 2017 vice chairman joint managing director company secretary 71 annual report 201617 consolidated statement change equity year ended 31st march 2017 equity share capital cr change equity change equity balance balance 31 balance 31 share capital share capital 1 april 2015 march 2016 march 2017 year year authorised 3000 3000 3000 issued 1774 001 1775 1775 subscribed paid 1768 001 1769 1769 b equity cr particular item foreign share comprehensive capital security currency non general based retained income total redemption premium translation total controlling reserve payment earnings measurement gain equity reserve account reserve interest reserve loss defined benefit plan 1st april 2015 211 7571 65073 043 15777 88675 88675 profit period 41561 41561 41561 comprehensive 558 023 535 535 income total comprehensive income 41561 558 023 42096 42096 utilised bonus share 001 001 001 transfer general reserve 32182 32182 exercise stock option 028 028 share based payment 012 012 012 employee dividend paid 12322 12322 12322 dividend distribution tax 1184 1184 1184 reversal dividend paid 003 003 003 reversal dividend 038 038 038 distribution tax 31st march 2016 210 7599 97255 027 11690 558 023 117317 117317 profit period 50683 50683 50683 comprehensive 242 011 253 253 income total comprehensive income 50683 242 011 50430 50430 exercise stock option 007 007 share based payment 145 145 145 employee dividend paid 11441 11441 11441 dividend distribution tax 1450 1450 1450 31st march 2017 210 7606 97255 165 49482 316 034 154999 154999 see accompanying note forming part financial statement per report even date attached kapoor parekh associate behalf board director chartered accountant nilesh parekh mannalal b agrawal partner chairman purushottam b agrawal yogesh agrawal arvind agrawal vice chairman managing director chief financial officer madhusudan b agrawal rajesh agrawal gaurang shah mumbai 3rd may 2017 vice chairman joint managing director company secretary 72 plan prepare perform financial statement consolidated note consolidated financial statement year ended 31st march 2017 1 corporate information 3 basis consolidation ajanta pharma limited holding company consolidated financial statement comprise public limited company incorporated domiciled financial statement holding company india share listed bombay stock exchange wholly owned subsidiary disclosed note 43 national stock exchange registered office financial statement holding company holding company located ajanta house charkop wholly owned subsidiary consolidated kandivali west mumbai consolidated financial line line basis adding together book statement cf comprises company value like item asset liability income subsidiary referred collectively group expense eliminating intragroup balance intra group transaction unrealised profit resulting group engaged development manufacturing presented extent possible marketing speciality pharmaceutical quality manner group independent finished dosage financial statement statement profit loss component comprehensive income consolidated financial statement group attributed equity holder holding year ended 31st march 2017 authorised company group issue company board director 3rd may 2017 financial statement holding company wholly owned subsidiary consolidated 2 basis preparation using uniform accounting policy like transaction financial statement group event similar circumstance prepared accordance indian accounting necessary adjustment made financial standard indas notified company statement subsidiary bring accounting indian accounting standard rule 2015 amended policy line group accounting policy company indian accounting standard amendment rule 2016 financial statement subsidiary used consolidation drawn reporting financial statement group first ind date holding company ie year ended financial statement covered ind 101 first 31st march 2017 time adoption indian accounting standard 4 functional presentation currency period including year ended functional currency subsidiary company 31st march 2016 group prepared financial respective local currency financial statement statement accordance accounting presented indian rupee inr rupee standard notified section 133 r functional currency company act 2013 read together company holding company account rule 2014 previous gaap 5 rounding amount explanation transition indas amount disclosed financial statement affected group equity net profit provided note rounded nearest cr amount note 62 less 50000 shown actual financial statement prepared 6 current versus noncurrent classification accrual basis historical cost basis except asset liability balance sheet following asset liability presented based currentnoncurrent classification measured fair value revalued amount wherever applicable asset current expected realised intended sold derivative financial instrument consumed normal operating cycleor certain financial asset measured fair value held primarily purpose tradingor 73 annual report 201617 note consolidated financial statement year ended 31st march 2017 expected realised within twelve month capital workinprogress respect asset reporting period ready intended use cash cash equivalent unless restricted carried cost comprising direct cost related exchanged used settle liability incidental expense attributable interest least twelve month reporting period identifiable revenue expense including asset classified noncurrent interest incurred respect various project expansion net income earned liability current project development stage prior intended expected settled normal operating cycle use considered pre operative expense disclosed capital workinprogress held primarily purpose trading due settled within twelve month capital expenditure tangible asset research reporting period development classified property plant unconditional right defer equipment depreciated settlement liability least twelve month basis property plant equipment reporting period property plant equipment eliminated liability treated noncurrent financial statement either disposal retired active use loss arising deferred tax asset liability classified non case retirement property plant current asset liability respectively equipment gain loss arising disposal property plant equipment 7 significant accounting policy recognised statement profit loss 71 property plant equipment year occurrence freehold land carried historical cost item property plant equipment depreciation holding company stated cost less accumulated depreciation depreciable amount asset cost impairment loss asset amount substituted cost less estimated residual value property plant cost includes cost acquisition installation equipment provided written value construction direct expense incurred method useful life asset bring asset working condition specified schedule ii company act finance cost incurred date asset 2013 property plant equipment ready intended use excludes cenvat added disposed year depreciation value added tax eligible credit setoff provided prorata basis premium leasehold land amortised period cost includes cost replacing part lease building constructed leasehold land plant equipment borrowing cost depreciated based useful life specified longterm construction project recognition schedule ii company act 2013 criterion met significant part plant lease period land beyond life equipment required replaced building case building constructed interval depreciated separately leasehold land amortised primary based specific useful life likewise lease period land major inspection performed cost recognised carrying amount asset residual value useful life method plant equipment replacement depreciation reviewed financial year recognition criterion satisfied repair end adjusted prospectively appropriate maintenance cost recognised statement profit loss incurred 74 plan prepare perform financial statement consolidated note consolidated financial statement year ended 31st march 2017 asset carrying amount written life expected pattern consumption immediately recoverable amount future economic benefit embodied asset asset carrying amount greater considered modify amortisation period estimated recoverable amount method appropriate treated change accounting estimate depreciation subsidiary depreciation property plant equipment gain loss arising derecognition provided rate required permissible intangible asset measured difference gaap respective country net disposal proceeds management belief estimated useful carrying amount asset recognised life realistic reflect fair approximation statement profit loss asset period asset likely used derecognised vehicle acquired finance lease research development depreciated period lease agreement revenue expenditure research expensed useful life whichever shorter respective head account period incurred transition ind group elected continue carrying value development expenditure incurred property plant equipment recognised individual project carried forward 1st april 2015 measured per previous gaap future recoverability reasonably regarded use carrying value deemed cost assured expenditure carried forward property plant equipment amortised period expected future sale related project carrying 72 intangible asset value development cost reviewed intangible asset recognised impairment annually asset yet probable future economic benefit use otherwise event change attributable asset flow group circumstance indicate carrying value cost asset measured reliably may recoverable intangible asset stated cost acquisition transition ind group elected less accumulated amortisation impairment continue carrying value intangible loss asset recognised 1st april 2015 measured per previous gaap use carrying value internally generated intangible excluding deemed cost intangible asset capitalised development cost capitalised related expenditure reflected profit 73 financial instrument loss period expenditure financial instrument contract give incurred rise financial asset one entity financial liability equity instrument another entity software amortised estimated useful life straight line basis date financial asset available intended use subject impairment classification test group classifies financial asset subsequently measured amortised cost fair value amortisation period amortisation comprehensive income fair value method intangible asset finite profit loss basis business model useful life reviewed least end managing financial asset contractual reporting period change expected useful cash flow characteristic financial asset 75 annual report 201617 note consolidated financial statement year ended 31st march 2017 initial recognition measurement investment equity instrument financial asset recognised initially equity instrument held trading fair value plus case financial asset classified fvtpl equity instrument recorded fair value profit loss classified fvtoci fair value change transaction cost attributable instrument excluding dividend acquisition financial asset recognised comprehensive income recycling amount subsequent measurement comprehensive income profit loss purpose subsequent measurement financial asset classified two broad investment debt instrument category debt instrument measured amortised cost fvtoci debt instrument financial asset fair value fvtpl fvtoci meet criterion categorization amortized financial asset amortised cost cost fvoci classified fvtpl debt instrument included within fvtpl category asset measured fair value gain measured fair value change recognised loss either recognised statement statement profit loss profit loss ie fair value profit loss fvtpl recognised comprehensive derecognition financial asset income ie fair value comprehensive financial asset primarily derecognised income fvtoci right receive cash flow asset expired group transferred financial asset measured amortised cost net right receive cash flow asset write impairment financial asset measured amortised cost impairment financial asset asset held within business model accordance ind 109 group whose objective hold asset collecting applies expected credit loss ecl model contractual cash flow contractual term measurement recognition impairment loss asset give rise specified date cash flow financial asset debt instrument solely payment principal interest trade receivables financial asset subsequently measured amortised cost using effective interest rate financial liability eir method less impairment loss classification arising impairment recognised group classifies financial liability statement profit loss subsequently measured amortised cost fvtpl financial asset measured fair value initial recognition measurement comprehensive income fvtoci financial liability recognised initially financial asset category measured fair value case loan borrowing initially well reporting date fair payable net directly attributable value asset held within business model transaction cost whose objective hold asset collecting contractual cash flow selling financial asset financial liability include trade fair value movement recognized payable loan borrowing including bank comprehensive income overdraft derivative financial instrument financial asset measured fair value subsequent measurement profit loss fvtpl financial liability fair value profit financial asset category measured loss include financial liability held trading initially well reporting date fair financial liability designated upon initial value change recognised profit loss recognition fair value profit 76 plan prepare perform financial statement consolidated note consolidated financial statement year ended 31st march 2017 loss interestbearing loan borrowing slow nonmoving material obsolesces subsequently measured amortised cost using defective inventory fully provided effective interest rate eir method gain valued net realisable value loss recognised profit loss liability derecognised well eir good material transit valued amortisation process amortised cost calculated actual cost incurred date balance taking account discount premium sheet material item held use acquisition fee cost integral production inventory written part eir eir amortisation included finished product used finance cost statement profit loss expected sold cost derecognition financial liability 75 cash cash equivalent financial liability derecognised cash cash equivalent comprise cash obligation liability discharged hand cash bank including fixed deposithighly cancelled expires existing financial liquid investment original maturity period liability replaced another three month less readily convertible lender substantially different term term known amount cash subject existing liability substantially modified insignificant risk change value exchange modification treated derecognition original liability 76 cash flow statement recognition new liability difference cash flow reported using indirect method respective carrying amount recognised whereby net profit tax adjusted statement profit loss effect transaction noncash nature deferral accrual past future operating derivative financial instrument cash receipt payment item income group us derivative financial instrument expense associated investing financing forward currency contract mitigate cash flow cash flow operating foreign currency risk derivative financial investing financing activity group instrument initially recognised fair value segregated date derivative contract entered subsequently remeasured fair 77 foreign currency transaction value derivative carried financial asset revenue transaction denominated foreign fair value positive financial currency normally recorded exchange liability fair value negative rate prevailing date transaction 74 inventory monetary item denominated foreign currency raw material packing material valued yearend remeasured exchange lower cost net realisable value cost rate prevailing balance sheet date non includes duty tax net cenvat monetary foreign currency item carried cost vat wherever applicable cost imported raw material packing material lying bonded income expense account exchange warehouse includes custom duty finished difference either settlement restatement product including traded good workin recognised statement profit loss progress valued lower cost net realisable value cost arrived fifo basis 78 revenue recognition revenue recognised extent cost inventory computed probable economic benefit flow include cost purchase cost conversion group revenue reliably standard overhead related cost measured regardless payment incurred bringing inventory made present condition 77 annual report 201617 note consolidated financial statement year ended 31st march 2017 revenue measured fair value liability regard gratuity plan consideration received receivable amount determined actuarial valuation performed disclosed revenue inclusive excise independent actuary balance duty excluding sale tax value added tax sheet date using projected unit credit service tax duty collected behalf method government net return trade discount allowance rebate amount collected company fully contributes ascertained behalf third party liability ajanta pharma limited group gratuity trust trust trustee revenue sale good recognised administer contribution made trust significant risk reward transferred contribution invested scheme buyer per term contract life insurance corporation india significant uncertainty exists regarding amount permitted law india consideration derived sale good retirement benefit obligation recognised balance sheet represents present revenue sale technology know value defined benefit obligation right licence intangible reduced fair value scheme asset recognised performance obligation asset resulting calculation completed per term agreement limited present value available income service recognised refund reduction future contribution service rendered scheme company recognizes net obligation defined benefit plan dividend income recognised right balance sheet asset liability receive dividend established interest income actuarial gain loss recognised recognised time proportion basis insurance full comprehensive income claim recognised revenue period occur effect certainty receipt prudent basis export plan amendment recognized benefit available prevalent scheme statement profit loss accounted extent considered receivable ii defined contribution plan 79 employee benefit contribution defined contribution plan case holding company recognised expense employee employee benefit payable wholly within rendered service entitling twelve month rendering service classified benefit short term employee benefit benefit salary wage shortterm compensated absence company pay provident fund performance incentive etc expected cost contribution publicly administered bonus exgratia recognised period provident fund per local regulation employee render related service company payment obligation contribution paid defined benefit plan contribution accounted defined company provides gratuity defined contribution plan contribution benefit retirement plan gratuity plan recognized employee benefit expense covering eligible employee gratuity due prepaid contribution plan provides lumpsum payment recognized asset extent vested employee retirement death cash refund reduction future incapacitation termination employment payment available amount based respective employee salary tenure employment company 78 plan prepare perform financial statement consolidated note consolidated financial statement year ended 31st march 2017 iii compensated absence subject provision republic act company policy compensated 7641 retirement law absence accumulating nonaccumulating nature expected compensated absence cost accumulating compensated absence compensated absence recognized determined actuarial valuation performed number paid leave day remaining independent actuary balance end reporting period sheet date using projected unit credit method included salary wage account additional amount expected paid recognized availed availed result unused entitlement employee accumulated balance sheet date 710 borrowing cost borrowing cost directly attributable compensated absence acquisition construction production asset expected occur within twelve month necessarily take substantial period time end period employee get ready intended use sale capitalised render related service recognised part cost asset borrowing liability present value defined cost expensed period benefit obligation balance sheet date occur borrowing cost consist interest cost entity incurs connection expense nonaccumulating compensated borrowing fund borrowing cost also includes absence recognized period exchange difference extent regarded absence occur adjustment borrowing cost iv sharebased compensation 711 lease company recognizes compensation determination whether arrangement expense relating sharebased payment contains lease based substance net profit using fairvalue accordance arrangement inception date whether ind 102 sharebased payment fulfilment arrangement dependent use specific asset asset arrangement case subsidiary mauritius conveys right use asset even right employee covered explicitly specified arrangement pension plan net present value severance allowance payable employment asset acquired lease significant right act 2008 provided obligation portion risk reward ownership arising item funded retained lessor classified operating lease lease rental charged case subsidiary philippine statement profit loss straight line basis shortterm benefit company recognizes liability net finance lease transfer substantially amount already paid expense risk benefit incidental ownership service rendered employee leased item capitalised accounting period short term benefit given commencement lease fair value company employee include salary leased property lower present wage social security contribution short value minimum lease payment lease term compensated absence bonus payment apportioned finance nonmonetary benefit charge reduction lease liability achieve constant rate interest postemployment benefit remaining balance liability finance company formal charge recognised finance cost retirement benefit plan however company statement profit loss 79 annual report 201617 note consolidated financial statement year ended 31st march 2017 leased asset depreciated useful life deferred income tax asset liability asset however reasonable measured using respective country tax certainty group obtain ownership rate tax law enacted end leased term asset depreciated substantively enacted balance sheet date shorter estimated useful life expected apply taxable income asset leased term year temporary difference expected recovered settled effect 712 earnings per share change tax rate deferred income tax basic earnings per equity share computed asset liability recognized income dividing net profit attributable equity expense period includes enactment holder company weighted average substantive enactment date deferred number equity share outstanding income tax asset recognized extent period diluted earnings per equity share probable future taxable profit computed dividing net profit attributable available deductible temporary equity holder company weighted difference tax loss utilized average number equity share considered group offset current tax asset current tax deriving basic earnings per equity share also liability legally enforceable right weighted average number equity share set recognized amount could issued upon conversion intends either settle net basis realize dilutive potential equity share dilutive asset settle liability simultaneously potential equity share adjusted proceeds receivable equity share deferred income tax provided actually issued fair value dilutive potential equity undistributed earnings subsidiary share deemed converted beginning expected earnings subsidiary period unless issued later date distributed foreseeable future dilutive potential equity share determined independently period presented 714 dividend shareholder annual dividend distribution shareholder 713 income tax recognised liability period income tax expense comprises current dividend approved shareholder deferred income tax interim dividend paid recognised approval board director dividend payable income tax expense recognized net profit corresponding tax dividend distribution statement profit loss except recognised directly equity extent relates item recognized directly equity case recognized 715 provision contingent liability contingent comprehensive income current income tax asset commitment current prior period recognized general amount expected paid recovered provision recognised group tax authority using respective country present obligation legal constructive result tax rate tax law enacted past event probable outflow substantively enacted balance sheet date resource required settle obligation deferred income tax asset liability respect reliable estimate made recognized temporary difference arising tax base asset liability provision excluding retirement benefit carrying amount financial statement compensated absence discounted deferred tax asset reviewed reporting present value determined based best date reduced extent estimate required settle obligation longer probable related tax benefit balance sheet date reviewed realised balance sheet date adjusted reflect current best estimate 80 plan prepare perform financial statement consolidated note consolidated financial statement year ended 31st march 2017 expectation discounted current pretax rate reflects provision reimbursed reimbursement risk specific decommissioning liability recognised separate asset unwinding discount recognised reimbursement virtually certain income statement finance cost expense relating provision presented estimated future cost decommissioning statement profit loss net virtually reviewed annually adjusted appropriate certain reimbursement change estimated future cost discount rate applied added deducted effect time value money material cost asset provision discounted using current pre tax rate reflects appropriate risk 716 fair value measurement specific liability discounting used group measure financial instrument increase provision due passage derivative fair value balance sheet time recognised finance cost date accordance ind 113 contingent liability disclosed case financials statement prepared historical cost basis except following present obligation arising past event material item statement financial probable outflow position resource required settle obligation derivative financial instrument measured present obligation arising past event fair value received bank reliable estimate possible mutual fund measured fair value possible obligation arising past event per net asset value nav unless probability outflow resource employee stock option plan esop fair remote value per actuarial valuation report contingent liability recognised fair value price would received financial statement contingent asset sell asset settle liability ordinary neither recognised disclosed financial transaction market participant statement measurement date commitment include amount purchase fair value asset liability measured order net advance issued party using assumption market participant completion asset noncancellable would use pricing asset liability operating lease assuming market participant act economic best interest provision contingent liability contingent asset commitment reviewed balance fair value measurement nonfinancial asset sheet date take account market participant ability generate economic benefit using asset asset retirement obligation highest best use selling another asset retirement obligation aro provided market participant would use asset operating lease arrangement highest best use company binding obligation end lease period restore leased premise group us valuation technique condition similar inception lease aro appropriate circumstance provided present value expected sufficient data available measure fair value cost settle obligation using discounted maximising use relevant observable input cash flow recognised part minimising use unobservable input cost particular asset cash flow 81 annual report 201617 note consolidated financial statement year ended 31st march 2017 asset liability fair value contains lease group separate measured disclosed financial statement payment consideration required categorised within fair value hierarchy arrangement lease described follows based lowest element basis level input significant fair value relative fair value measurement whole group determined based level 1 quoted unadjusted market price evaluation term condition active market identical asset arrangement contract liability nature operating lease level 2 valuation technique lowest level input significant fair b multiple element contract vendor value measurement directly indirectly group entered multiple element observable contract vendor supply good level 3 valuation technique rendering service consideration lowest level input significant fair paid ismay determined independent value measurement unobservable value supply received service availed accordingly supply service asset liability recognised accounted based relative financial statement recurring basis fair value overall consideration group determines whether transfer supply finite life contract occurred level hierarchy defined significant accounting policy assessing categorisation based lowest accounted property plant level input significant fair value equipment andor intangible asset measurement whole end since group economic ownership reporting period asset group belief current treatment represents substance purpose fair value disclosure arrangement company determined class asset liability basis nature characteristic c determination functional currency risk asset liability level entity group determines fair value hierarchy explained functional currency currency primary economic environment 717 critical accounting judgement estimate entity operates item included assumption financial statement entity preparation group financial statement measured using functional currency ind requires management make judgement 21 effect change foreign estimate assumption affect exchange rate prescribes factor reported amount revenue expense asset considered purpose determination liability disclosure contingent functional currency management us liability end reporting period judgement determine functional however uncertainty assumption currency faithfully represents estimate could result outcome economic effect underlying require material adjustment carrying transaction event condition amount asset liability future period property plant equipment arrangement containing lease determination estimated useful life inception arrangement tangible asset assessment group determines whether arrangement component cost may contains lease inception capitalized useful life tangible asset reassessment arrangement based life useful livesrates 82 plan prepare perform financial statement consolidated note consolidated financial statement year ended 31st march 2017 prescribed gaap respective amount timing future taxable income country assumption also need given wide range international business made company assesses whether relationship longterm nature asset may capitalised complexity existing contractual agreement component cost asset may difference arising actual result capitalised assumption made future change assumption could necessitate future e intangible asset adjustment tax income expense internal technical user team assess already recorded group establishes remaining useful life intangible asset provision based reasonable estimate management belief assigned useful possible consequence audit tax life reasonable authority respective country operates amount provision f recognition measurement defined based various factor experience benefit obligation previous tax audit differing interpretation obligation arising defined tax regulation taxable entity benefit plan determined basis responsible tax authority difference actuarial assumption key actuarial interpretation may arise wide variety assumption include discount rate trend issue depending condition prevailing salary escalation vested future benefit respective country life expectancy discount rate determined reference market yield deferred tax asset recognised end reporting period unused tax loss extent government bond period maturity probable taxable profit underlying bond correspond available loss probable maturity postemployment utilised significant management judgement benefit obligation required determine amount deferred tax asset recognised g recognition deferred tax asset based upon likely timing level income tax future taxable profit future tax planning deferred tax asset recognised strategy recent business performance deductible temporary difference development extent probable taxable profit available deductible h recognition measurement temporary difference utilised provision management assumes taxable profit recognition measurement available recognising deferred provision based assessment tax asset probability outflow resource past experience circumstance management judgment required known balance sheet date actual calculation provision income tax outflow resource future date may deferred tax asset liability therefore vary figure included company review balance sheet provision date carrying amount deferred tax asset factor used estimate may contingency differ actual outcome could lead management judgement required significant adjustment amount estimating possible outflow resource reported financial statement respect contingenciesclaim litigation group uncertainty exist respect possible predict outcome pending interpretation complex tax regulation matter accuracy 83 annual report 201617 note consolidated financial statement year ended 31st march 2017 j allowance uncollected account 718 recent accounting pronouncement receivable advance standard issued yet effective trade receivables carry interest march 2017 ministry corporate affair stated normal value issued company indian accounting reduced appropriate allowance standard amendment rule 2017 notifying estimated irrecoverable amount individual amendment ind 7 statement cash flow trade receivables written ind 102 sharebased payment management seems collectible amendment accordance recent impairment made expected credit amendment made international accounting loss present value standard board iasb ia 7 statement cash shortfall expected life cash flow ifrs 2 sharebased payment financial asset respectively amendment applicable group 1st april 2017 impairment provision financial asset based assumption risk amendment ind 7 statement cash flow default expected loss rate judgement amendment ind 7 requires entity making assumption selecting provide disclosure enable user financial input impairment calculation statement evaluate change liability based past history existing market arising financing activity including condition well forward looking estimate change arising cash flow noncash end reporting period change amendment effective annual period beginning 1st april k insurance claim 2017 application amendment result insurance claim recognised additional disclosure provided group company reasonable certainty recovery amendment ind 102 sharebased payment amendment ind 102 address three l impairment review main area effect vesting condition impairment exists carrying measurement cashsettled sharebased value asset cash generating unit payment transaction classification share cgu exceeds recoverable amount based payment transaction net settlement recoverable amount higher fair feature withholding tax obligation value less cost sell value use accounting modification term value use calculation based condition sharebased payment transaction discounted cash flow model calculating change classification cash settled value use certain assumption equity settled required made respect highly uncertain matter including management amendment effective annual expectation growth ebitda long term period beginning 1st april 2017 growth rate selection discount amendment expected impact rate reflect risk involved group 84 plan prepare perform financial statement consolidated note consolidated financial statement year ended 31st march 2017 8 property plant equipment capital workinprogress 81 current year cr gross block depreciation amortisation net block particular consolidation deduction consolidation deduction 1st april addition 31st march 1st april addition 31st march 31st march adjustment adjustment adjustment adjustment 2016 2017 2016 2017 2017 property plant equipment freehold land 14371 004 14367 14367 leasehold land 3121 3121 235 058 294 2827 leasehold improvement 119 004 116 074 002 002 074 041 building 14429 056 6759 21133 6110 008 807 6910 14223 plant equipment 26988 044 11791 1518 37217 11248 027 3940 1161 14001 23216 furniture fixture 5140 008 849 366 5616 3103 006 640 348 3389 2226 vehicle 1461 051 068 455 1024 981 034 116 330 733 290 office equipment 1915 015 442 304 2038 1410 013 308 289 1416 622 computer 1823 433 017 2239 1508 247 017 1738 501 total 69367 181 20344 2660 86870 24669 090 6119 2145 28554 58316 b intangible asset computer software 613 002 419 1030 237 002 195 430 600 anda development cost 1593 1593 1593 1593 total 2206 002 419 2623 1831 002 195 2023 600 total b 71573 183 20763 2660 89492 26500 091 6314 2145 30577 58915 c capital work progress including pre operative expense 8504 cr refer note 59 33803 intangible asset development 123 total b c 92840 addition includes 4577 cr used research development depreciation 193 cr considered preoperative expenditure refer note 59 8 property plant equipment capital workinprogress 82 previous year cr gross block depreciation amortisation net net block block particular consolidation addition deduction consolidation deduction 1st april 31st march 1st april addition 31st march 31st march 1st april adjustment adjustment adjustment adjustment 2015 2016 2015 2016 2016 2015 property plant equipment freehold land 1638 010 12723 14371 14371 1638 leasehold land 3121 3121 177 058 235 2886 2944 leasehold improvement 110 009 119 066 006 002 074 045 044 building 14198 117 114 14429 5343 003 764 6110 8319 8855 plant equipment 22899 116 7431 3458 26988 11518 069 2458 2797 11248 15740 11381 furniture fixture 4854 011 566 291 5140 2711 007 627 242 3103 2037 2143 vehicle 1344 021 117 020 1461 805 012 184 020 981 480 539 office equipment 1703 027 223 038 1915 1141 023 282 036 1410 505 562 computer 2340 273 790 1823 2068 208 768 1508 315 272 total 52207 311 21447 4598 69367 23829 120 4583 3863 24669 44698 28378 b intangible asset computer software 432 180 612 110 127 237 375 322 anda development cost 1593 1593 1593 1593 total 2025 180 2205 1703 127 1830 375 322 total b 54232 311 21628 4598 71572 25532 120 471 3863 26499 45073 28700 c capital work progress including pre operative expense 4089 cr refer note 59 23842 17020 intangible asset development 138 total b c 69052 45719 addition includes 4286 cr used research development depreciation 267 cr considered preoperative expenditure refer note 59 85 annual report 201617 note consolidated financial statement year ended 31st march 2017 9 non current financial investment cr 31 march 2017 31 march 2016 1 april 2015 long term trade investment unquoted investment investment share turkmenderman ajanta pharma ltd 200000 share u 10 fully paidup others opgs power gujarat private limited 195000 31st march 2016 nil 1st april 2015 nil share 019 cr yr 37050 31st march 2016 nil 1st april 2015 nil sub total b investment mutual fund quoted face value unit icici prudential fmp series 70367 10 572 day plan n regular plan cumulative 5000000 icici prudential fmp series 71369 10 562 day plan e regular plan cumulative 5000000 kotak fmp series 124 growth 10 575 5038705 hdfc fmp 372d october 2013 1 10 1139 series 28 regular growth 10000000 birla sun life fixed term plan 10 1126 series ja 366 day 10000000 idfc fixed term plan series 49 10 561 regular plangrowth 5000000 sub total b 4535 total b 4535 aggregate value quoted investment 4535 market value aggregate value unquoted investment figure bracket previous year 86 plan prepare perform financial statement consolidated note consolidated financial statement year ended 31st march 2017 10 non current financial asset others cr 31 march 2017 31 march 2016 1 april 2015 unsecured considered good security deposit 695 499 397 deposit account bank original maturity 12 month lien 135 327 430 others cy nil py 20000 010 interest accrued fixed deposit bank 100 101 087 930 927 923 11 defered tax asset net 31 march 2017 31 march 2016 1 april 2015 others 2445 858 506 2445 858 506 12 non current asset others 31 march 2017 31 march 2016 1 april 2015 capital advance 1393 1630 538 1393 1630 538 13 inventory 31 march 2017 31 march 2016 1 april 2015 raw material 5477 5849 5924 packing material 1997 2043 2340 workinprocess 1487 1158 1235 finished good 7786 8787 5380 stockintrade 4355 2621 1024 21102 20458 15903 includes transit stock finished good 2629 1320 850 includes transit stock stockintrade 014 016 87 annual report 201617 note consolidated financial statement year ended 31st march 2017 14 current financial investment cr 31 march 2017 31 march 2016 1 april 2015 investment fair value profit loss fvtpl mutual fund quoted face value unit bsl short term fund growth 10 15782029 5719 franklin india low duration fund growth 10 42773165 7897 birla sun life cash plus daily dividend 100 014 14007 franklin india short term income plan 10 59811 2025 reliance regular saving fund debt plan g 10 6685326 1515 sbi magnum insta cash fund daily dividend 10 59711 1000 utitreasury advantage 1000 1611 fundinstitutional plan 160730 icici prudential fmp series 70367 day 10 620 plan n regular plan cumulative 5000000 icici prudential interval annual plan 10 397 378 iii regular growth 2480000 2484343 icici prudential fmp series 71368 day 10 610 plan regular plan cumulative 5000000 kotak fmp series 124 growth 10 621 5038705 hdfc fmp 372d october 2013 1 series 10 1234 28 regular growth 10000000 birla sun life fixed term plan series 10 1222 ja 366 day 88 plan prepare perform financial statement consolidated note consolidated financial statement year ended 31st march 2017 14 current financial investment contd cr 31 march 2017 31 march 2016 1 april 2015 10000000 idfc fixed term plan series 49 10 608 regular plangrowth 5000000 birla sun life dynamic bond 10 1335 fund retail growth 5067712 sbi dynamic bond fund 10 1017 regular plan growth 5610098 18156 7678 1989 aggregate value quoted investment 18156 7678 1989 market value figure bracket previous year 15 trade receivables cr 31 march 2017 31 march 2016 1 april 2015 trade receivables considered good 32184 37235 25876 doubtful debt 490 allowance doubtful debt 490 32184 37235 25876 16 cash cash equivalent 31 march 2017 31 march 2016 1 april 2015 balance bank current account 7961 5287 4523 cash hand 009 014 011 deposit account original maturity 3 month less 915 bank overdraft used cash management purpose 2778 1159 1282 5192 4143 4167 89 annual report 201617 note consolidated financial statement year ended 31st march 2017 17 bank balance cash cash equivalent cr 31 march 2017 31 march 2016 1 april 2015 earmarked balance bank unpaid dividend 095 073 030 unpaid sale proceeds fractional share 038 cy 5926 31st march 2016 6240 deposit account original maturity 3 month 002 4000 upto 12 month deposit account original maturity 12 month lien 315 115 060 others 007 4099 412 195 8227 18 current financial asset others 31 march 2017 31 march 2016 1 april 2015 interest receivable 047 025 519 forward contract 077 046 393 124 071 912 19 current tax asset net 31 march 2017 31 march 2016 1 april 2015 income tax paid net provision 1123 1764 1123 1764 20 current asset 31 march 2017 31 march 2016 1 april 2015 balance statutorygovt authority excise authority 4070 2850 3012 vat receivable 398 375 232 octroi refund receivable 052 052 052 prepaid expense 289 182 018 advance supplier 375 275 766 advance employee 330 362 323 advance recoverable cash kind 854 688 642 6368 4784 5046 90 plan prepare perform financial statement consolidated note consolidated financial statement year ended 31st march 2017 21 share capital 31 march 2017 31 march 2016 1 april 2015 cr cr cr share fv 2 share fv 2 share fv 2 authorised equity share 150000000 3000 150000000 3000 150000000 3000 issued equity share 88771500 1775 88767750 1775 88710000 1774 subscribed paidup equity share fully paid 88005000 1760 88001250 1760 87943500 1759 add share forfeited amount 766500 009 766500 009 766500 009 originally paid 1769 1769 1768 211 reconciliation number equity share outstanding beginning end year 31 march 2017 31 march 2016 1 april 2015 cr cr cr share fv 2 share fv 2 share fv 2 equity share outstanding 88001250 1760 87943500 1759 87876750 1758 beginning year add equity share allotted 2500 38500 001 44500 001 year option excercised esop cr yr 5000 add equity share allotted 1250 19250 22250 year bonus esop cr yr 2500 31st march 2016 38500 1st april 2015 44500 less equity share bought back year equity share outstanding 88005000 1760 88001250 1760 87943500 1759 end year 212 termsrights attached equity share company one class equity share voting right par value 2 per share company declares pay dividend indian rupee interim dividend paid recognised approval board director year ended 31st march 2017 amount dividend per equity share recognised distribution equity shareholder 13 pr yr 14 includes interim dividend 13 pr yr 8 per equity share event liquidation company holder equity share entitled receive remaining asset company distribution preferential amount distribution proportion number equity share held shareholder 91 annual report 201617 note consolidated financial statement year ended 31st march 2017 213 detail equity share held shareholder holding 5 31 march 2017 31 march 2016 1 april 2015 name shareholder share holding share holding share holding fv 2 fv 2 fv 2 mr yogesh agrawal trustee yogesh agrawal trust 12749999 1449 mr rajesh agrawal trustee rajesh agrawal trust 12749999 1449 mr ravi p agrawal trustee ravi agrawal trust 12659999 1439 mr aayush agrawal trustee aayush agrawal trust 12660000 1439 gab investment private limited 8392262 954 8392262 954 8392263 954 ganga export represented 5137500 584 mr yogesh agrawal mr rajesh agrawal mr ravi p agrawal mr aayush agrawal mr yogesh agrawal na na 6383560 725 6383560 726 mr rajesh agrawal na na 6411102 729 6411102 729 mr mannalal b agrawal 5406720 614 5406720 615 mr purushottam b agrawal 5389425 612 5389425 613 mr madhusudan b agrawal 5388750 612 5388750 613 mr manisha agrawal mr richa r agrawal 5137500 584 mr aayush agrawal mr vimal agrawal mr mamta agrawal 5137500 584 31 march 2017 31 march 2016 1 april 2015 share share share fv 2 fv 2 fv 2 214 equity share reserved issuance employee stock option scheme 2011 company equity share 1158750 1162500 1220250 215 aggregate number equity share issued last five year pursuant employee stock option scheme equity share 170250 166500 108750 216 equity share allotted fully paid bonus share period five year immediately preceding balance sheet date bonus share issued fy 201314 29292250 29292250 29292250 bonus share allotment esop fy 201415 22250 22250 22250 bonus share allotment esop fy 201516 19250 19250 bonus share allotment esop fy 201617 1250 217 company subsidiary company 92 plan prepare perform financial statement consolidated note consolidated financial statement year ended 31st march 2017 22 non current financial liability borrowing cr 31 march 2017 31 march 2016 1 april 2015 term loan secured bank foreign currency 473 2232 vehicle loan secured bank foreign currency 104 106 099 loan unsecured deferred sale tax loan government maharashtra 908 995 104 1487 3325 221 term loan secured first charge property plant equipment company second charge entire current asset company present future pari passu basis addition personal guarantee director 222 vehicle loan secured vehicle acquired scheme repayble equal monthly instalment upto 31st december 2020 rate interest 7 pa pryr 7 pa 23 non current financial liability 31 march 2017 31 march 2016 1 april 2015 trade security deposit payable 009 046 250 009 046 250 24 non current provision 31 march 2017 31 march 2016 1 april 2015 provision employee benefit net gratuity 066 leave benefit 315 259 410 315 259 476 25 deferred tax liability net 31 march 2017 31 march 2016 1 april 2015 difference tax base property plant equipment 3936 2951 1684 unrealised gainloss security carried fvocifvtpl b 205 deferred tax asset mat credit entitlement c 565 unabsorbed loss 416 120 disallowance income tax e 637 607 392 deferred tax liability net ab cd e 2734 1929 1378 93 annual report 201617 note consolidated financial statement year ended 31st march 2017 26 current financial liability borrowing cr 31 march 2017 31 march 2016 1 april 2015 working capital loan repayable demand bank secured rupee loan 553 995 508 foreign currency loan 2452 working capital loan repayable demand bank unsecured foreign currency loan 1178 553 4625 508 261 working capital loan secured first charge current asset second charge property plant equipment company pari passu basis addition personal guarantee director 27 current financial liability trade payable 31 march 2017 31 march 2016 1 april 2015 trade payable 13957 14557 10906 13957 14557 10906 28 current financial liability 31 march 2017 31 march 2016 1 april 2015 current maturity longterm borrowing secured refer note 221 222 foreign currency term loan bank 1893 1786 rupee term loan bank 200 vehicle loan 024 044 054 unsecured deferred sale tax loan 086 083 unpaid dividend 095 073 029 unpaid sale proceeds fractional share 038 interest accrued 002 002 capital creditor 2429 1938 2077 others 005 015 017 2552 4051 4286 amount due outstanding credited investor education protection fund 31st march 2017 29 current liability 31 march 2017 31 march 2016 1 april 2015 payable advance received customer 283 422 432 statutory due payable 507 639 352 others 3209 560 763 3999 1621 1547 94 plan prepare perform financial statement consolidated note consolidated financial statement year ended 31st march 2017 30 current provision cr 31 march 2017 31 march 2016 1 april 2015 provision employee benefit net gratuity 307 298 247 leave benefit 073 070 076 provision sale return expired good refer note 51 900 767 645 1280 1135 968 31 current tax liability net 31 march 2017 31 march 2016 1 april 2015 provision tax net payment 256 256 32 revenue operation 31 march 2017 31 march 2016 sale product finished good 160632 126974 stockintrade 32629 45713 operating revenue export incentive 6683 2000 royalty fee 190 others 220 060 200164 174937 33 income 31 march 2017 31 march 2016 exchange difference net 813 dividend investment fvtpl 067 255 gain financial instrument fvtpl 1683 545 interest deposit bank 054 323 interest others 185 029 miscellaneous income 397 150 2386 2115 34 cost material consumed 31 march 2017 31 march 2016 raw material consumed 28584 30359 packing material consumed 9201 9650 37785 40009 95 annual report 201617 note consolidated financial statement year ended 31st march 2017 35 purchase stockintrade cr 31 march 2017 31 march 2016 purchase stockintrade 4736 6301 36 change inventory finished good workinprogress stockintrade 31 march 2017 31 march 2016 inventory beginning year workinprocess 1158 1235 finished good 8787 5380 stockintrade 2621 1024 12566 7639 inventory end year workinprocess 1487 1158 finished good 7786 8787 stockintrade 4355 2621 b 13628 12566 total change inventory finished good workinprogress b 1062 4927 stockintrade 37 empolyee benefit expense 31 march 2017 31 march 2016 salary wage bonus allowance 27345 23818 expense employee stock option scheme 145 031 contribution provident fund 1722 1542 staff welfare expense 331 273 29542 25664 38 finance cost 31 march 2017 31 march 2016 interest expense 124 250 borrowing cost including bank charge 226 239 349 489 39 depreciation 31 march 2017 31 march 2016 depreciation tangible asset refer note 8 5926 4317 depreciation intangible asset refer note 8 195 127 6121 4443 96 plan prepare perform financial statement consolidated note consolidated financial statement year ended 31st march 2017 40 expense cr 31 march 2017 31 march 2016 selling expense 20468 17975 clearing forwarding 6266 5461 travelling expense 3649 3537 processing charge 1734 1741 power fuel 1870 1549 advertisement publicity 358 1156 consumption store spare part 5599 3618 rent 703 906 rate tax 054 039 legal professional fee 1393 1025 postage telephone expense 680 663 repair maintenance building 419 586 plant machinery 1785 1152 computer others 532 693 insurance 559 454 donation 006 003 exchange difference net 1243 impairment loss financial asset 2327 095 excise duty collected sale 1838 1539 loss salediscard property plant equipment net 389 692 corporate social responsibility expense refer note 50 893 639 miscellaneous expense 7499 5661 60262 49184 41 capital management group policy maintain strong capital base maintain investor creditor market confidence sustain future development business management monitor return capital well level dividend equity shareholder board director seek maintain balance higher return might possible higher level borrowing advantage security afforded sound capital position group target achieve return capital 35 201617 return 41 201516 return 44 group monitor capital using ratio adjusted net debt adjusted equity purpose adjusted net debt defined total liability comprising interestbearing loan borrowing obligation finance lease less cash cash equivalent short term investment adjusted equity comprises component equity group policy keep ratio 100 adjusted net debt equity ratio 31st march 2017 follows cr particular 31 march 2017 31 march 2016 1 april 2015 debt debt current liability 22446 27476 21796 less cash cash equivalent current investment 23348 11821 6156 net debt 902 15655 15640 equity b 156768 119086 90443 net debt equity ratio ab 013 018 97 annual report 201617 note consolidated financial statement year ended 31st march 2017 42 earnings per share eps numerator denominator used calculate basic diluted earnings per share particular 31 march 2017 31 march 2016 basic diluted earnings per share profit attributable equity shareholder basic eps cr 50683 41561 add dilutive effect profit cr b nil nil profit attributable equity shareholder computing diluted eps cr cab 50683 41561 weighted average number equity share outstanding basic eps 88004688 87996438 add dilutive effect option outstanding number equity share e 24466 6738 weighted average number equity share diluted eps fde 88029153 88003176 face value per equity share 2 2 basic earnings per share ad 5759 4723 diluted earnings per share cf 5758 4723 account employee stock option scheme esos refer note 45 43 consolidated financial statement present consolidated account holding company following subsidiary company 431 detail subsidiary group country voting power name company incorporation held 31 march 2017 ajanta pharma mauritius ltd apml mauritius 100 ajanta pharma mauritius intl ltdapmil wholly owned subsidiary apml mauritius 100 ajanta pharma usa inc apui usa 100 ajanta pharma philippine inc appi philippine 100 ajanta pharma uk ltd ap uk england wale 100 ajanta pharma nigeria ltd apnl nigeria 100 432 financial statement subsidiary used consolidation period 1st april 2016 31st march 2017 433 financial statement information subsidiary audited auditor 434 ajanta pharma uk ltd wholly owned subsidiary incorporated 30th november 2010 however transaction 31st march 2017 44 employee benefit respect holding company required ind 19 employee benefit disclosure 441 defined contribution plan company offer employee defined contribution plan form provident fund pf employee pension scheme eps government certain state plan employee state insurance esi pf eps cover substantially regular employee esi cover certain employee contribution made government fund employee company pay predetermined contribution provident fund esi scheme contribution pension fund made company 98 plan prepare perform financial statement consolidated note consolidated financial statement year ended 31st march 2017 contribution normally based certain proportion employee salary year company recognised following amount account cr particular 31 march 2017 31 march 2016 provident fund employee pension scheme 1348 1143 employee state insurance 163 181 total 1511 1324 442defined benefit plan gratuity company make annual contribution employee group gratuitycum life assurance cash accumulation scheme lic funded defined benefit plan qualifying employee scheme provides payment vested employee 4421 normal retirement early retirement withdrawal resignation per provision payment gratuity act 1972 vesting period 5 year service 4422 death service per provision payment gratuity act 1972 without vesting period death benefit company provides death benefit defined benefit plan death benefit plan certain category employee death benefit plan provides lump sum payment vested employee death compensation received insurance company restricted limit set forth said plan death benefit plan nonfunded isclosures defined benefit plan ie gratuity funded plan based actuarial report 31st march 2017 cr particular 31 march 2017 31 march 2016 change defined benefit obligation opening defined benefit obligation 1431 1137 current service cost 300 256 interest cost 105 082 actuarial loss gain change financial assumption 008 034 experience adjustment 006 075 benefit paid 178 085 closing defined benefit obligation 1660 1431 ii change value plan asset opening value plan asset 1132 824 expense deducted fund 010 adjustment opening fund 002 interest income 093 068 return plan asset excluding amount included interest income 015 006 contribution employer 320 327 benefit paid 178 085 closing value plan asset 1352 1132 iii amount recognized balance sheet present value funded obligation year end 1660 1431 fair value plan asset year end 1352 1132 net asset liability recognised year end 308 299 99 annual report 201617 note consolidated financial statement year ended 31st march 2017 cr particular 31 march 2017 31 march 2016 iv expense recognised statement profit loss current service cost 300 256 net interest cost 012 014 expense deducted fund 010 adjustment opening fund 002 expense recognised statement comprehensive income net actuarial lossgain recognized current year change financial assumption 008 034 experience adjustment 006 075 return plan asset excluding amount included interest income 015 006 v asset information others policy insurance 100 100 vi principal actuarial assumption used discount rate pa 720 795 salary growth rate pa 530 600 sensitivity analysis reasonably possible change reporting date one relevant actuarial assumption holding assumption constant would affected defined benefit obligation amount shown cr 31 march 2017 31 march 2016 increase decrease increase decrease discount rate 05 movement 1581 1744 1366 1501 salary growth rate 05 movement 1741 1583 1500 1367 although analysis take account full distribution cash flow expected plan provide approximation sensitivity assumption estimate future increase compensation level considered actuarial valuation taken account inflation seniority promotion relevant factor supply demand employment market expected contribution defined benefit plan next financial year line fy 201617 443 leave encashment holding company employee entitled compensated absence allowed accumulated encashed per company rule liability compensated absence nonfunded provided based report independent actuary using projected unit credit method accordingly 387 cr pr yr 329 cr liability yearend compensated absence per actuarial valuation provided account employee retirement benefit obligation respect subsidiary mauritius employee covered pension plan net present value severance allowance payable provided 003 cr pr yr 005 cr employee retirement benefit obligation respect subsidiary philippine short term benefit includes salary wage government contribution due within 12 month end period employee render related service company short term employee benefit amounted 1158 cr pr yr 1022 cr company yet set retirement plan since ten employee served least five year 100 plan prepare perform financial statement consolidated note consolidated financial statement year ended 31st march 2017 45 share based payment holding company implemented employee stock option scheme 2011 esos 2011 approved shareholder compensation committee board director year 15500 option granted company aforesaid esos 2011 employee company grant date option exercise price vesting period 26 july 2016 15500 2 13082017 13082019 option granted exercise price accordance relevant sebi guideline force time grant option entitles holder exercise right apply seek allotment one equity share 2 particular option esos 2011 31 march 2017 31 march 2016 particular no no option outstanding beginning year 12750 91500 add option granted year 15500 9000 less option exercised year 3750 57750 less option lapsed year nil 30000 option outstanding year end 24500 12750 46 financial instrument fair value risk management fair value measurement cr financial instrument category 31 march 2017 31 march 2016 1 april 2015 amortised amortised amortised fvtpl fvtpl fvtpl cost cost cost financial asset forward exchange contract 077 046 393 investment mutual fund 18156 7678 6524 trade receivables 32184 37235 25876 non current financial asset 929 926 923 others cash cash equivalent 5192 4142 4167 bank balance cash 412 195 8227 cash equivalent interest receivable 047 025 519 total financial asset 18233 38764 7724 42523 6917 39712 financial liability borrowing 681 8137 5955 non current financial 009 046 250 liability capital creditor 2429 1938 2077 current financial liability 100 090 087 trade payable 13957 14557 10906 total financial liability 17176 24768 19275 101 annual report 201617 note consolidated financial statement year ended 31st march 2017 fair value hierarchy cr financial asset liability 31 march 2017 31 march 2016 1 april 2015 measured fair value level level level ii iii ii iii ii iii financial asset recurring fair value measurement forward exchange contract 077 046 393 investment mutual fund 18156 7678 6524 non recurring fair value measurement trade receivables 32184 37235 25876 non current financial asset 929 926 923 others cash cash equivalent 5192 4142 4167 bank balance cash 412 195 8227 cash equivalent interest receivable 047 025 519 total financial asset 18156 077 38764 7678 046 42523 6524 393 39712 financial liability borrowing 681 8137 5955 non current financial 009 046 250 liability capital creditor 2429 1938 2077 current financial liability 100 090 087 trade payable 13957 14557 10906 total financial liability 17176 24768 19275 level 1 hierarchy level 1 includes financial instrument measured using quoted price includes mutual fund quoted price mutual fund valued using closing nav level 2 fair value financial instrument traded active market like forward contract determined using valuation technique maximise use observable market data rely little possible entityspecific estimate significant input required fair value instrument observable instrument included level 2 level 3 one significant input based observable market data instrument included level 3 case unlisted equity security etc included level 3 financial risk management framework management responsible group exposure following risk arising developing monitoring company financial instrument risk management policy credit risk guidance audit committee liquidity risk market risk group risk management policy established identify analyse risk risk management framework faced set appropriate risk limit group board director overall control monitor risk adherence responsibility establishment limit risk management policy system oversight company risk management reviewed regularly reflect change 102 plan prepare perform financial statement consolidated note consolidated financial statement year ended 31st march 2017 market condition group activity based internal rating criterion group training procedure deviation credit limit require aim maintain disciplined constructive approval director 90 control environment employee customer transacting understand role obligation group 4 year monitored individual group audit committee oversees business manager located management monitor compliance countriesplaces outstanding customer group risk management policy receivables regularly monitored procedure review adequacy company concentration risk management framework relation credit risk customer base risk faced group audit widely distributed economically committee assisted oversight role geographically internal audit internal audit undertakes regular ad hoc review risk 31st march 2017 group management control procedure 53 customer 31st march 2016 61 result reported audit customer 1st april 2015 51 customer committee owed company 050 cr accounted ii credit risk approximately 50 3 year credit risk risk counter party ie 31st march 2017 31st march 2016 meet obligation financial 1st april 2015 receivables instrument customer contract leading outstanding financial loss group exposed credit risk operating activity primarily impairment analysis performed trade receivables financing reporting date individual activity including deposit bank basis major client addition mutual fund foreign exchange transaction large number minor receivables financial instrument grouped homogenous group assessed impairment collectively trade receivables calculation based historical customer credit risk managed data maximum exposure credit business unit subject risk reporting date carrying group established policy procedure value class financial asset control relating customer credit group hold collateral risk management trade receivables security group evaluates noninterest bearing concentration risk respect mainly stockist distributor trade receivables low customer customer generally 14 located several jurisdiction day 150 day credit term credit operate largely independent market limit established customer expected credit loss trade receivables simplified approach cr 31 march 2017 31 march 2016 1 april 2015 gross carrying amount 32674 37235 25876 average expected loss rate 150 000 000 carrying amount trade receivables net impairment 32184 37235 25876 103 annual report 201617 note consolidated financial statement year ended 31st march 2017 b financial instrument optimising return financial instrument holding company limit exposure affected market risk include loan credit risk investing liquid debt borrowing deposit investment security issued mutual fund derivative financial instrument credit ranking atleast 3 crisil equivalent rating agency group activity expose variety holding company monitor change financial risk including effect credit risk tracking published external change foreign currency exchange credit ranking based ongoing rate interest rate group us assessment counterparty risk derivative financial instrument holding company adjusts exposure foreign exchange contract manage various counterparties exposure foreign exchange fluctuation investment subsidiary transaction carried within company guideline set risk management committee iii liquidity risk liquidity risk risk group may sensitivity analysis prepared able meet present future cash basis amount net debt collateral obligation without incurring ratio fixed floating interest rate unacceptable loss group objective debt derivative proportion time maintain optimum level financial instrument foreign currency liquidity meet cash collateral constant requirement group closely monitor liquidity position deploys robust cash analysis excludes impact management system maintains adequate movement market variable source financing including bilateral loan carrying value postemployment benefit debt overdraft bank optimised obligation provision non cost working capital requirement financial asset liability adequately addressed internally generated fund trade receivables kept within sensitivity relevant income manageable level statement item effect assumed change respective market risk group aim maintain level cash based financial asset financial cash equivalent highly liability held 31st march 2017 31st marketable debt investment amount march 2016 excess expected cash outflow financial liability next six month currency risk ratio cash cash equivalent group exposed currency risk highly marketable debt investment extent mismatch current liability 103 31st march 2017 31st currency march 2016 043 1st april 2015 028 sale purchase borrowing denominated respective iv market risk functional currency group market risk risk change currency market price foreign exchange transaction primarily denominated rate interest rate equity price u dollar euro mauritian rupee affect group income value philippine peso nigerian naira holding financial instrument objective market risk management point time group manage control market risk exposure cover foreign currency risk taking within acceptable parameter appropriate percentage foreign 104 plan prepare perform financial statement consolidated note consolidated financial statement year ended 31st march 2017 currency exposure approved risk management committee line laid policy approved board group us forward exchange contract mitigate currency risk maturity less one year reporting date respect monetary asset liability denominated foreign currency group policy ensure net exposure kept acceptable level buying selling foreign currency spot rate necessary address shortterm imbalance following table analysis foreign currency risk 31st march 2017 cr particular u euro mauritian philippine nigerian total dollar rupee peso niara bank balance 4475 067 935 260 603 6340 trade receivables 19370 413 2837 3691 275 26586 asset 125 546 440 314 049 1474 trade payable 2089 257 511 760 nil 3617 borrowing financial liability 083 199 nil 128 812 1222 net asset liability 21797 570 3700 3377 115 29560 following table analysis foreign currency risk 31st march 2016 cr particular u euro mauritian philippine nigerian total dollar rupee peso niara bank balance 2590 011 367 959 524 4451 trade receivables 26734 711 2250 3156 331 33182 asset 569 594 353 203 006 1725 trade payable 792 205 091 621 nil 1709 borrowing financial liability 4881 471 1179 150 174 6855 net asset liability 24221 640 1700 3547 687 30795 following table analysis foreign currency risk 1st april 2015 cr particular u euro mauritian philippine nigerian total dollar rupee peso niara bank balance 1070 020 2564 428 007 4089 trade receivables 16050 915 517 2470 108 20061 asset 470 341 342 185 015 1353 trade payable 859 066 097 564 nil 1585 borrowing financial liability 4473 044 nil 153 007 4677 net asset liability 12258 1167 3326 2367 124 19241 105 annual report 201617 note consolidated financial statement year ended 31st march 2017 year ended 31st march 2017 every percentage point depreciation appreciation exchange rate indian rupee respective currency affected company incremental profit tax per cr particular change effect profit currency tax exchange rate u dollar usd 1 1 218 218 euro 1 1 006 006 mauritian rupee mur 1 1 037 037 philippine peso php 1 1 038 038 nigerian niara nn 1 1 001 001 year ended 31st march 2016 every percentage point depreciation appreciation exchange rate indian rupee respective currency affected company incremental profit tax per cr particular change effect profit currency tax exchange rate u dollar usd 1 1 242 242 euro 1 1 006 006 mauritian rupee mur 1 1 017 017 philippine peso php 1 1 035 035 nigerian niara nn 1 1 007 007 year ended 1st april 2015 every percentage point depreciation appreciation exchange rate indian rupee respective currency affected company incremental profit tax per cr particular change effect profit currency tax exchange rate u dollar usd 1 1 123 123 euro 1 1 012 012 mauritian rupee mur 1 1 033 033 philippine peso php 1 1 024 024 nigerian niara nn 1 1 001 001 b interest rate risk interest rate risk risk fair value future cash flow financial instrument fluctuate change market interest rate group exposure risk change market interest rate relates primarily group debt interest obligation group engages financing activity market linked rate change interest rate environment may impact future rate borrowing 106 plan prepare perform financial statement consolidated note consolidated financial statement year ended 31st march 2017 interest rate profile group interest bearing financial instrument reported management follows cr particular 31 march 2017 31 march 2016 1 april 2015 foreign currency term loan 128 2517 4170 foreign currency packing credit nil 3630 nil total 128 6147 4170 reasonably possible change 100 basis point interest rate reporting date would impacted profit tax per analysis assumes variable particular foreign currency exchange rate remain constant cr particular 31 march 2017 31 march 2016 1 april 2015 increase interest rate 1 001 061 042 decrease interest rate 1 001 061 042 c price risk group exposure price risk equity investment group 47 disclosure operating lease ind 17 lease holding company subsidiary company taken various premise operating lease generally cancellable range 11 month 5 year renewable mutual consent mutually agreeable term lease agreement price escalation clause restriction imposed lease arrangement sub lease contingent rent lease payment 703 cr pr yr 906 cr recognised statement profit loss rent note 40 future minimum lease payment payment profile noncancellable operating lease cr particular 31 march 2017 31 march 2016 later one year 329 610 later one year later five year 493 905 less five year nil nil finance lease cr total minimum future present value particular lease payment interest minimum lease outstanding outstanding payment within one year 024 nil 024 044 nil 044 later one year later five year 104 nil 104 106 nil 106 figure bracket indicate previous year figure future obligation towards lease rental lease agreement 31st march 2017 amount 950 cr pr yr 1665 cr 107 annual report 201617 note consolidated financial statement year ended 31st march 2017 48 contingent liability commitment contingent liability cr particular 31 march 2017 31 march 2016 claim company acknowledged debt 090 070 ii sale tax demand disputed company pending appeal nil 022 iii custom duty import advance license scheme pending fulfilment 144 076 export obligation iv disputed octroi 052 052 amount paid protest 052 cr pr yr 052 cr v excise duty service tax disputed company 264 054 amount paid protest 025 cr pr yr 025 cr vi income tax demand disputed company pending appeal 833 1752 amount paid protest 786 cr pr yr 217 cr respect clause vi management advised demand likely either deleted substantially reduced accordingly provision considered necessary future cash outflow respect liability clause dependent term agreed upon party respect clause ii vi dependent decision relevant authority respective dispute commitment estimated amount contract remaining executed capital account provided net advance 13228 cr pr yr 10366 cr b commitment noncancellable operating lease refer note 47 49 related party disclosure required ind 24 given relationship category director key management personnel relative mr mannalal b agrawal chairman mr purushottam b agrawal executive vice chairman mr madhusudan b agrawal executive vice chairman mr yogesh agrawal managing director mr rajesh agrawal joint managing director mr chandrakant khetan nonexecutive director dr anil kumar nonexecutive director mr k h viswanathan nonexecutive director mr prabhakar dalal nonexecutive director dr anjana grewal nonexecutive director mr arvind agrawal chief financial officer mr gaurang shah company secretary dr ramesh jhawar director apui mr vinayak muzumdar director apml mr suttian deerpaul director apml mr sam gioskos director appi relative key management personnel category ii enterprise person covered category ii able exercise significant control gab investment private limited seth bhagwandas agrawal charitable trust ganga export represented mr yogesh agrawal mr rajesh agrawal mr ravi agrawal mr aayush agrawal yogesh agrawal trust trustee mr yogesh agrawal wef 7 march 2017 rajesh agrawal trust trustee mr rajesh agrawal wef 7 march 2017 ravi agrawal trust trustee mr ravi p agrawal wef 7 march 2017 ajanta pharma limited group gratuity trust 108 plan prepare perform financial statement consolidated note consolidated financial statement year ended 31st march 2017 b following transaction carried related party cr sr particular category 31 march 2017 31 march 2016 1 key management compensation short term employee benefit mr purushottam b agrawal 207 188 mr madhusudan b agrawal 207 188 mr yogesh agrawal 207 188 mr rajesh agrawal 207 147 mr arvind agrawal 084 070 mr gaurang shah 037 033 mr ramesh jhawar 255 148 mr vinayak muzumdar mr suttian deerpaul 066 051 mr sam gioskos 059 057 postemployment benefit 009 013 2 commission sitting fee nonexecutive director mr mannalal b agrawal 124 123 mr chandrakant khetan 006 004 dr anil kumar 006 002 mr k h viswanathan 005 003 mr prabhakar dalal 005 003 dr anjana grewal 005 003 3 rent mr manisha agrawal nil 079 mr smriti agrawal nil 079 mr aayush agrawal nil 079 4 dividend paid 4682 7915 ii 3762 1175 5 purchase property mr yogesh agrawal 260 nil mr rajesh agrawal 260 nil mr ravi p agrawal 260 nil mr aayush agrawal 260 nil 6 sale vehicle mr mannalal b agrawal 110 nil mr ravi p agrawal 023 nil 7 corporate social responsibility expense 619 105 seth bhagwandas agrawal charitable trust ii 8 contribution made group gratuity trust premium paid 331 336 lic premium paid ii c amount outstanding 31st march 2017 cr sr particular category 31 march 2017 31 march 2016 1 april 2015 1 commission payable nonexecutive director mr mannalal b agrawal 120 120 151 mr chandrakant khetan 001 nil 003 dr anil kumar 001 nil 003 mr k h viswanathan 001 nil 002 mr prabhakar dalal 001 nil 002 dr anjana grewal 001 nil 002 group completed independent evaluation international domestic transaction year ended 31st march 2017 reviewed year ended 31st march 2016 determine whether transaction associated enterprise undertaken arm length price based internal external transfer pricing review validation group belief transaction associated enterprise undertaken basis arm length principle 109 annual report 201617 note consolidated financial statement year ended 31st march 2017 50 contribution towards corporate social responsibility particular csr expenditure follows gross amount required spent group year 842 cr previous year 609 cr b amount spend year sr particular cash yet paid cash total construction acquisition asset nil nil nil b purpose 893 nil 893 including paid related party 619 cr refer note 49 c amount spend previous year sr particular cash yet paid cash total construction acquisition asset nil nil nil b purpose 639 nil 639 including paid related party 105 cr refer note 49 51 provision anticipated sale return expired good ind 37 cr particular 31 march 2017 31 march 2016 balance beginning year 767 645 add provision made year 571 489 less amount written backutilized year 438 367 balance end year 900 767 52 disclosure specified bank note sbns year holding company specified note denomination note defined mca notification gsr308e dated march 312017 detail specified bank note sbn held transacted period november 8 2016 december 30 2016 denomination wise sbns note per notification given particular sbns denomination total note closing cash hand november 8 2016 827500 581490 1408990 permitted receipt nil 1665581 1665581 permitted payment nil 1263085 1263085 amount deposited bank 827500 50000 877500 closing cash hand december 30 2016 nil 934086 934086 53 group one segment activity namely pharmaceutical 54 remuneration auditor excluding service tax cr particular 31 march 2017 31 march 2016 audit fee 033 032 tax audit fee 004 004 certification matter 008 008 110 plan prepare perform financial statement consolidated note consolidated financial statement year ended 31st march 2017 55 research development expenditure revenue expense research development incurred year except depreciation particular 31 march 2017 31 march 2016 cost materialconsumablesspare 5107 3207 employee benefit expense 4656 3082 utility 470 309 expense 5062 4049 total 15295 10647 56 note foreign currency exposure asset liability year group entered forward exchange contract derivative instrument mitigate foreign currency risk establish amount currency indian rupee required available settlement date certain payable receivables following outstanding foreign currency forward contract entered group 31 march 2017 31 march 2016 particular foreign currency foreign currency buy sell cross currency amt cr amt cr euro 008 025 sell inr usd 010 050 sell inr yearend foreign currency exposure mitigated derivative instrument otherwise foreign currency foreign currency cr cr foreign currency particular amt cr amt cr 31 march 2017 31 march 2016 31 march 2017 31 march 2016 amount receivable 25373 27633 391 417 usd 3865 3394 056 045 euro 001 nil 000 nil gbp 064 540 001 008 chf 023 nil 001 nil aed nil 012 nil 020 jpy amount payable 804 5444 012 082 usd 257 205 004 003 euro nil 002 nil 000 gbp 006 nil 010 nil jpy gbp 1030 gbp 2082 57 case holding company excise duty includes 003 cr pr yr 012 cr net impact excise duty provision opening closing stock 58 company invested jv turkmenderman ajanta pharma ltd tdapl two decade back management control however later company surrendered management control favour local partner since control tdapl operates severe restriction significantly impairs ability transfer fund hence company impaired entire investment tdapl considered unrelated party company making effort divest investment since last year without success 111 annual report 201617 note consolidated financial statement year ended 31st march 2017 59 case holding company preoperative expense pending capitalisation included capital workinprogress refer note 8 represent direct attributable expenditure setting plant prior date commencement commercial production capitalised completion project commencement commercial operation detail preoperative expense cr particular 31 march 2017 31 march 2016 opening balance 4089 1566 add incurred year employee benefit expense 1821 846 professional fee 081 037 travelling expense 137 056 depreciation 193 267 others 2869 1352 total 9190 4124 less income 111 035 less capitalised tangible asset 575 nil closing balance 8504 4089 60 additional information required schedule iii company act 2013 enterprise consolidated subsidiary 31st march 2017 net asset ie total asset share share total share profit loss minus total liability comprehensive income comprehensive income name enterprise amount amount amount amount consolidated consolidated consolidated consolidated cr cr cr cr net asset net asset net asset net asset holding company ajanta pharma ltd 956 149877 901 45664 45 011 905 45654 foreign subsidiary apml 36 5587 94 4784 369 094 93 4690 appi 19 2949 29 1456 1044 264 24 1192 apui 1 1539 21 1084 291 074 2 1011 apnl 01 105 03 137 167 042 02 095 total 156768 50683 253 50430 31st march 2016 net asset ie total asset share share total share profit loss minus total liability comprehensive income comprehensive income name enterprise amount amount amount amount consolidated consolidated consolidated consolidated cr cr cr cr net asset net asset net asset net asset holding company ajanta pharma ltd 956 113838 861 35793 42 023 866 36435 foreign subsidiary apml 32 3782 126 5235 725 389 12 5063 appi 2 2421 42 1741 26 139 44 1840 apui 08 945 28 1161 59 031 28 1193 apnl 0 010 01 047 02 001 01 049 total 119086 41561 535 42096 112 plan prepare perform financial statement consolidated note consolidated financial statement year ended 31st march 2017 also refer note 434 refer annexure b director report salient feature financial statement subsidiary 61 income tax income tax expense benefit recognized income statement consists following cr 31 march 2017 31 march 2016 current tax current tax profit year 15740 14420 adjustment current tax prior period 009 303 total current tax expense 15749 14117 deferred tax expensebenefit origination reversal timing difference 1615 211 total income tax recognised income statement 14135 14328 b reconciliation effective tax rate following reconciliation group effective tax rate year ended 31st march 2017 accounting profit income tax 64817 55889 enacted tax rate india 3461 3461 computed expected tax benefit expense 22432 19342 tax effect due nontaxable income india tax purpose 1755 2188 overseas tax 1581 915 overseas tax provision reversal 036 1669 effect nondeductible expense 1315 1510 effect exempt nonoperating income 023 088 tax effect chargeable different rate 1094 1158 additional deduction rd expense 6780 5166 investment allowance plant machinery 1357 193 deductible expense 158 010 adjustment current tax prior period 009 303 income tax benefit expense 14135 14329 effective tax rate 2181 2564 113 annual report 201617 note consolidated financial statement year ended 31st march 2017 c deferred tax asset liability tax effect significant temporary difference resulted deferred tax asset liability description created difference given cr 31 march 2017 31 march 2016 1 april 2015 deferred tax liability property plant equipment 3721 2581 1684 gain financial instrument fair value profit loss 215 360 205 others 004 429 120 total deferred tax liability 3932 2512 1769 deferred tax asset leave encashment 134 114 168 bonus 190 provision expired good 311 265 223 remeasurement gain loss defined benefit plan 018 012 mat credit entitlement 565 provision loss allowance 170 temporary difference related subsidiary 2388 858 506 others 057 total deferred tax asset 3643 1441 897 deferred tax liability set 2734 1929 1378 deferred tax asset set 2445 858 506 movement deferred tax liability net opening balance 1929 1378 remeasurement gain loss defined benefit plan 006 012 tax benefitexpense period recognised profit loss 386 873 others 425 309 closing balance 2734 1929 movement deferred tax asset net opening balance 858 506 temporary difference related subsidiary 1530 353 others 057 closing balance 2445 858 charge relating temporary difference year ended 31st march 2017 primarily account property plant equipment gain investment fvtpl partially offset provision expired good provision loss allowance compensated absence mat credit entitlement credit temporary difference year ended 31st march 2016 primarily account property plant equipment gain investment fvtpl partially offset provision expired good compensated absence provision loss allowance forward contract receivable 114 plan prepare perform financial statement consolidated note consolidated financial statement year ended 31st march 2017 62 firsttime adoption ind payment transaction vested date pursuant company india accounting transition ind standard rule 2015 group adopted 31st march 2017 reporting date first time adoption appendix c ind 17 requires entity india accounting standard ind consequently assess whether contract arrangement 1st april 2015 transition date preparation contains lease assessment financial statement financial statement carried inception contract year ended 31st march 2017 first financials arrangement however group used ind prepared accordance ind upto financial 101 exemption assessed arrangement year ended 31st march 2016 group prepared based embedded lease based condition financial statement accordance accounting place date transition standard notified section 133 company act 2013 read together company exception account rule 2014 previous gaap preparing following mandatory exception financial statement opening balance sheet applied accordance ind 101 preparing prepared 1st april 2015 ie date transition financial statement ind figure previous period year ended 31st march 2016 restated derecognition financial asset financial regrouped reclassified wherever required liability comply ind schedule iii company group elected apply derecognition act 2013 make comparable requirement financial asset financial liability ind 109 prospectively note explains principal adjustment made transaction occurring date group restating financial statement prepared transition ind accordance previous gaap including balance sheet 1st april 2015 financial statement classification measurement financial year ended 31st march 2016 asset group classified financial asset exemption accordance ind 109 basis ind 101 allows first time adopter certain exemption fact circumstance exist date retrospective application certain transition ind requirement ind deferred sale tax loan transition ind group applied per ind 101 group applied requirement following exemption ind 109 financial instrument ind 20 accounting government grant group elected continue carrying disclosure government assistance value property plant equipment prospectively sale tax deferred loan existing recognised 1st april 2015 measured per date transition ind previous gaap use carrying value recognised corresponding benefit loan deemed cost property plant market rate interest government equipment grant group used previous gaap carrying amount loan date transition group elected continue carrying ind carrying amount loan value intangible asset recognised opening ind balance sheet per ind 1st april 2015 measured per previous 109 loan classified amortised gaap use carrying value deemed cost since difference cost intangible asset carrying amount amount paid impact effective interest rate ie ind 102 share based payment discountingunwinding required applied equity instrument share based 115 annual report 201617 note consolidated financial statement year ended 31st march 2017 reconciliation equity previously reported igaap ind cr particular 31 march 2016 date transition 1 april 2015 adjustment adjustment previous previous transition ind transition ind gaap gaap ind ind asset 1 noncurrent asset property plant equipment 44698 44698 28378 28378 b capital workinprogress 23842 23842 17020 17020 c intangible asset 460 084 376 431 109 322 intangible asset development 138 138 e financial asset investment 4004 531 4535 ii others 926 926 923 923 f deferred tax asset net 858 858 506 506 g noncurrent asset 1630 1630 538 538 2 current asset inventory 20458 20458 15903 15903 b financial asset investment 6639 1039 7678 1946 043 1989 ii trade receivables 37235 37235 25876 25876 iii cash cash equivalent 5301 1159 4142 5449 1282 4167 iv bank balance iii 195 195 8227 8227 v financial asset 073 002 071 894 018 912 c current tax asset net 1764 1764 current asset 4784 4784 5046 5046 total asset 148143 652 148796 114635 293 114342 equity liability equity equity share capital 1769 1769 1768 1768 b equity 115437 1880 117317 82341 6333 88674 liability 1 noncurrent liability financial liability borrowing 1487 1487 3325 3325 ii financial liability 046 046 250 250 b provision 259 259 476 476 c deferred tax liability net 1998 069 1929 1516 138 1378 2 current liability financial liability borrowing 5783 1158 4625 1790 1282 508 ii trade payable 14557 14557 10906 10906 iii financial liability 4051 4051 4286 4286 b current liability 1621 1621 1547 1547 c provision 1135 1135 6174 5206 968 current tax liability net 256 256 total equity liability 148143 653 148796 114635 293 114342 116 plan prepare perform financial statement consolidated note consolidated financial statement year ended 31st march 2017 reconciliation statement profit loss previously reported igaap ind year ended 31st march 2016 cr adjustment particular previous gaap ind transition ind income revenue operation 172753 2184 174937 income 1663 452 2115 total income 174416 2636 177052 expense cost material consumed 40009 40009 purchase stockintrade 6301 6301 change inventory finished good workinprogress 4927 4927 stockintrade employee benefit expense 25699 035 25664 finance cost 489 489 depreciation amortisation expense 4506 063 4443 expense 47599 1585 49184 total expense 119676 1487 121163 profit tax 54740 1149 55889 tax expense current tax 14117 14117 deferred tax 482 272 211 profit year 40141 1420 41561 comprehensive income comprehensive income reclassified profit loss subsequent year exchange difference translation foreign operation 558 558 income tax effect net comprehensive income reclassified profit loss 558 558 subsequent year comprehensive income reclassified profit loss subsequent year remeasurement gain loss defined benefit plan 035 035 income tax effect 012 012 net comprehensive income reclassified profit 023 023 loss subsequent year comprehensive income year net tax 535 535 total comprehensive income year net tax 1955 42096 measurement recognition difference ind previous gaap year ended 31st march 2016 1 fair valuation investment previous gaap investment equity instrument mutual fund classified long term investment current investment based intended holding period realisability long term investment carried cost less provision temporary decline value investment current investment carried lower cost fair value ind investment required measured fair value resulting fair value change investment recognised retained earnings date transition subsequently profit loss year ended 31st march 2016 increased retained earnings 465 cr 31st march 2016 1st april 2015 574 cr 2 foreign currency translation previous gaap group recognised translation difference foreign operation separate 117 annual report 201617 note consolidated financial statement year ended 31st march 2017 component equity ind cumulative gain loss charged profit loss currency translation difference foreign ind remeasurements comprising actuarial operation deemed zero gain loss effect asset ceiling 1st april 2015 resulting adjustment recognised excluding amount included net interest net retained earnings defined benefit liability return plan asset excluding amount included net interest net 3 proposed dividend defined benefit liability recognised immediately previous gaap proposed dividend including balance sheet corresponding debit credit dividend distribution tax ddt recognised retained earnings comprehensive liability period relate irrespective income thus employee benefit expense reduced declared ind proposed 035 cr recognised comprehensive dividend recognised liability period income 023 cr net deferred tax year declared company usually approved ended 31st march 2016 shareholder general meeting paid 5 deferred tax therefore dividend liability proposed dividend previous gaap requires deferred tax accounting using including dividend distribution tax liability amounting income statement approach focus 5851 cr derecognised retained difference taxable profit accounting earnings date transition profit period ind 12 requires entity account deferred tax using balance sheet proposed dividend including dividend distribution tax approach focus temporary difference liability amounting 5851 cr derecognised carrying amount asset liability transition date recognised balance sheet tax base application retained earnings year ended 31st march ind 12 approach resulted recognition 2016 declared paid deferred tax new temporary difference required indian gaap 4 defined benefit obligation previous gaap ind group addition various transitional adjustment recognised cost related post employment lead different temporary difference deferred defined benefit plan actuarial basis tax adjustment recognised correlation previous gaap entire cost related post underlying transaction either retained earnings employment defined benefit plan including actuarial separate component equity change increased decreased deferred tax follows cr particular 31 march 2016 1 april 2015 financial instrument 359 205 employee benefit 012 nil provision nil 223 stock reserve 858 506 others 416 120 increase deferred tax 927 644 6 comprehensive income ind item income expense recognised period included profit loss period unless standard requires permit otherwise item income expense recognised profit loss shown statement profit loss comprehensive income includes remeasurements defined benefit plan concept comprehensive income exist previous gaap 118 plan prepare perform financial statement consolidated note consolidated financial statement year ended 31st march 2017 7 statement cash flow presented inclusive excise duty excise duty transition previous gaap ind paid presented face statement material impact statement cash flow profit loss part expense change resulted increase total revenue ind bank overdraft repayable demand total expense year ended 31st march 2016 form integral part cash management inr 1539 cr impact total process included cash cash equivalent equity profit purpose presentation statement cash flow previous gaap bank overdraft 9 cash discount considered part borrowing movement previous gaap cash discount 011 cr bank overdraft shown part financing recognised part expense activity consequently cash cash equivalent adjusted revenue ind reduced 1158 cr 31st march 2016 year ended 31st march 2016 1st april 2015 1282 cr impact total equity profit 8 excise duty 10 retained earnings previous gaap revenue sale change decreased increased retained product presented exclusive excise duty earnings follows ind revenue sale good cr particular 31 march 2016 1 april 2015 financial instrument net 269 388 proposed dividend nil 5851 provision net 422 422 deferred tax asset stock reserve 858 506 others 331 010 increase retained earnings 1880 6333 preparation indas financial statement group made several presentation difference previous gaap indas difference impact reported profit total equity accordingly asset liability reclassified another line item indas date transition financial statement line item described differently indas compared previous gaap although asset liability included line item unaffected per report even date attached kapoor parekh associate behalf board director chartered accountant nilesh parekh mannalal b agrawal partner chairman purushottam b agrawal yogesh agrawal arvind agrawal vice chairman managing director chief financial officer madhusudan b agrawal rajesh agrawal gaurang shah mumbai 3rd may 2017 vice chairman joint managing director company secretary 119 annual report 201617 independent auditor report conducted audit standalone ind financial member statement accordance standard auditing ajanta pharma limited specified section 14310 act standard require comply ethical requirement plan report standalone ind financial perform audit obtain reasonable assurance statement whether standalone ind financial statement free audited accompanying standalone ind financial material misstatement statement ajanta pharma limited company comprise balance sheet 31st march 2017 audit involves performing procedure obtain audit statement profit loss including comprehensive evidence amount disclosure income cash flow statement statement standalone ind financial statement procedure change equity year ended summary selected depend auditor judgment including significant accounting policy explanatory assessment risk material misstatement information herein referred standalone ind standalone ind financial statement whether due financial statement fraud error making risk assessment auditor considers internal financial control relevant company management responsibility standalone preparation standalone ind financial statement ind financial statement give true fair view order design audit procedure company board director responsible appropriate circumstance audit also includes matter stated section 1345 company act 2013 evaluating appropriateness accounting policy used act respect preparation presentation reasonableness accounting estimate made standalone ind financial statement give company director well evaluating overall true fair view state affair financial position presentation standalone ind financial statement profit financial performance including comprehensive income cash flow change equity company believe audit evidence obtained accordance accounting principle generally accepted sufficient appropriate provide basis audit india including indian accounting standard ind opinion standalone ind financial statement prescribed section 133 act read relevant rule issued thereunder opinion opinion best information according responsibility also includes maintenance adequate explanation given u aforesaid standalone ind accounting record accordance provision act financial statement give information required safeguarding asset company preventing act manner required give true fair view detecting fraud irregularity selection conformity accounting principle generally accepted application appropriate accounting policy making india including ind state affair financial judgment estimate reasonable prudent position company 31st march 2017 profit design implementation maintenance adequate internal financial performance including comprehensive income financial control operating effectively ensuring cash flow change equity year ended accuracy completeness accounting record date relevant preparation presentation standalone ind financial statement give true fair view report legal regulatory free material misstatement whether due fraud error requirement 1 required company auditor report order auditor responsibility 2016 order issued central government responsibility express opinion standalone india term section 14311 act give ind financial statement based audit annexure statement matter specified paragraph 3 4 order taken account provision act accounting auditing standard matter required included audit report provision act rule made thereunder 120 plan prepare perform financial statement standalone independent auditor report 2 required section 143 3 act report company disclosed impact pending litigation 31st march 2017 sought obtained information financial position standalone ind explanation best knowledge financial statement refer note 46 belief necessary purpose audit standalone ind financial statement b opinion proper book account required ii company entered long law kept company far term contract including derivative contract appears examination book requiring provision applicable law accounting standard material foreseeable balance sheet statement profit c loss loss cash flow statement statement change equity dealt report delay transferring iii agreement book account amount required transferred investor education protection fund opinion aforesaid standalone ind company financial statement comply indian accounting standard prescribed section 133 company provided requisite iv act read relevant rule issued thereunder disclosure standalone ind financial statement holding well dealing e basis written representation received specified bank note period director 31st march 2017 taken 8th november 2016 30th december 2016 record board director none accordance book director disqualified 31st march 2017 account maintained company refer appointed director term section 164 note 50 standalone ind financial 2 act statement f respect adequacy internal financial kapoor parekh associate control financial reporting company chartered accountant operating effectiveness control refer icai frn 104803w separate report annexure b nilesh parekh g respect matter included auditor report accordance rule 11 partner company audit auditor rule 2014 mno 33528 opinion best information mumbai 3rd may 2017 according explanation given u 121 annual report 201617 annexure independent auditor report annexure referred para 1 heading report unsecured company firm limited liability legal regulatory requirement report partnership party covered register even date member ajanta pharma limited maintained section 189 company act standalone ind financial statement year ended 2013 accordingly paragraph 3iii order 31st march 2017 applicable company 1 respect fixed asset opinion according information 4 explanation given u company complied company maintained proper record provision section 185 186 company showing full particular including quantitative detail act 2013 situation fixed asset 5 company accepted deposit public b informed u management company policy physically verifying fixed asset broadly reviewed book account 6 phased manner period maintained company pursuant rule opinion reasonable regard size prescribed central government maintenance company nature asset cost record section 1481 company informed material discrepancy act 2013 relation product manufactured noticed verification opinion prima facie prescribed account properly dealt book account record made maintained made detailed examination record view c according information explanation given determine whether accurate complete u title deed immovable property company held name company 7 according information explanation given u 2 according information explanation given u inventory physically verified company generally regular management reasonable interval year depositing undisputed statutory due including except stock third party provident fund employee state insurance income confirmation certificate obtained tax sale tax service tax custom duty excise company discrepancy noticed physical duty value added tax cess material verification physical stock book record statutory due appropriate authority material adequately dealt year undisputed amount book account payable respect aforesaid material statutory due 31st march 2017 arrears according information explanation given 3 period six month date u company granted loan secured became payable b basis examination document record company due income tax sale tax service tax custom duty excise duty value added tax cess 31st march 2017 deposited account dispute except enumerated herein pending respective authority mentioned name statute nature amount period forum dispute pending due cr amount relate central excise act 1944 excise 006 fy 200708 commissioner central excise fy 200809 thaneii central excise act 1944 excise 004 fy 200607 assistant commissioner central fy 201011 excise thaneii central excise act 1944 excise 016 fy 201011 superintendent central excise fy 201516 custom service tax aurangabad 122 plan prepare perform financial statement standalone annexure independent auditor report name statute nature amount period forum dispute pending due cr amount relate central excise act 1944 excise 013 fy 201011 additional comissioner central fy 201516 excise custom service tax aurangabad central excise act 1944 excise 011 fy 201516 joint comissioner central excise fy 201617 custom service tax aurangabad finance act 1994 service tax 187 fy 201213 additional comissioner central fy 201415 excise custom service tax aurangabad income tax act 1961 penalty 047 fy 201112 commissioner income tax appeal mumbai net amount paid protest otherwise amount per demand order including interest penalty wherever quantified based audit procedure information 8 188 company act 2013 detail explanation given u opinion company related party transaction disclosed defaulted repayment loan borrowing standalone ind financial statement required financial institution bank government company applicable ind outstanding debenture year 14 according information explanation given u company made preferential allotment 9 according information explanation given private placement share fully partly convertible u company raised money way debenture year review accordingly initial public offer public offer including debt paragraph 3xiv order applicable instrument taken term loan company year according information explanation given 15 10 course examination book u company entered noncash record company carried accordance transaction director person connected generally accepted auditing practice india director accordingly paragraph 3xv order according information explanation given applicable company u neither come across instance material fraud company company officer according information explanation given 16 employee noticed reported year u company required registered informed case management section 45ia reserve bank india act 1934 accordingly paragraph 3xvi order opinion according information 11 applicable company explanation given u managerial remuneration paid provided accordance requisite kapoor parekh associate approval mandated provision section 197 read chartered accountant schedule v company act 2013 icai frn 104803w opinion according information 12 nilesh parekh explanation given u company nidhi company accordingly paragraph 3xii order partner applicable company mno 33528 mumbai 3rd may 2017 13 company entered transaction related party compliance provision section 177 123 annual report 201617 annexure b independent auditor report annexure referred para 2 f heading ethical requirement plan perform audit report legal regulatory requirement obtain reasonable assurance whether adequate internal report even date member ajanta pharma financial control financial reporting established limited standalone ind financial statement maintained control operated effectively year ended 31st march 2017 material respect report internal financial control audit involves performing procedure obtain audit financial reporting clause sub evidence adequacy internal financial section 3 section 143 company act control system financial reporting operating 2013 act effectiveness audit internal financial control audited internal financial control financial financial reporting included obtaining understanding reporting ajanta pharma limitedthe company internal financial control financial reporting assessing 31st march 2017 conjunction audit standalone risk material weakness exists testing ind financial statement company year ended evaluating design operating effectiveness internal date control based assessed risk procedure selected depend auditor judgement including assessment management responsibility internal risk material misstatement financial statement financial control whether due fraud error company management responsible establishing maintaining internal financial control based believe audit evidence obtained internal control financial reporting criterion established sufficient appropriate provide basis audit company considering essential component opinion company internal financial control system internal control stated guidance note audit financial reporting internal financial control financial reporting issued institute chartered accountant india icai meaning internal financial control responsibility include design implementation financial reporting maintenance adequate internal financial control company internal financial control financial reporting operating effectively ensuring orderly efficient process designed provide reasonable assurance conduct business including adherence company regarding reliability financial reporting policy safeguarding asset prevention preparation financial statement external purpose detection fraud error accuracy completeness accordance generally accepted accounting principle accounting record timely preparation company internal financial control financial reporting presentation reliable financial information required includes policy procedure 1 pertain company act 2013 maintenance record reasonable detail accurately fairly reflect transaction disposition auditor responsibility asset company 2 provide reasonable assurance responsibility express opinion company transaction recorded necessary permit preparation internal financial control financial reporting based financial statement accordance generally accepted audit conducted audit accordance guidance accounting principle receipt expenditure note audit internal financial control financial company made accordance reporting issued icai standard auditing authorisation management director company issued icai deemed prescribed section 3 provide reasonable assurance regarding prevention 14310 company act 2013 extent applicable timely detection unauthorised acquisition use disposition audit internal financial control applicable company asset could material effect audit internal financial control standard financial statement mentioned guidance note require comply 124 plan prepare perform financial statement standalone annexure b independent auditor report inherent limitation internal financial reporting operating effectively 31st march 2017 control financial reporting based internal control financial reporting criterion inherent limitation internal financial control established company considering essential financial reporting including possibility collusion component internal control stated guidance note improper management override control material audit internal financial control financial reporting misstatement due error fraud may occur issued icai detected also projection evaluation internal financial control financial reporting future period kapoor parekh associate subject risk internal financial control chartered accountant financial reporting may become inadequate icai frn 104803w change condition degree compliance policy procedure may deteriorate nilesh parekh opinion partner opinion company material respect mno 33528 adequate internal financial control system financial mumbai 3rd may 2017 reporting internal financial control financial 125 annual report 201617 balance sheet 31st march 2017 cr particular note 31 march 2017 31 march 2016 1 april 2015 asset 1 noncurrent asset property plant equipment 8 56697 42908 26816 b capital workinprogress 8 33803 23842 17020 c intangible asset 8 596 375 316 intangible asset development 8 123 138 e financial asset investment 9 1726 1725 6247 ii financial asset 10 909 909 876 f noncurrent asset 11 1393 1630 538 2 current asset inventory 12 17928 18978 15305 b financial asset investment 13 18156 7678 1989 ii trade receivables 14 33600 35048 24085 iii cash cash equivalent 15 481 1949 1059 iv bank balance iii 16 412 195 8228 v financial asset 17 124 071 912 c current tax asset net 18 1123 1763 current asset 19 5415 4160 4504 total asset 172486 141369 107895 equity liability equity equity share capital 20 1769 1769 1768 b equity 148625 111401 82682 liability 1 noncurrent liability financial liability borrowing 21 1382 3227 ii financial liability 22 009 045 250 b provision 23 315 259 476 c deferred tax liability net 24 2738 2358 1497 2 current liability financial liability borrowing 25 553 3447 508 ii trade payable 26 13878 14504 10812 iii financial liability 27 2528 4007 4233 b current liability 28 791 1061 1218 c provision 29 1280 1136 967 current tax liability net 30 256 total equity liability 172486 141369 107895 see accompanying note forming part financial statement per report even date attached kapoor parekh associate behalf board director chartered accountant nilesh parekh mannalal b agrawal partner chairman purushottam b agrawal yogesh agrawal arvind agrawal vice chairman managing director chief financial officer madhusudan b agrawal rajesh agrawal gaurang shah mumbai 3rd may 2017 vice chairman joint managing director company secretary 126 plan prepare perform financial statement standalone statement profit loss year ended 31st march 2017 cr note 31 march 2017 31 march 2016 income revenue operation 31 182271 157360 income 32 6695 8687 total income 188966 166047 expense cost material consumed 33 37331 39721 purchase stockintrade 34 5923 5781 change inventory finished good workinprogress stockintrade 35 729 4101 employee benefit expense 36 26978 23503 finance cost 37 283 419 depreciation amortisation expense 38 5948 4268 expense 39 47709 40200 total expense 124901 109791 profit tax 64065 56256 tax expense current tax 13698 13189 deferred tax 386 872 profit year 49981 42195 comprehensive income comprehensive income reclassified profit loss subsequent year remeasurement gain loss defined benefit plan 017 035 income tax effect 006 012 net comprehensive income reclassified profit loss 011 023 subsequent year comprehensive income year net tax 011 023 total comprehensive income year net tax 49970 42172 exceptional item discontinuing operation earning per equity share face value 2 41 basic 5679 4795 diluted 5678 4795 see accompanying note forming part financial statement per report even date attached kapoor parekh associate behalf board director chartered accountant nilesh parekh mannalal b agrawal partner chairman purushottam b agrawal yogesh agrawal arvind agrawal vice chairman managing director chief financial officer madhusudan b agrawal rajesh agrawal gaurang shah mumbai 3rd may 2017 vice chairman joint managing director company secretary 127 annual report 201617 statement cash flow year ended 31st march 2017 cr 31 march 2017 31 march 2016 cash flow operating activity profit tax 64065 56256 adjustment reconcile profit tax net cash flow depreciation amortisation expense 5948 4268 provision expired good 133 122 loss sale discard property plant equipment net 389 692 interest expense 283 419 dividend subsidiary 4318 6691 gain financial instrument fvtpl 1683 545 income investment deposit 120 578 employee stock option expense 145 031 receivable written 2327 095 operating profit working capital change 67168 54069 change working capital decrease increase trade receivables 389 11058 decrease increase current financial asset 1255 344 decrease increase current asset 224 214 decrease increase inventory 1049 3673 increase decrease non current financial liability 036 206 increase decrease current liability 209 336 increase decrease non current provision 056 217 increase decrease current provision 011 046 increase decrease trade payable 626 3692 cash generated operation 65964 42875 direct tax paid net refund 13058 15208 net cash generated operating activity 52906 27667 b cash flow investing activity capital expenditure property plant equipment including capital advance 30345 29503 proceeds sale property plant equipment 128 042 bank balance considered cash cash equivalent net 024 8146 dividend subsidiary 4318 6691 purchase investment 35920 21900 proceeds investment 26778 21539 income investment deposit 099 1059 investment subsidiary 013 net cash generated used investing activity 34966 13939 128 plan prepare perform financial statement standalone statement cash flow year ended 31st march 2017 cr 31 march 2017 31 march 2016 c cash flow financing activity proceeds long term borrowing 473 repayment long term borrowing 3361 2408 proceeds repayment short term borrowing 2894 2939 proceeds issue equity share esop cy 5000 001 interest paid 284 420 dividend paid 11419 12277 dividend distribution tax paid 1450 1146 net cash generated used financing activity 19408 12838 net increase decrease cash cash equivalent 1469 890 cash cash equivalent beginning year 1949 1059 cash cash equivalent end year refer note 15 481 1949 figure bracket indicates outflow see accompanying note forming part financial statement per report even date attached kapoor parekh associate behalf board director chartered accountant nilesh parekh mannalal b agrawal partner chairman purushottam b agrawal yogesh agrawal arvind agrawal vice chairman managing director chief financial officer madhusudan b agrawal rajesh agrawal gaurang shah mumbai 3rd may 2017 vice chairman joint managing director company secretary 129 annual report 201617 statement change equity year ended 31st march 2017 equity share capital cr balance change equity balance change equity balance 1 april 2015 share capital 31 march 2016 share capital 31 march 2017 year year authorised 3000 3000 3000 issued 1774 001 1775 1775 subscribed paid 1768 001 1769 1769 b equity cr particular capital security general share retained item total redemption premium reserve based earnings comprehensive equity reserve account payment income reserve measurement gain loss defined benefit plan 1st april 2015 211 7571 57100 043 17757 82682 profit period 42195 42195 comprehensive income 023 023 total comprehensive income 42195 023 42172 utilised bonus share 001 001 transfer general reserve 33000 33000 exercise stock option 028 028 share based payment employee 012 012 dividend paid 12322 12322 dividend distribution tax 1184 1184 reversal dividend paid 005 005 reversal dividend distribution tax 038 038 31st march 2016 210 7599 90100 027 13488 023 111401 profit period 49981 49981 comprehensive income 011 011 total comprehensive income 49981 011 49970 exercise stock option 007 007 share based payment employee 145 145 dividend paid 11441 11441 dividend distribution tax 1450 1450 31st march 2017 210 7606 90100 165 50579 034 148625 see accompanying note forming part financial statement per report even date attached kapoor parekh associate behalf board director chartered accountant nilesh parekh mannalal b agrawal partner chairman purushottam b agrawal yogesh agrawal arvind agrawal vice chairman managing director chief financial officer madhusudan b agrawal rajesh agrawal gaurang shah mumbai 3rd may 2017 vice chairman joint managing director company secretary 130 plan prepare perform financial statement standalone note standalone financial statement year ended 31st march 2017 1 corporate information 4 rounding amount janta pharma limited company public limited amount disclosed financial statement company incorporated domiciled india share note rounded nearest cr amount listed bombay stock exchange national stock less 50000 shown actual exchange registered office company located ajanta house charkop kandivali west mumbai 5 current versus noncurrent classification asset liability balance sheet company engaged development manufacturing presented based currentnoncurrent classification marketing speciality pharmaceutical finished dosage asset current expected realised intended sold financial statement company year consumed normal operating cycle ended 31st march 2017 authorised issue held primarily purpose trading company board director 3rd may 2017 expected realised within twelve month reporting period 2 basis preparation cash cash equivalent unless restricted exchanged used settle liability financial statement company least twelve month reporting period prepared accordance indian accounting asset classified noncurrent standard indas notified company indian accounting standard rule 2015 amended liability current company indian accounting standard expected settled normal operating cycle amendment rule 2016 held primarily purpose trading financial statement company first ind due settled within twelve month financial statement covered ind 101 reporting period firsttime adoption indian accounting standard unconditional right defer settlement liability least twelve month period including year ended reporting period 31st march 2016 company prepared financial liability treated noncurrent statement accordance accounting standard notified section 133 deferred tax asset liability classified non company act 2013 read together company current asset liability respectively account rule 2014 previous gaap 6 significant accounting policy explanation transition indas 61 property plant equipment affected company equity net profit provided freehold land carried historical cost note 61 item property plant equipment stated cost less accumulated depreciation financial statement prepared impairment loss accrual basis historical cost basis except following asset liability cost includes cost acquisition installation measured fair value revalued amount wherever construction direct expense incurred applicable bring asset working condition derivative financial instrument finance cost incurred date asset certain financial asset measured fair value ready intended use excludes cenvat value added tax eligible credit setoff 3 functional presentation currency financial statement presented indian cost includes cost replacing part rupee inr rupee r plant equipment borrowing cost functional currency company longterm construction project recognition 131 annual report 201617 note standalone financial statement year ended 31st march 2017 criterion met significant part plant case building constructed leasehold land equipment required replaced interval amortised primary lease period company depreciates separately based land specific useful life likewise major inspection performed cost recognised asset residual value useful life method carrying amount plant equipment depreciation reviewed financial year replacement recognition criterion end adjusted prospectively appropriate satisfied repair maintenance cost recognised statement profit loss asset carrying amount written incurred immediately recoverable amount asset carrying amount greater capital workinprogress respect asset estimated recoverable amount ready intended use carried cost comprising direct cost related transition ind company elected incidental expense attributable interest continue carrying value property plant equipment recognised identifiable revenue expense including 1st april 2015 measured per previous gaap interest incurred respect various project use carrying value deemed cost expansion net income earned property plant equipment project development stage prior intended use considered pre operative expense 62 intangible asset disclosed capital work progress intangible asset recognised probable future economic benefit capital expenditure tangible asset research attributable asset flow company development classified property plant cost asset measured equipment depreciated reliably basis property plant equipment intangible asset stated cost acquisition property plant equipment eliminated less accumulated amortisation impairment financial statement either disposal loss retired active use loss arising case retirement property plant equipment internally generated intangible excluding gain loss arising disposal property capitalised development cost capitalised plant equipment recognised statement related expenditure reflected profit profit loss year occurrence loss period expenditure incurred depreciable amount asset cost asset amount substituted cost less software amortised estimated useful estimated residual value depreciation life straight line basis date property plant equipment provided available intended use subject impairment written value method useful test life asset specified schedule ii company act 2013 property plant amortisation period amortisation equipment added disposed method intangible asset finite year depreciation provided prorata useful life reviewed least end basis premium leasehold land amortised reporting period change expected useful period lease building constructed life expected pattern consumption leasehold land depreciated based future economic benefit embodied asset useful life specified schedule ii considered modify amortisation period company act 2013 lease period method appropriate treated land beyond life building change accounting estimate 132 plan prepare perform financial statement standalone note standalone financial statement year ended 31st march 2017 gain loss arising derecognition subsequent measurement intangible asset measured difference purpose subsequent measurement net disposal proceeds financial asset classified two broad carrying amount asset recognised category statement profit loss asset financial asset fair value fvtpl fvtoci derecognised financial asset amortised cost research development asset measured fair value gain revenue expenditure research expensed loss either recognised statement respective head account profit loss ie fair value profit loss period incurred fvtpl recognised comprehensive income ie fair value comprehensive development expenditure incurred income fvtoci individual project carried forward future recoverability reasonably regarded financial asset measured amortised cost net assured expenditure carried forward write impairment amortised period expected future financial asset measured amortised cost sale related project carrying asset held within business model value development cost reviewed whose objective hold asset collecting impairment annually asset yet contractual cash flow contractual term use otherwise event change asset give rise specified date cash flow circumstance indicate carrying value solely payment principal interest may recoverable financial asset subsequently measured amortised cost using effective interest rate transition ind company elected eir method less impairment loss continue carrying value intangible arising impairment recognised asset recognised 1st april 2015 measured statement profit loss per previous gaap use carrying value deemed cost intangible asset financial asset measured fair value comprehensive income fvtoci 63 financial instrument financial asset category measured financial instrument contract give initially well reporting date fair rise financial asset one entity financial value asset held within business model liability equity instrument another entity whose objective hold asset collecting contractual cash flow selling financial asset financial asset fair value movement recognized classification comprehensive income company classifies financial asset subsequently measured amortised cost fair financial asset measured fair value value comprehensive income profit loss fvtpl fair value profit loss basis financial asset category measured business model managing financial asset initially well reporting date fair contractual cash flow characteristic value change recognised profit loss financial asset investment subsidiary initial recognition measurement investment equity instrument subsidiary financial asset recognised initially measured cost per ind 27 fair value plus case financial asset financial statement investment subsidiary recorded fair value profit loss company carried cost carrying amount transaction cost attributable reduced recognise impairment acquisition financial asset value investment 133 annual report 201617 note standalone financial statement year ended 31st march 2017 investment equity instrument recognition fair value profit equity instrument held trading loss interestbearing loan borrowing classified fvtpl equity instrument subsequently measured amortised cost using classified fvtoci fair value change effective interest rate eir method gain instrument excluding dividend loss recognised profit loss recognised comprehensive income liability derecognised well eir recycling amount amortisation process amortised cost calculated comprehensive income profit loss taking account discount premium acquisition fee cost integral investment debt instrument part eir eir amortisation included debt instrument measured amortised finance cost statement profit loss cost fvtoci debt instrument meet criterion categorization derecognition financial liability amortized cost fvoci classified financial liability derecognised fvtpl debt instrument included within obligation liability discharged fvtpl category measured fair value cancelled expires existing financial change recognised statement profit liability replaced another loss lender substantially different term term existing liability substantially modified derecognition financial asset exchange modification treated financial asset primarily derecognised derecognition original liability right receive cash flow asset recognition new liability difference expired company transferred respective carrying amount recognised right receive cash flow asset statement profit loss impairment financial asset derivative financial instrument accordance ind 109 company company us derivative financial instrument applies expected credit loss ecl model forward currency contract mitigate measurement recognition impairment loss foreign currency risk derivative financial financial asset debt instrument instrument initially recognised fair value trade receivables date derivative contract entered subsequently remeasured fair financial liability value derivative carried financial asset classification fair value positive financial company classifies financial liability liability fair value negative subsequently measured amortised cost fvtpl 64 inventory initial recognition measurement raw material packing material valued financial liability recognised initially fair lower cost net realisable value cost value case loan borrowing includes duty tax net cenvat payable net directly attributable transaction vat wherever applicable cost imported raw cost material packing material lying bonded warehouse includes custom duty finished financial liability include trade product including traded good workin payable loan borrowing including bank progress valued lower cost net overdraft derivative financial instrument realisable value cost arrived fifo basis cost inventory computed subsequent measurement include cost purchase cost conversion financial liability fair value profit standard overhead related cost loss include financial liability held trading incurred bringing inventory financial liability designated upon initial present condition 134 plan prepare perform financial statement standalone note standalone financial statement year ended 31st march 2017 slow nonmoving material obsolesces revenue measured fair value defective inventory fully provided consideration received receivable amount valued net realisable value disclosed revenue inclusive excise duty excluding sale tax value added tax good material transit valued service tax duty collected behalf actual cost incurred date balance government net return trade discount sheet material item held use allowance rebate amount collected production inventory written behalf third party finished product used expected sold cost revenue sale good recognised significant risk reward transferred 65 cash cash equivalent buyer per term contract cash cash equivalent comprise cash significant uncertainty exists regarding amount hand cash bank including fixed deposithighly consideration derived liquid investment original maturity period sale good three month less readily convertible known amount cash subject revenue sale technology know insignificant risk change value right licence intangible recognised performance obligation 66 cash flow statement completed per term agreement cash flow reported using indirect method income service recognised whereby net profit tax adjusted service rendered effect transaction noncash nature deferral accrual past future operating dividend income recognised right cash receipt payment item income receive dividend established interest income expense associated investing financing recognised time proportion basis insurance cash flow cash flow operating claim recognised revenue investing financing activity company certainty receipt prudent basis export benefit segregated available prevalent scheme accounted extent considered receivable 67 foreign currency transaction revenue transaction denominated foreign 69 employee benefit currency normally recorded exchange employee benefit payable wholly within rate prevailing date transaction twelve month rendering service classified short term employee benefit benefit monetary item denominated foreign currency salary wage shortterm compensated yearend remeasured exchange absence performance incentive etc rate prevailing balance sheet date expected cost bonus exgratia recognised nonmonetary foreign currency item carried period employee render cost related service income expense account exchange defined benefit plan difference either settlement restatement company provides gratuity defined recognised statement profit loss benefit retirement plan gratuity plan covering eligible employee gratuity 68 revenue recognition plan provides lumpsum payment revenue recognised extent vested employee retirement death probable economic benefit flow incapacitation termination employment company revenue reliably amount based respective measured regardless payment employee salary tenure made employment company 135 annual report 201617 note standalone financial statement year ended 31st march 2017 liability regard gratuity plan performed independent actuary determined actuarial valuation performed balance sheet date using projected independent actuary balance sheet unit credit method additional amount date using projected unit credit method expected paidavailed result unused entitlement accumulated company fully contributes ascertained balance sheet date liability ajanta pharma limited group gratuity trust trust trustee compensated absence administer contribution made trust expected occur within twelve month contribution invested scheme end period employee life insurance corporation india render related service recognised permitted law india liability present value defined benefit obligation balance sheet date retirement benefit obligation recognised balance sheet represents present expense nonaccumulating compensated value defined benefit obligation absence recognized period reduced fair value scheme asset absence occur asset resulting calculation limited present value available iv sharebased compensation refund reduction future contribution company recognizes compensation scheme company recognizes expense relating sharebased payment net obligation defined benefit plan net profit using fairvalue accordance balance sheet asset liability actuarial ind as102 sharebased payment gain loss recognised full comprehensive income period 610 borrowing cost occur effect plan borrowing cost directly attributable amendment recognized statement acquisition construction production asset profit loss necessarily take substantial period time get ready intended use sale capitalised ii defined contribution plan part cost asset borrowing contribution defined contribution plan cost expensed period recognised expense employee occur borrowing cost consist interest rendered service entitling cost entity incurs connection benefit company pay provident fund borrowing fund borrowing cost also includes contribution publicly administered provident exchange difference extent regarded fund per local regulation company adjustment borrowing cost payment obligation contribution paid contribution 611 lease accounted defined contribution determination whether arrangement plan contribution recognized contains lease based substance employee benefit expense arrangement inception date whether due prepaid contribution recognized fulfilment arrangement dependent asset extent cash refund use specific asset asset arrangement reduction future payment available conveys right use asset even right explicitly specified arrangement iii compensated absence company policy compensated asset acquired lease significant absence accumulating portion risk reward ownership nonaccumulating nature expected retained lessor classified operating cost accumulating compensated absence lease lease rental charged determined actuarial valuation statement profit loss straight line basis 136 plan prepare perform financial statement standalone note standalone financial statement year ended 31st march 2017 612 earnings per share recognized income expense period basic earnings per equity share computed includes enactment substantive dividing net profit attributable equity enactment date deferred income tax asset holder company weighted average recognized extent probable number equity share outstanding future taxable profit available period diluted earnings per equity share deductible temporary difference computed dividing net profit attributable tax loss utilized company offset equity holder company weighted current tax asset current tax liability average number equity share considered legally enforceable right set deriving basic earnings per equity share also recognized amount intends either weighted average number equity share settle net basis realize asset could issued upon conversion settle liability simultaneously dilutive potential equity share dilutive potential equity share adjusted 614 dividend shareholder proceeds receivable equity share annual dividend distribution shareholder actually issued fair value dilutive potential equity recognised liability period share deemed converted beginning dividend approved shareholder period unless issued later date interim dividend paid recognised dilutive potential equity share determined approval board director dividend payable independently period presented corresponding tax dividend distribution recognised directly equity 613 income tax income tax expense comprises current 615 provision contingent liability contingent deferred income tax asset commitment general income tax expense recognized net profit provision recognised company statement profit loss except present obligation legal constructive extent relates item recognized directly result past event probable equity case recognized outflow resource required settle comprehensive income current income tax obligation respect reliable estimate current prior period recognized made amount expected paid recovered tax authority using tax rate tax law provision excluding retirement benefit enacted substantively enacted compensated absence discounted balance sheet date deferred income present value determined based best tax asset liability recognized estimate required settle obligation temporary difference arising tax balance sheet date reviewed base asset liability carrying balance sheet date adjusted reflect amount financial statement deferred tax current best estimate asset reviewed reporting date reduced extent longer probable expectation related tax benefit realised provision reimbursed reimbursement recognised separate asset deferred income tax asset liability reimbursement virtually certain measured using tax rate tax law expense relating provision presented enacted substantively enacted statement profit loss net virtually balance sheet date expected certain reimbursement apply taxable income year temporary difference expected effect time value money material recovered settled effect change tax provision discounted using current pre rate deferred income tax asset liability tax rate reflects appropriate risk 137 annual report 201617 note standalone financial statement year ended 31st march 2017 specific liability discounting used financials statement prepared increase provision due passage historical cost basis except following time recognised finance cost material item statement financial position contingent liability disclosed case derivative financial instrument measured present obligation arising past event fair value received bank probable outflow mutual fund measured fair value resource required settle obligation per net asset value nav present obligation arising past event employee stock option plan esop fair reliable estimate possible value per actuarial valuation report possible obligation arising past event unless probability outflow resource fair value price would received remote sell asset settle liability ordinary transaction market participant contingent liability recognised measurement date financial statement contingent asset neither recognised disclosed financial fair value asset liability measured statement using assumption market participant would use pricing asset liability commitment include amount purchase order assuming market participant act net advance issued party completion economic best interest asset noncancellable operating lease fair value measurement nonfinancial asset provision contingent liability contingent asset take account market participant ability commitment reviewed balance generate economic benefit using asset sheet date highest best use selling another market participant would use asset asset retirement obligation highest best use asset retirement obligation aro provided operating lease arrangement company us valuation technique company binding obligation end appropriate circumstance lease period restore leased premise sufficient data available measure fair value condition similar inception lease aro maximising use relevant observable input provided present value expected minimising use unobservable input cost settle obligation using discounted cash flow recognised part asset liability fair value cost particular asset cash flow measured disclosed financial statement discounted current pretax rate reflects categorised within fair value hierarchy risk specific decommissioning liability described follows based lowest unwinding discount recognised level input significant fair value income statement finance cost measurement whole estimated future cost decommissioning level 1 quoted unadjusted market price reviewed annually adjusted appropriate active market identical asset change estimated future cost liability discount rate applied added deducted level 2 valuation technique cost asset lowest level input significant fair value measurement directly indirectly 616 fair value measurement observable company measure financial instrument level 3 valuation technique derivative fair value balance sheet lowest level input significant fair date accordance ind 113 value measurement unobservable 138 plan prepare perform financial statement standalone note standalone financial statement year ended 31st march 2017 asset liability recognised amendment effective annual financial statement recurring basis period beginning 1st april 2017 company determines whether transfer amendment expected impact occurred level hierarchy company assessing categorisation based lowest level input significant fair value 7 critical accounting judgement estimate measurement whole end assumption reporting period preparation company financial statement requires management make judgement estimate purpose fair value disclosure assumption affect reported amount company determined class asset revenue expense asset liability liability basis nature characteristic disclosure contingent liability end risk asset liability level reporting period however uncertainty fair value hierarchy explained assumption estimate could result outcome require material adjustment carrying 617 recent accounting pronouncement amount asset liability future period standard issued yet effective march 2017 ministry corporate affair arrangement containing lease issued company indian accounting inception arrangement company standard amendment rule 2017 notifying determines whether arrangement contains amendment ind 7 statement cash flow lease inception reassessment ind 102 sharebased payment arrangement contains lease company amendment accordance recent separate payment consideration amendment made international accounting required arrangement standard board iasb ia 7 statement lease element cash flow ifrs 2 sharebased payment basis relative fair value respectively amendment applicable company 1st april 2017 company determined based evaluation term condition arrangement amendment ind 7 statement cash flow contract nature operating amendment ind 7 requires entity lease provide disclosure enable user financial statement evaluate change liability b multiple element contract vendor arising financing activity including company entered multiple element change arising cash flow noncash contract vendor supply good change amendment effective rendering service consideration paid ismay annual period beginning 1st april determined independent value supply 2017 application amendment result received service availed accordingly additional disclosure provided company supply service accounted based relative fair value overall consideration amendment ind 102 sharebased payment supply finite life contract amendment ind 102 address three defined significant accounting policy main area effect vesting condition accounted property plant measurement cashsettled sharebased equipment andor intangible asset since payment transaction classification share company economic ownership asset based payment transaction net settlement company belief current treatment feature withholding tax obligation represents substance arrangement accounting modification term condition sharebased payment transaction c property plant equipment change classification cash settled determination estimated useful life equity settled tangible asset assessment 139 annual report 201617 note standalone financial statement year ended 31st march 2017 component cost may capitalized probability outflow resource useful life tangible asset based life past experience circumstance known prescribed schedule ii company act balance sheet date actual outflow 2013 assumption also need made resource future date may therefore vary company assesses whether asset may figure included provision capitalised component cost asset may capitalised h contingency management judgement required estimating intangible asset possible outflow resource internal technical user team assess respect contingenciesclaimlitigations remaining useful life intangible asset company possible predict management belief assigned useful life outcome pending matter accuracy reasonable allowance uncollected account receivable e recognition measurement defined advance benefit obligation trade receivables carry interest obligation arising defined benefit plan stated normal value reduced determined basis actuarial assumption appropriate allowance estimated irrecoverable key actuarial assumption include discount rate amount individual trade receivables written trend salary escalation vested future management deems collectible benefit life expectancy discount rate impairment made expected credit loss determined reference market yield present value cash shortfall end reporting period government expected life financial asset bond period maturity underlying bond correspond probable maturity impairment provision financial asset postemployment benefit obligation based assumption risk default expected loss rate judgement making recognition deferred tax asset income tax f assumption selecting input deferred tax asset recognised impairment calculation based past history deductible temporary difference extent existing market condition well forward looking probable taxable profit estimate end reporting period available deductible temporary difference utilised management j insurance claim assumes taxable profit available insurance claim recognised company recognising deferred tax asset reasonable certainty recovery management judgment required k impairment review calculation provision income tax impairment exists carrying value deferred tax asset liability company asset cash generating unit cgu exceeds review balance sheet date carrying recoverable amount recoverable amount amount deferred tax asset factor used higher fair value less cost sell estimate may differ actual outcome value use value use calculation based could lead significant adjustment discounted cash flow model calculating amount reported standalone financial value use certain assumption required statement made respect highly uncertain matter including management expectation growth recognition measurement provision g ebitda long term growth rate selection recognition measurement discount rate reflect risk involved provision based assessment 140 plan prepare perform financial statement standalone note standalone financial statement year ended 31st march 2017 8 property plant equipment capital workinprogress 81 current year cr gross block depreciation amortisation net block particular addition deduction addition deduction 1st april 2016 adjustment 31st march 1st april 2016 adjustment 31st march 31st march 2017 2017 2017 property plant equipment freehold land 14200 14200 14200 lease hold land 3121 3121 235 058 293 2828 building 13700 6759 20459 6037 774 6811 13648 plant equipment 22115 6510 1518 27107 10152 2590 1160 11582 15525 laboratory equipment 3355 5278 8633 180 1321 1501 7132 furniture fixture 4973 825 366 5432 2989 622 348 3263 2169 vehicle 906 017 455 468 647 047 330 364 104 office equipment 1537 434 304 1667 1076 291 289 1078 589 computer 1823 432 017 2238 1507 246 017 1736 502 total 65730 20255 2660 83325 22822 5949 2143 26628 56697 b intangible asset anda development cost 1593 1593 1593 1593 computer software 597 413 1010 222 192 414 596 total 2190 413 2603 1815 192 2007 596 total b 67920 20668 2660 85928 24637 6141 2143 28635 57293 c capital work progress including pre operative expense 8504 cr refer note 59 33803 intangible asset development 123 total fixed asset b c 91219 addition includes 4577 cr used research development depreciation 193 cr considered preoperative expenditure refer note 59 8 property plant equipment capital workinprogress 82 previous year cr gross block depreciation amortisation net block net block particular addition deduction addition deduction 1st april adjustment 31st march 1st april adjustment 31st march 31st march 1st april 2016 2016 2016 2016 2016 2015 tangible asset freehold land 1477 12723 14200 14200 1477 lease hold land 3121 3121 177 058 235 2886 2944 building 13700 13700 5304 733 6037 7663 8396 plant equipment 21504 4069 3458 22115 10702 2248 2798 10152 11963 10802 laboratory equipment 3355 3355 180 180 3175 furniture fixture 4704 558 290 4973 2616 613 241 2989 1984 2088 vehicle 876 047 016 906 548 114 015 647 260 328 office equipment 1358 217 038 1537 851 261 036 1076 461 507 computer 2341 273 790 1823 2067 208 768 1507 316 274 total 49081 21242 4593 65730 22265 4415 3858 22822 42908 26816 b intangible asset anda development cost 1593 1593 1593 1593 computer software 418 179 597 102 120 222 375 316 total 2011 179 2190 1695 120 1815 375 316 total b 51092 21421 4593 67920 23960 4535 3858 24637 43283 27132 c capital work progress including pre operative expense 4089 cr refer note 59 23842 17020 intangible asset development 138 total fixed asset b c 67263 44152 addition includes 4286 cr used research development depreciation 267 cr considered preoperative expenditure refer note 59 141 annual report 201617 note standalone financial statement year ended 31st march 2017 9 non current financial investment cr 31 march 2017 31 march 2016 1 april 2015 long term trade investment unquoted investment investment equity instrument subsidiary company ajanta pharma mauritius ltd 613791 ordinary share mauritian 944 944 944 rupee 100 fully paid ajanta pharma usa inc 10000 common stock u 100 607 607 607 fully paid ajanta pharma philippine inc 81995 share philippine peso 100 138 138 138 fully paid ajanta pharma nigeria ltd 10000000 31st march 2016 036 036 023 10000000 1st april 2015 5875000 ordinary share nigerian naira 1 fully paid investment share turkmenderman ajanta pharma ltd 200000 share u 10 fully paidup others opgs power gujarat private limited 195000 31st march 2016 nil 1st april 2015 nil share 019 cr yr 37050 31st march 2016 nil 1st april 2015 nil sub total 1726 1725 1712 b investment mutual fund quoted face value unit icici prudential fmp series 70367 day 10 572 plan n regular plan cumulative 5000000 icici prudential fmp series 71369 day 10 562 plan e regular plan cumulative 5000000 kotak fmp series 124 growth 10 575 5038705 hdfc fmp 372d october 2013 1 series 10 1139 28 regular growth 10000000 birla sun life fixed term plan series ja 10 1126 366 day 10000000 idfc fixed term plan series 49 regular 10 561 plangrowth 5000000 sub total b 4535 total 1726 1725 6247 aggregate value quoted investment 4535 market value aggregate value unquoted investment 1726 1725 1712 figure bracket previous year 142 plan prepare perform financial statement standalone note standalone financial statement year ended 31st march 2017 10 non current financial asset others cr 31 march 2017 31 march 2016 1 april 2015 security deposit 675 482 349 deposit account bank original maturity 12 month lien 135 327 430 others cy nil py 20000 010 interest accrued fixed deposit bank 099 100 087 909 909 876 11 non current asset others 31 march 2017 31 march 2016 1 april 2015 capital advance 1393 1630 538 1393 1630 538 12 inventory 31 march 2017 31 march 2016 1 april 2015 raw material 5325 5627 5768 packing material 1908 1926 2214 workinprogress 1398 1096 1126 finished good 4996 7382 4285 finished good transit 2629 1320 850 stockintrade 1658 1611 1062 stockintrade transit 014 016 17928 18978 15305 13 current financial investment 31 march 2017 31 march 2016 1 april 2015 investment fair value profit loss fvtpl mutual fund quoted face value unit utitreasury advantage fundinstitutional plan 1000 1611 160730 birla sun life cash plus daily dividend 100 014 ular plan 14007 birla sun life dynamic bond fund growth 10 1335 regular plan 5067712 143 annual report 201617 note standalone financial statement year ended 31st march 2017 13 current financial investment contd cr 31 march 2017 31 march 2016 1 april 2015 franklin india low duration fund growth 10 42773165 7897 franklin india short term income plan 10 59811 2025 retail plan birla sun life short term fund growth 10 9183266 5719 regular plan reliance regular saving funddebt plan 10 6685326 1515 growth plan growth option sbi magnum insta cash fund direct plan 10 59711 1000 daily dividend sbi dynamic bond fund regular plan 10 1017 growth 5610098 icici prudential fmp series 70367 day 10 620 plan n regular plan cumulative 5000000 icici prudential interval annual plan iii 10 397 378 regular growth 2480000 2584343 icici prudential fmp series 71369 day 10 610 plan e regular plan cumulative 5000000 kotak fmp series 124 growth regular plan 10 621 5038705 hdfc fmp 372d october 2013 1 series 10 1234 28 regular growth 10000000 birla sun life fixed term plan series ja 10 1222 366 day 10000000 idfc fixed term plan series 49 regular 10 608 plangrowth 5000000 18156 7678 1989 aggregate value quoted investment 18156 7678 24085 market value figure bracket previous year 144 plan prepare perform financial statement standalone note standalone financial statement year ended 31st march 2017 14 trade receivables cr 31 march 2017 31 march 2016 1 april 2015 trade receivables considered good 33600 35048 24085 doubtful debt 490 allowance doubtful debt 490 33600 35048 24085 includes receivable subsidiary refer note 47c1 15 cash cash equivalent 31 march 2017 31 march 2016 1 april 2015 balance bank current account 3253 3096 1415 deposit account original maturity 3 month less 915 cash hand 007 011 011 bank overdraft used cash management purpose 2778 1158 1282 481 1949 1059 16 bank balance cash cash equivalent 31 march 2017 31 march 2016 1 april 2015 earmarked balance bank unpaid dividend 095 073 030 unpaid sale proceeds fractional share cy 5926 31st march 038 2016 6240 deposit account original maturity 3 month upto 002 4000 12 month deposit account original maturity 12 month lien 315 115 060 others 007 4100 412 195 8228 17 current financial asset others 31 march 2017 31 march 2016 1 april 2015 interest receivable 047 025 519 forward contract 077 046 393 124 071 912 18 current tax asset net 31 march 2017 31 march 2016 1 april 2015 income tax paid net provision 1123 1763 1123 1763 145 annual report 201617 note standalone financial statement year ended 31st march 2017 19 current asset cr 31 march 2017 31 march 2016 1 april 2015 balance statutorygovt authority excise authority 4071 2850 3012 vat receivable 398 375 233 octroi refund receivable 052 052 052 prepaid expense 139 121 018 advance supplier 375 275 766 advance employee 330 362 323 advance recoverable cash kind 050 125 100 5415 4160 4504 20 share capital 31 march 2017 31 march 2016 1 april 2015 cr cr cr share fv 2 share fv 2 share fv 2 authorised equity share 150000000 3000 150000000 3000 150000000 3000 issued equity share 88771500 1775 88767750 1775 88710000 1774 subscribed paid equity share fully paid 88005000 1760 88001250 1760 87943500 1759 add share forfeited amount 766500 009 766500 009 766500 009 originally paid 1769 1769 1768 201 reconciliation number equity share outstanding beginning end year 31 march 2017 31 march 2016 1 april 2015 cr cr cr share fv 2 share fv 2 share fv 2 equity share outstanding 88001250 1760 87943500 1759 87876750 1758 beginning year add equity share allotted 2500 38500 001 44500 001 year option exercised esop cy 5000 add equity share allotted 1250 19250 22250 year bonus esop cryr 2500 31st march 2016 38500 1st april 2015 44500 less equity share bought back year equity share outstanding end 88005000 1760 88001250 1760 87943500 1759 year 202 termsrights attached equity share company one class equity share voting right par value 2 per share company declares pay dividend indian rupee interim dividend paid recognised approval board director 146 plan prepare perform financial statement standalone note standalone financial statement year ended 31st march 2017 year ended 31st march 2017 amount dividend per equity share recognised distribution equity shareholder 13 pr yr 14 includes interim dividend 13 pr yr 8 per equity share event liquidation company holder equity share entitled receive remaining asset company distribution preferential amount distribution proportion number equity share held shareholder 203 detail equity share held shareholder holding 5 cr 31 march 2017 31 march 2016 1 april 2015 holding holding holding name shareholder share share share fv 2 fv 2 fv 2 mr yogesh agrawal trustee yogesh agrawal trust 12749999 1449 mr rajesh agrawal trustee rajesh agrawal trust 12749999 1449 mr ravi purushottam agrawal trustee ravi agrawal trust 12659999 1439 mr aayush madhusudan agrawal trustee aayush 12660000 1439 agrawal trust gab investment private limited 8392262 954 8392262 954 8392262 954 ganga export represented mr yogesh 5137500 584 agrawal mr rajesh agrawal mr ravi p agrawal mr aayush agrawal mr yogesh agrawal na na 6383560 725 6383560 726 mr rajesh agrawal na na 6411102 729 6411102 729 mr mannalal b agrawal 5406720 614 5406720 615 mr purushottam b agrawal 5389425 612 5389425 613 mr madhusudan b agrawal 5388750 612 5388750 613 mr manisha agrawal mr richa r agrawal 5137500 584 mr aayush agrawal mr vimal agrawal mr mamta agrawal 5137500 584 31 march 2017 31 march 2016 1 april 2015 share share share fv 2 fv 2 fv 2 204 equity share reserved issuance employee stock option scheme 2011 company equity share 1158750 1162500 1220250 205 aggregate number equity share issued last five year pursuant employee stock option scheme 2011 equity share 170250 166500 108750 206 equity share allotted fully paid bonus share period five year immediately preceding balance sheet date bonus share issued fy 20132014 29292250 29292250 29292250 bonus share allotment esop fy 201415 22250 22250 22250 bonus share allotment esop fy 201516 19250 19250 bonus share allotment esop fy 201617 1250 207 company subsidiary company 147 annual report 201617 note standalone financial statement year ended 31st march 2017 21 non current financial liability borrowing cr 31 march 2017 31 march 2016 1 april 2015 term loan secured bank foreign currency 473 2232 loan unsecured deferred sale tax loan government maharashtra 909 995 1382 3227 211 term loan secured first charge fixed asset company second charge entire current asset company present future pari passu basis addition personal guarantee director 22 non current financial liability 31 march 2017 31 march 2016 1 april 2015 trade security deposit payable 009 045 250 009 045 250 23 non current provision 31 march 2017 31 march 2016 1 april 2015 provision employee benefit net gratuity 066 leave benefit 315 259 410 315 259 476 24 deferred tax liability net 31 march 2017 31 march 2016 1 april 2015 difference tax base property plant equipment 3721 2581 1684 unrealised gainloss security carried fvocifvtpl 215 359 205 deferred tax asset mat credit entitlement b 565 disallowance income tax c 633 582 392 deferred tax liability net b c 2738 2358 1497 25 current financial liability borrowing 31 march 2017 31 march 2016 1 april 2015 working capital loan repayable demand bank secured rupee loan 553 995 508 foreign currency loan 2452 553 3447 508 148 plan prepare perform financial statement standalone note standalone financial statement year ended 31st march 2017 251 working capital loan secured first charge current asset second charge fixed asset company pari passu basis addition personal guarantee director 26 current financial liability trade payable cr 31 march 2017 31 march 2016 1 april 2015 trade payable 13878 14504 10812 13878 14504 10812 refer note 53 micro small medium enterprise disclosure 27 current financial liability 31 march 2017 31 march 2016 1 april 2015 current maturity longterm borrowing secured refer note 211 foreign currency term loan bank 1893 1786 rupee term loan bank 200 unsecured deferred sale tax loan 086 083 unpaid dividend 095 073 030 unpaid sale proceeds fractional share 038 interest accrued 002 002 capital creditor 2429 1938 2077 others 004 015 017 2528 4007 4233 amount due outstanding credited investor education protection fund 31st march 2017 28 current liability 31 march 2017 31 march 2016 1 april 2015 payable advance received customer 283 422 865 statutory due payable 508 639 353 791 1061 1218 29 current provision 31 march 2017 31 march 2016 1 april 2015 provision employee benefit net gratuity 307 299 247 leave benefit 073 070 076 provision sale return expired good refer note 49 900 767 645 1280 1136 968 149 annual report 201617 note standalone financial statement year ended 31st march 2017 30 current tax liability net cr 31 march 2017 31 march 2016 1 april 2015 provision tax net payment 256 256 31 revenue operation 31 march 2017 31 march 2016 sale product finished good 157111 139534 stockintrade 18257 15576 operating revenue export incentive 6683 2000 royalty fee 190 others 220 060 182271 157360 32 income 31 march 2017 31 march 2016 dividend subsidiary company 4318 6691 dividend investment fvtpl 067 255 gain financial instrument fvtpl 1683 545 interest deposit bank 053 323 interest others 182 017 exchange difference net 707 miscellaneous income 391 149 6695 8687 33 cost material consumed 31 march 2017 31 march 2016 raw material consumed 28247 30151 packing material consumed 9084 9570 37331 39721 34 purchase stockintrade 31 march 2017 31 march 2016 purchase stockintrade 5923 5781 150 plan prepare perform financial statement standalone note standalone financial statement year ended 31st march 2017 35 change inventory finished good workinprogress stockintrade cr 31 march 2017 31 march 2016 inventory beginning year workinprocess 8701 5135 finished good 1096 1126 stockintrade 1627 1062 11424 7323 inventory end year workinprocess 7625 8701 finished good 1398 1096 stockintrade 1672 1627 b 10695 11424 total change inventory finished good workinprogress stockintrade b 729 4101 36 employee benefit expense 31 march 2017 31 march 2016 salary wage bonus allowance 24872 21715 contribution provident fund 1711 1531 expense employee stock option scheme 145 031 staff welfare expense 250 226 26978 23503 37 finance cost 31 march 2017 31 march 2016 interest expense 124 250 borrowing cost including bank charge 159 170 283 419 38 depreciation 31 march 2017 31 march 2016 depreciation tangible asset refer note 8 5756 4148 depreciation intangible asset refer note 8 192 120 5948 4268 151 annual report 201617 note standalone financial statement year ended 31st march 2017 39 expense cr 31 march 2017 31 march 2016 selling expense 11868 11522 clearing forwarding 3925 3802 travelling expense 3202 3183 processing charge 1734 1741 power fuel 1836 1515 advertisement publicity 358 1081 consumption store spare part 5337 3618 rent 631 844 rate tax 054 039 legal professional fee 1358 1025 postage telephone expense 640 624 repair maintenance building 414 564 plant machinery 1773 1143 computer others 526 682 insurance 547 446 donation 006 003 exchange rate difference net 853 impairment loss financial asset 2327 095 excise duty collected sale 1838 1539 loss salediscard property plant equipment net 389 692 corporate social responsibility expense refer note 48 872 639 miscellaneous expense 7221 5402 47709 40200 40 capital management company policy maintain strong capital base maintain investor creditor market confidence sustain future development business management monitor return capital well level dividend equity shareholder board director seek maintain balance higher return might possible higher level borrowing advantage security afforded sound capital position company target achieve return capital 35 201617 return 43 201516 return 47 company monitor capital using ratio adjusted net debt adjusted equity purpose adjusted net debt defined total liability comprising interestbearing loan borrowing obligation finance lease less cash cash equivalent current investment adjusted equity comprises component equity company policy keep ratio 100 adjusted net debt equity ratio 31st march 2017 follows cr organisation 31 march 2017 31 march 2016 1 april 2015 debt debt current liability 19354 25841 21691 less cash cash equivalent current investment 18637 9627 3048 net debt 717 16213 18643 equity b 150394 113170 84450 net debt equity ratio ab 001 014 022 152 plan prepare perform financial statement standalone note standalone financial statement year ended 31st march 2017 41 earnings per share eps numerator denominator used calculate basic diluted earnings per share 31 march 2017 31 march 2016 basic diluted earnings per share profit attributable equity shareholder basic eps cr 49981 42195 add dilutive effect profit cr b nil nil profit attributable equity shareholder diluted eps cr cab 49981 42195 weighted average number equity share outstandingfor basic eps 88004688 87996438 add dilutive effect option outstandingnumber equity share e 24466 6738 weighted average number equity share diluted eps fde 88029154 88003176 face value per equity share 2 2 basic earnings per share ad 5679 4795 diluted earnings per share cf 5678 4795 account employee stock option scheme esosrefer note 43 42 employee benefit required ind 19 employee benefit disclosure 421 defined contribution plan company offer employee defined contribution plan form provident fund pf employee pension scheme eps government certain state plan employee state insurance esi pf eps cover substantially regular employee esi cover certain employee contribution made government fund employee company pay predetermined contribution provident fund esi scheme contribution pension fund made company contribution normally based certain proportion employee salary year company recognised following amount account cr particular 31 march 2017 31 march 2016 provident fund employee pension scheme 1348 1143 employee state insurance 163 181 1511 1324 defined benefit plan gratuity company make annual contribution employee group gratuitycum life assurance cash accumulation scheme lic funded defined benefit plan qualifying employee scheme provides payment vested employee 4221 normal retirement early retirement withdrawal resignation per provision payment gratuity act 1972 vesting period 5 year service 4222 death service per provision payment gratuity act 1972 without vesting period death benefit company provides death benefit defined benefit plan death benefit plan certain category employee death benefit plan provides lump sum payment vested employee death compensation received insurance company restricted limit set forth said plan death benefit plan nonfunded 153 annual report 201617 note standalone financial statement year ended 31st march 2017 disclosure defined benefit plan ie gratuity funded plan based actuarial report 31st march 2017 cr particular 31 march 2017 31 march 2016 change defined benefit obligation opening defined benefit obligation 1431 1137 current service cost 300 256 interest cost 105 082 actuarial loss gain change fi nancial assumption 008 034 experience adjustment 006 075 benefit paid 178 085 closing defined benefit obligation 1660 1431 ii change value plan asset opening value plan asset 1132 824 expense deducted fund nil 010 adjustment opening fund nil 002 interest income 093 068 return plan asset excluding amount included interest income 015 006 contribution employer 320 327 benefit paid 178 085 closing value plan asset 1352 1132 iii amount recognised balance sheet present value funded obligation year end 1660 1431 fair value plan asset year end 1352 1132 net asset liability recognised year end 308 299 iv expense recognised statement profit loss current service cost 300 256 net interest cost 012 014 expense deducted fund nil 010 adjustment opening fund nil 002 expense recognised statement comprehensive income net actuarial lossgain recognized current year change financial assumption 008 034 experience adjustment 006 075 return plan asset excluding amount included interest income 015 006 v asset information others policy insurance 100 100 vi principal actuarial assumption used discount rate pa 720 795 salary growth rate pa 530 600 154 plan prepare perform financial statement standalone note standalone financial statement year ended 31st march 2017 sensitivity analysis reasonably possible change reporting date one relevant actuarial assumption holding assumption constant would affected defined benefit obligation amount shown cr particular 31 march 2017 31 march 2016 increase decrease increase decrease discount rate 05 movement 1581 1744 1366 1501 salary growth rate 05 movement 1741 1583 1500 1367 although analysis take account full distribution cash flow expected plan provide approximation sensitivity assumption estimate future increase compensation level considered actuarial valuation taken account inflation seniority promotion relevant factor supply demand employment market expected contribution defined benefit plan next financial year line fy 201617 423 leave encashment company employee entitled compensated absence allowed accumulated encashed per company rule liability compensated absence nonfunded provided based report independent actuary using projected unit credit method accordingly 387 cr pr yr 329 cr liability yearend compensated absence per actuarial valuation provided account 43 share based payment company implemented employee stock option scheme 2011 esos 2011 approved earlier year shareholder company compensation committee board director year 15500 option granted company aforesaid esos 2011 employee company grant date option exercise price vesting period 26 july 2016 15500 2 13082017 13082019 option granted exercise price accordance relevant sebi guideline force time grant option entitles holder exercise right apply seek allotment one equity share 2 particular option esos 2011 cr 31 march 2017 31 march 2016 particular no no option outstanding beginning year 12750 91500 add option granted year 15500 9000 less option exercised year 3750 57750 less option lapsed year nil 30000 option outstanding year end 24500 12750 155 annual report 201617 note standalone financial statement year ended 31st march 2017 44 financial instrument fair value risk management fair value measurement cr financial instrument 31 march 2017 31 march 2016 1 april 2015 category fvpl amortised fvpl amortised fvpl amortised cost cost cost financial asset forward exchange contract 077 046 393 investment mutual fund 18156 7678 6524 investment unquoted equity share cy 37050 trade receivables 33600 35048 24085 non current financial asset 909 909 876 others cash cash equivalent 481 1949 1059 bank balance 412 195 8228 cash cash equivalent interest receivable 047 025 519 total financial asset 18233 35449 7724 38127 6917 34767 financial liability bank borrowing 553 6808 5804 non current financial 009 045 250 liability capital creditor 2429 1938 2077 current financial 099 090 087 liability trade payable 13878 14504 10812 total financial liability 16968 23385 19030 156 plan prepare perform financial statement standalone note standalone financial statement year ended 31st march 2017 fair value hierarchy section explains judgement estimate made determining fair value financial instrument recognised measured fair value b measured amortised cost fair value disclosed financial statement provide indication reliability input used determining fair value company classified financial instrument three level prescribed accounting standard explanation level follows underneath table cr financial asset liability 31 march 2017 31 march 2016 1 april 2015 measured fair value level level level ii iii ii iii ii iii financial asset recurring fair value measurement forward exchange contract 077 046 393 investment mutual fund 18156 7678 6524 non recurring fair value measurement investment unquoted equity share cy 37050 trade receivables 33600 35048 24085 non current financial asset 909 909 876 others cash cash equivalent 481 1949 1059 bank balance cash 412 195 8228 cash equivalent interest receivable 047 025 519 total financial asset 18156 077 35449 7678 046 38127 6524 393 34767 financial liability non recurring fair value measurement bank overdraft 553 6808 5804 non current financial 009 045 250 liability capital creditor 2429 1938 2077 current financial 099 090 087 liability trade payable 13878 14504 10812 total financial liability 16968 23385 19030 level 1 level 1 hierarchy includes financial instrument measured using quoted price includes mutual fund quoted price mutual fund valued using closing nav level 2 fair value financial instrument traded active market like forward contract determined using valuation technique maximise use observable market data rely little possible entityspecific estimate significant input required fair value instrument observable instrument included level 2 level 3 one significant input based observable market data instrument included level 3 case unlisted equity security etc included level 3 157 annual report 201617 note standalone financial statement year ended 31st march 2017 b financial risk management trade receivables company exposure following risk arising customer credit risk managed financial instrument business unit subject company credit risk established policy procedure liquidity risk control relating customer credit risk market risk management trade receivables mainly wholesaler noninterest bearing risk management framework generally 14 day 150 day credit company board director overall term credit limit established responsibility establishment oversight customer based internal rating criterion company risk management framework deviation credit limit require management responsible developing approval director 90 monitoring company risk management policy customer transacting guidance audit committee company 4 year monitored individual business company risk management policy manager located country established identify analyse risk place outstanding customer receivables faced set appropriate risk limit regularly monitored company control monitor risk adherence concentration credit risk customer limit risk management policy system base widely distributed economically reviewed regularly reflect change market geographically condition company activity company training management standard 31st march 2017 company 42 procedure aim maintain disciplined customer excluding subsidiary constructive control environment 31st march 2016 55 customer 1st april employee understand role obligation 2015 45 customer owed company 050 cr accounted company audit committee oversees approximately 50 3 year ie management monitor compliance company 31st march 2017 31st march 2016 1st april risk management policy procedure 2015 receivables outstanding review adequacy risk management framework relation risk faced company impairment analysis performed audit committee assisted oversight role reporting date individual internal audit internal audit undertakes basis major client addition large regular ad hoc review risk management number minor receivables grouped control procedure result homogenous group assessed reported audit committee impairment collectively calculation based exchange loss historical data ii credit risk maximum exposure credit risk credit risk risk counter party reporting date carrying value meet obligation financial instrument class financial asset company customer contract leading financial hold collateral security company loss company exposed credit risk evaluates concentration risk operating activity primarily trade receivables respect trade receivables low financing activity including deposit customer located several jurisdiction bank mutual fund financial institution operate largely independent market foreign exchange transaction financial instrument 158 plan prepare perform financial statement standalone note standalone financial statement year ended 31st march 2017 expected credit loss trade receivables simplified approach cr 31 march 2017 31 march 2016 1 april 2015 gross carrying amount 34090 35048 24085 average expected loss rate export sale 144 carrying amount trade receivables net impairment 33600 35048 24085 b financial instrument highly marketable debt investment company limit exposure credit risk outflow 096 31st march 2017 31st march investing liquid debt security issued 2016 037 1st april 2015 014 mutual fund credit ranking least 3 crisil iv market risk equivalent rating agency company monitor market risk risk change change credit risk tracking published market price foreign exchange external credit ranking based ongoing rate interest rate equity price assessment counterparty risk company affect company income value adjusts exposure various counterparties holding financial instrument objective market risk management iii liquidity risk manage control market risk exposure liquidity risk risk company may within acceptable parameter able meet present future cash optimising return financial instrument collateral obligation without incurring affected market risk include loan unacceptable loss company objective borrowing deposit investment time maintain optimum level derivative financial instrument liquidity meet cash collateral requirement company closely monitor company activity expose variety liquidity position deploys robust cash financial risk including effect management system maintains adequate change foreign currency exchange rate source financing including bilateral interest rate company us derivative loan debt overdraft bank financial instrument foreign exchange optimised cost working capital requirement contract manage exposure foreign adequately addressed internally exchange fluctuation transaction generated fund trade receivables kept carried within guideline set within manageable level risk management committee company aim maintain level sensitivity analysis prepared cash cash equivalent highly basis amount net debt marketable debt investment amount ratio fixed floating interest rate excess expected cash outflow debt derivative proportion financial liability next six month financial instrument foreign currency ratio cash cash equivalent constant 159 annual report 201617 note standalone financial statement year ended 31st march 2017 analysis excludes impact currency transaction movement market variable primarily denominated u dollar euro carrying value postemployment benefit obligation provision non point time company cover financial asset liability foreign currency risk taking appropriate percentage foreign currency exposure sensitivity relevant income statement approved risk management committee item effect assumed change line laid policy approved respective market risk based board company us forward exchange financial asset financial liability held contract mitigate currency risk 31st march 2017 31st march 2016 maturity less one year reporting date respect monetary currency risk asset liability denominated foreign group exposed currency risk currency company policy ensure extent mismatch net exposure kept acceptable currency sale purchase level buying selling foreign currency borrowing denominated spot rate necessary address respective functional currency company shortterm imbalance following table analysis foreign currency risk financial instrument 31st march 2017 cr particular u dollar euro total bank balance 1562 067 1629 trade receivables 27652 972 28624 financial asset 125 546 671 trade payable 804 257 1061 financial liability 083 199 282 net asset liability 28452 1129 29581 following table analysis foreign currency risk financial instrument 31st march 2016 cr particular u dollar euro total bank balance 2247 011 2258 trade receivables 30294 1544 31838 financial asset 569 594 1163 trade payable 624 205 829 financial liability 4881 471 5352 net asset liability 27605 1473 29078 following table analysis foreign currency risk financial instrument 1st april 2015 cr particular u dollar euro total bank balance 962 020 982 trade receivables 17419 935 18354 financial asset 470 341 811 trade payable 764 066 830 financial liability 4473 465 4938 net asset liability 13613 766 14379 160 plan prepare perform financial statement standalone note standalone financial statement year ended 31st march 2017 year ended 31st march 2017 every percentage point depreciation appreciation exchange rate indian rupee respective currency affected company incremental profit tax per cr particular change effect profit currency tax exchange rate u dollar usd 1 1 285 285 euro 1 1 011 011 year ended 31 march 2016 every percentage point depreciationappreciation exchange rate indian rupee respective currency affected company incremental profit tax per cr particular change effect profit currency tax exchange rate u dollar usd 1 1 276 276 euro 1 1 015 015 year ended 1st april 2015 every percentage point depreciationappreciation exchange rate indian rupee respective currency affected company incremental profit tax per cr particular change effect profit currency tax exchange rate u dollar usd 1 1 136 136 euro 1 1 008 008 b interest rate risk interest rate risk risk fair value future cash flow financial instrument fluctuate change market interest rate company exposure risk change market interest rate relates primarily company debt interest obligation company engages financing activity market linked rate change interest rate environment may impact future rate borrowing interest rate profile company interestbearing financial instrument reported management follows cr particular 31 march 2017 31 march 2016 1 april 2015 foreign currency term loan nil 2366 4018 foreign currency packing credit nil 2452 nil nil 4818 4018 161 annual report 201617 note standalone financial statement year ended 31st march 2017 reasonably possible change 100 basis point interest rate reporting date would impacted profit tax per analysis assumes variable particular foreign currency exchange rate remain constant cr particular 31 march 2017 31 march 2016 1 april 2015 increase interest rate 1 nil 048 040 decrease interest rate 1 nil 048 040 c price risk company exposure price risk equity investment company except subsidiary 45 disclosure operating lease ind 17 lease company taken various premise operating lease generally cancellable range 11 month 5 year renewable mutual consent mutually agreeable term lease agreement price escalation clause restriction imposed lease arrangement sub lease contingent rent lease payment 631 cr pr yr 844 cr recognised statement profit loss rent note 39 future minimum lease payment payment profile noncancellable operating lease cr particular 31 march 2017 31 march 2016 later one year 291 572 later one year later five year 320 735 later five year nil nil 46 contingent liability commitment contingent liability cr particular 31 march 2017 31 march 2016 claim company acknowledged debt 090 070 ii sale tax demand disputed company pending appeal nil 022 iii custom duty import advance license scheme pending fulfilment 144 076 export obligation iv disputed octroi 052 052 amount paid protest 052 cr pr yr 052 cr v excise duty service tax disputed company 264 054 amount paid protest 025 cr pr yr 025 cr vi income tax demand disputed company pending appeal 833 1752 amount paid protest 786 cr pr yr 217 cr vii unpaid allotment money respect share ajanta pharma uk ltd wholly owned 008 009 subsidiary equivalent uk pound 10000 pr yr uk pound 10000 respect clause vi management advised demand likely either deleted substantially reduced accordingly provision considered necessary 162 plan prepare perform financial statement standalone note standalone financial statement year ended 31st march 2017 future cash outflow respect liability clause dependent term agreed upon party respect clause ii vi dependent decision relevant authority respective dispute respect clause vii dependent call made investee company commitment estimated amount contract remaining executed capital account provided net advance 13228 cr pr yr 10366 cr b commitment noncancellable operating lease refer note 45 47 related party disclosure required ind 24 given relationship category subsidiary ajanta pharma mauritius ltd apml ajanta pharma mauritius international ltd apmil ajanta pharma nigeria limited apnl ajanta pharma usa inc apui ajanta pharma philippine inc appi ajanta pharma uk ltd apuk category ii director key management personnel relative mr mannalal b agrawal chairman mr purushottam b agrawal executive vice chairman mr madhusudan b agrawal executive vicechairman mr yogesh agrawal managing director mr rajesh agrawal joint managing director mr chandrakant khetan nonexecutive director dr anil kumar nonexecutive director mr k h viswanathan nonexecutive director mr prabhakar dalal nonexecutive director dr anjana grewal nonexecutive director mr arvind agrawal chief financial officer mr gaurang shah company secretary relative key management personnel category iiienterprise person covered category ii able exercise significant control gab investment private limited seth bhagwandas agrawal charitable trust ganga export represented mr yogesh agrawal mr rajesh agrawal mr ravi agrawal mr aayush agrawal yogesh agrawal trust trustee yogesh agrawal wef 7th march 2017 rajesh agrawal trust trustee rajesh agrawal wef 7th march 2017 ravi agrawal trust trustee ravi p agrawal wef 7th march 2017 ajanta pharma limited group gratuity trust 163 annual report 201617 note standalone financial statement year ended 31st march 2017 b following transaction carried related party cr sr particular category 31 march 2017 31 march 2016 1 sale good apml 3503 3732 appi 6897 4747 apmil 3408 6023 apui 18340 2228 apnl 558 690 2 dividend subsidiary company apml 3654 5547 appi 664 1144 3 expense reimbursement apui 1534 1111 4 key management compensation short term employee benefit mr purushottam b agrawal ii 207 188 mr madhusudan b agrawal ii 207 188 mr yogesh agrawal ii 207 188 mr rajesh agrawal ii 207 147 mr arvind agrawal ii 084 070 mr gaurang shah ii 037 033 postemployment benefit ii 009 013 5 commission sitting fee nonexecutive director mr mannalal b agrawal ii 124 123 mr chandrakant khetan ii 006 004 dr anil kumar ii 006 002 mr k h viswanathan ii 005 003 mr prabhakar dalal ii 005 003 dr anjana grewal ii 005 003 6 rent mr manisha agrawal ii nil 079 mr smriti rajesh agrawal ii nil 079 mr aayush agrawal ii nil 079 7 dividend paid ii 4682 7915 iii 3762 1175 8 investment subsidiary apnl nil 013 9 purchase property mr yogesh agrawal ii 260 nil mr rajesh agrawal ii 260 nil mr ravi p agrawal ii 260 nil mr aayush agrawal ii 260 nil 10 sale vehicle mr mannalal b agrawal ii 110 nil mr ravi p agrawal ii 023 nil 11 corporate social responsibility expense seth bhagwandas agarwal charitable trust iii 619 105 12 contribution made group gratuity trust premium paid lic premium paid iii 331 336 13 bad debt apnl 162 nil 164 plan prepare perform financial statement standalone note standalone financial statement year ended 31st march 2017 c amount outstanding 31st march 2017 cr sr particular category 31 march 2017 31 march 2016 1 april 2015 1 trade receivables appi 1820 1800 1174 apui 12913 1491 098 apnl 278 713 127 apmil 085 404 nil 2 receivable appi nil nil 083 3 investment apml 944 944 944 appi 138 138 138 apui 607 607 607 apnl 036 036 023 4 trade payable apui nil 241 044 5 advance received apml 245 657 389 6 commission payable nonexecutive director mr mannalal b agrawal ii 120 120 151 mr chandrakant khetan ii 001 nil 003 dr anil kumar ii 001 nil 003 mr k h viswanathan ii 001 nil 002 mr prabhakar dalal ii 001 nil 002 dr anjana grewal ii 001 nil 002 company completed independent evaluation international domestic transaction year ended 31st march 2017 reviewed year ended 31st march 2016 determine whether transaction associated enterprise undertaken arm length price based internal external transfer pricing review validation company belief transaction associated enterprise undertaken basis arm length principle 48 contribution towards corporate social responsibility particular csr expenditure follows gross amount required spent company year 842 cr previous year 609 b amount spend year sr particular cash yet paid cash total construction acquisition asset nil nil nil b purpose 872 nil 872 includes paid related party 619 cr refer note 47 c amount spend previous year sr particular cash yet paid cash total construction acquisition asset nil nil nil b purpose 639 nil 639 includes paid related party 105 cr refer note 47 165 annual report 201617 note standalone financial statement year ended 31st march 2017 49 provision anticipated sale return expired good ind 37 cr particular 31 march 2017 31 march 2016 balance beginning year 767 645 add provision made year 571 489 less amount written backutilized year 438 367 balance end year 900 767 50 disclosure specified bank note sbns year company specified note denomination note defined mca notification gsr308e dated 31st march 2017 detail specified bank note sbn held transacted period 8th november 2016 30th december 2016 denomination wise sbns note per notification given sbns total particular denomination note closing cash hand 8th november 2016 827500 581490 1408990 permitted receipt nil 1665581 1665581 permitted payment nil 1263085 1263085 amount deposited bank 827500 50000 877500 closing cash hand 30th december 2016 nil 934086 934086 51 company one segment activity namely pharmaceutical 52 remuneration auditor excluding service tax cr particular 31 march 2017 31 march 2016 audit fee 020 020 tax audit fee 004 004 certification matter 008 008 53 detail due micro small enterprise defined micro small medium enterprise development act 2006 information determined extent party identified basis information available company cr 31 march 2017 31 march 2016 principle amount interest due thereon remaining unpaid supplier end accounting year principle amount due micro small enterprise nil 159 interest due nil 014 b amount interest paid buyer term section 16 micro small nil nil medium enterprise development act 2006 along amount payment made supplier beyond appointed day accounting year c amount interest due payable period delay making payment nil 014 paid beyond appointed day year without adding interest specified micro small medium enterprise development act 2006 amount interest accrued remaining unpaid end accounting year nil 050 e amount interest remaining due payable even succeeding nil nil year date interest due actually paid small enterprise purpose disallowance deductible expenditure section 23 micro small medium enterprise development act 2006 166 plan prepare perform financial statement standalone note standalone financial statement year ended 31st march 2017 54 research development expenditure revenue expense research development incurred year except depreciation cr particular 31 march 2017 31 march 2016 cost materialconsumablesspares 4845 3207 employee benefit expense 4656 3082 utility 470 309 expense 5062 4049 total 15033 10647 55 note foreign currency exposure asset liability year company entered forward exchange contract derivative instrument mitigate foreign currency risk establish amount currency indian rupee required available settlement date certain payable receivables following outstanding foreign currency forward contract entered company 31 march 2017 31 march 2016 particular foreign currency foreign currency buy sell cross currency amt cr amt cr euro 008 025 sell inr usd 010 050 sell inr yearend foreign currency exposure mitigated derivative instrument otherwise cr cr foreign currency foreign currency foreign currency particular amt cr amt cr 31 march 2017 31 march 2016 31 march 2017 31 march 2016 amount receivable 36407 33026 561 498 usd 1070 1171 015 016 euro 064 540 001 008 chf 001 nil 000 nil gbp 023 nil 001 nil aed nil 012 nil 020 jpy amount payable 890 5444 014 082 usd 458 205 007 003 euro nil 002 nil 000 gbp 006 nil 010 nil jpy gbp 1030 py gbp 2082 56 excise duty includes 003 cr pr yr 012 cr net impact excise duty provision opening closing stock 57 company granted loan advance nature loan stipulated regulation 343 53f read schedule v security exchange board india listing obligation disclosure requirement regulation 2015 purpose loan employee per company policy security deposit paid towards premise taken leave license basis considered hence investment loan share parent company andor subsidiary company 167 annual report 201617 note standalone financial statement year ended 31st march 2017 58 company invested jv turkmenderman ajanta pharma ltd tdapl two decade back management control however later company surrendered management control favour local partner since control tdapl operates severe restriction significantly impairs ability transfer fund hence company impaired entire investment tdapl considered unrelated party company making effort divest investment since last year without success 59 preoperative expense pending capitalisation included capital workinprogress refer note 8 represent direct attributable expenditure setting plant prior date commencement commercial production capitalised completion project commencement commercial operation detail pre operative expense cr particular 31 march 2017 31 march 2016 opening balance 4089 1566 add incurred year employee benefit expense 1821 846 professional fee 081 037 travelling expense 137 056 depreciation 193 267 others 2869 1352 total 9190 4124 less income 111 035 less capitalised tangible asset 575 nil closing balance 8504 4089 60 income tax income tax expensebenefit recognized income statement consists following cr 31 march 2017 31 march 2016 current tax current tax profit year 13689 13492 adjustment current tax prior period 009 303 total current tax expense 13699 13189 deferred tax expensebenefit origination reversal timing difference 386 873 total income tax expense recognized income statement 14084 14061 b reconciliation effective tax rate following reconciliation company effective tax rate year ended 31st march 2017 accounting profit income tax 64065 56256 enacted tax rate india 3461 3461 computed expected tax benefitexpenses 22172 19470 effect nondeductible expense 1315 1510 effect exempt nonoperating income 023 088 tax effect chargeable different rate 1094 1158 additional deduction r expense 6780 5166 investment allowance plant machinery 1357 193 others deductible expense 158 010 adjustment current tax prior period 009 303 income tax benefitexpenses 14084 14061 effective tax rate 2198 2500 168 plan prepare perform financial statement standalone note standalone financial statement year ended 31st march 2017 c deferred tax asset liability tax effect significant temporary difference resulted deferred tax asset liability description created difference given cr particular 31 march 2017 31 march 2016 1 april 2015 deferred tax liability property plant equipment 3721 2581 1684 gain financial instrument fair value profit loss 215 359 205 total deferred tax liability 3936 2940 1889 deferred tax asset leave encashment 134 114 168 bonus 190 provision expired good 311 265 223 remeasurement gain loss defined benefit plan 018 012 mat credit entitlement 565 provision loss allowance 170 total deferred tax asset 1198 582 392 deferred tax liability set 2738 2358 1497 movement deferred tax liability net opening balance 2358 1498 remeasurement gain loss defined benefit plan 006 012 tax benefitexpense period recognised profit loss 386 873 closing balance 2738 2358 charge relating temporary difference year ended 31st march 2017 primarily account property plant equipment gain investment fvtpl partially offset provision expired good provision loss allowance compensated absence mat credit entitlement credit temporary difference year ended 31st march 2016 primarily account property plant equipment gain investment fvtpl partially offset provision expired good compensated absence provision loss allowance forward contract receivable 61 firsttime adoption ind pursuant company indian accounting standard rule 2015 company adopted 31st march 2017 reporting date first time adoption indian accounting standard indas consequently 1st april 2015 transition date preparation financial statement financial statement year ended 31st march 2017 first financials prepared accordance indas upto financial year ended 31st march 2016 company prepared financial statement accordance accounting standard notified section 133 company act 2013 read together company account rule 2014 previous gaap preparing financial statement opening balance sheet prepared 1st april 2015 ie date transition indas figure previous period year ended 31st march 2016 restated regrouped reclassified wherever required comply indas schedule iii company act 2013 make comparable note explains principal adjustment made company restating financial statement prepared accordance previous gaap including balance sheet 1st april 2015 financial statement year ended 31st march 2016 169 annual report 201617 note standalone financial statement year ended 31st march 2017 exemption exception ind 101 allows firsttime adopter certain exemption following exception applied retrospective application certain accordance ind 101 preparing financial requirement ind statement transition ind company applied derecognition financial asset financial following exemption liability company elected continue carrying company elected apply derecognition value property plant equipment requirement financial asset financial recognised 1st april 2015 measured per liability ind 109 prospectively previous gaap use carrying value transaction occurring date deemed cost property plant transition ind equipment classification measurement financial asset company elected continue carrying company classified financial asset value intangible asset recognised accordance ind 109 basis 1st april 2015 measured per previous gaap fact circumstance exist date use carrying value deemed cost transition ind intangible asset government loan ind 102 sharebased payment per ind 101 company applied applied equity instrument sharebased requirement ind 109 financial instrument payment transaction vested date ind 20 accounting government transition ind grant disclosure government assistance prospectively sale tax deferral loan existing appendix c ind 17 requires entity date transition ind as assess whether contract arrangement recognised corresponding benefit loan contains lease assessment belowmarket rate interest government carried inception contract grant company used previous gaap arrangement however company used ind carrying amount loan date transition 101 exemption assessed arrangement ind as carrying amount loan based embedded lease based condition opening ind balance sheet per ind place date transition 109 loan classified amortised cost since difference company elected apply previous gaap carrying amount amount paid carrying amount investment subsidiary impact effective interest rate ie deemed cost date transition ind discounting unwinding required 170 plan prepare perform financial statement standalone note standalone financial statement year ended 31st march 2017 reconciliation equity previouly reported igaap ind cr particular 31 march 2016 date transition 1 april 2015 previous gaap adjustment ind previous gaap adjustment ind transition transition ind ind asset 1 noncurrent asset property plant equipment 42908 42908 26816 26816 b capital workinprogress 23842 23842 17020 17020 c investment property goodwill e intangible asset 375 375 316 316 f intangible asset development 138 138 g biological asset bearer plant h financial asset investment 1725 1725 5716 531 6247 ii trade receivables iii loan iv others 909 909 876 876 deferred tax asset net j noncurrent asset 1630 1630 538 538 2 current asset inventory 18978 18978 15305 15305 b financial asset investment 6639 1039 7678 1946 043 1989 iitrade receivables 35048 35048 24085 24085 iiicash cash equivalent 3107 1158 1949 2341 1282 1059 ivbank balance iii 195 195 8228 8228 vloans viothers 073 002 071 894 018 912 c current tax asset net 1763 1763 current asset 4160 4160 4504 4504 total asset 141490 121 141369 108585 690 107895 equity liability equity equity share capital 1769 1769 1768 1768 b equity 110710 691 111401 76865 5817 82682 liability 1 noncurrent liability financial liability borrowing 1382 1382 3227 3227 ii trade payable iii financial liability 046 001 045 250 250 b provision 259 259 476 476 c deferred tax liability net 2011 347 2358 1516 019 1497 noncurrent liability 2 current liability financial liability borrowing 4605 1158 3447 1790 1282 508 ii trade payable 14504 14504 10812 10812 iii financial liability 4007 4007 4233 4233 b current liability 1061 1061 1218 1218 c provision 1136 1136 6174 5206 968 current tax liability net 256 256 total equity liability 141490 121 141369 108585 690 107895 171 annual report 201617 note standalone financial statement year ended 31st march 2017 reconciliation statement profit loss previously reported igaap ind year ended 31st march 2016 cr previous gaap adjustment ind transition ind continuing operation income revenue operation gross 155176 2184 157360 income 8235 452 8687 total income 163411 2636 166047 expense cost material consumed 39721 39721 purchase stockintrade 5781 5781 change inventory finished good workinprogress 4101 4101 stockintrade employee benefit expense 23538 035 23503 finance cost 419 419 depreciation amortisation expense 4268 4268 expense 38653 1547 40200 total expense 108279 1511 109791 profit tax 55132 1125 56256 tax expense current tax 13189 13189 deferred tax charge credit 495 377 872 profit year 41448 748 42195 comprehensive income comprehensive income reclassified profit loss subsequent year remeasurement gain loss defined benefit plan 035 035 income tax effect 012 012 net comprehensive income reclassified profit 023 023 loss subsequent year comprehensive income year net tax 023 023 total comprehensive income year net tax 41448 725 42172 easurement recognition difference ind previous gaap year ended 31st march 2016 1 fair valuation investment previous gaap investment equity instrument mutual fund classified long term investment current investment based intended holding period realisability long term investment carried cost less provision temporary decline value investment current investment carried lower cost fair value ind investment required measured fair value resulting fair value change investment recognised retained earnings date transition subsequently profit loss year ended 31st march 2016 increased retained earnings 679 cr net deffered tax 31st march 2016 1st april 2015 375 cr 2 proposed dividend previous gaap proposed dividend including dividend distribution tax ddt recognised liability period relate irrespective declared ind proposed dividend recognised liability period declared company usually approved shareholder general meeting paid 172 plan prepare perform financial statement standalone note standalone financial statement year ended 31st march 2017 therefore dividend liability proposed dividend retained earnings comprehensive including dividend distribution tax liability amounting income thus employee benefit expense reduced 5851 cr derecognised retained 035 cr recognised comprehensive earnings date transition income 023 cr net deffered tax year ended 31st march 2016 proposed dividend including dividend distribution tax liability amounting 5851 cr 4 deferred tax derecognised transition date previous gaap requires deferred tax accounting using recognised retained earnings year ended income statement approach focus 31st march 2016 declared paid difference taxable profit accounting profit period ind 12 requires entity 3 defined benefit obligation account deferred tax using balance sheet oth previous gaap ind company b approach focus temporary difference recognised cost related postemployment carrying amount asset liability defined benefit plan actuarial basis balance sheet tax base application previous gaap entire cost related post ind 12 approach resulted recognition employment defined benefit plan including actuarial deferred tax new temporary difference gain loss charged profit loss required previous gaap ind remeasurements comprising actuarial gain loss effect asset ceiling excluding addition various transitional adjustment amount included net interest net defined lead different temporary difference deferred benefit liability return plan asset excluding tax adjustment recognised correlation amount included net interest net defined underlying transaction either retained earnings benefit liability recognised immediately separate component equity balance sheet corresponding debit credit change increased decreased deferred tax liability follows cr particular 31 march 2016 1 april 2015 financial instrument 359 205 employee benefit 012 nil provision nil 223 increase deferred tax liability 347 019 5 comprehensive income ind item income expense recognised period included profit loss period unless standard requires permit otherwise item income expense recognised profit loss shown statement profit loss comprehensive income includes remeasurements defined benefit plan concept comprehensive income exist previous gaap 6 statement cash flow transition previous gaap ind material impact statement cash flow ind bank overdraft repayable demand form integral part cash management process included cash cash equivalent purpose presentation statement cash flow previous gaap bank overdraft considered part borrowing movement bank overdraft shown part financing activity consequently cash cash equivalent reduced 1158 cr 31st march 2016 1st april 2015 1282 cr 173 annual report 201617 note standalone financial statement year ended 31st march 2017 7 excise duty u nder previous gaap revenue sale product presented exclusive excise duty ind revenue sale good presented inclusive excise duty excise duty paid presented face statement profit loss part expense change resulted increase total revenue total expense year ended 31st march 2016 inr 1539 cr impact total equity profit 8 cash discount nder previous gaap cash discount 011 cr recognised part expense adjusted u revenue ind year ended 31st march 2016 impact total equity profit 9 retained earnings change decreased increased retained earnings follows cr particular 31 march 2016 1 april 2015 financial instrument net 269 388 proposed dividend nil 5851 provision net 422 422 increase retained earnings 691 5817 preparation indas financial statement company made several presentation difference previous gaap indas difference impact reported profit total equity accordingly asset liability reclassified another line item indas date transition financial statement line item described differently indas compared previous gaap although asset liability included line item unaffected see accompanying note forming part financial statement per report even date attached kapoor parekh associate behalf board director chartered accountant nilesh parekh mannalal b agrawal partner chairman purushottam b agrawal yogesh agrawal arvind agrawal vice chairman managing director chief financial officer madhusudan b agrawal rajesh agrawal gaurang shah mumbai 3rd may 2017 vice chairman joint managing director company secretary 174 cin l24230mh1979plc022059 redg office ajanta house charkop kandivali west mumbai 400 067 tel 022 66061000 fax 022 66061200 website wwwajantapharmacom email investorgrievanceajantapharmacom notice notice hereby given thirtyeighth annual general office conclusion annual general meeting till meeting member ajanta pharma limited held conclusion 43rd annual general meeting subject wednesday 5th day july 2017 1100 aspee ratification appointment shareholder every auditorium laxminarayan mandir complex marve road next annual general meeting held annual general nutan school malad west mumbai 400064 transact meeting remuneration mutually agreed following business board director m bsr co llp ordinary business resolved board director company secretary hereby authorized 1 receive consider adopt settle question difficulty doubt may arise audited standalone financial statement giving effect resolution act company financial year ended 31st march deed thing may necessary expedient 2017 together report board desirable purpose giving effect resolution director auditor thereon special business b audited consolidated financial statement company financial year ended 31st march 2017 6 consider thought fit pas without together report auditor modification following resolution ordinary resolution 2 confirm interim dividend paid equity share year ended 31st march 2017 final resolved pursuant section 148 company act 2013 company audit auditor appoint director place mr madhusudan b 3 rule 2014 remuneration 350 lac plus service tax agrawal din 00073872 retires rotation reimbursement actual travel outofpocket eligible offer reappointment expense fixed board m sevekari khare associate cost accountant audit cost record 4 appoint director place mr rajesh agrawal maintained company financial year ending din 00302467 retires rotation 31st march 2018 hereby ratified eligible offer reappointment 5 consider thought fit pas without order board director modification following resolution ordinary resolution gaurang shah resolved pursuant provision section 139 3rd may 2017 avp legal 142 applicable provision company company secretary act 2013 company audit auditor rule registered office 2014 m bsr co llp chartered accountant firm ajanta house charkop registration 101248ww100022 hereby kandivali west appointed statutory auditor company hold mumbai 400 067 175 note 8 term section 124 company act 2013 explanatory statement pursuant section 102 1 dividend remaining unpaid period seven company act 2013 set detail relating year due date payment required special business meeting annexed hereto transferred investor education protection fund accordingly unpaid dividend lying dividend 2 member entitled attend vote account year 20092010 transferred meeting entitled appoint proxy investor education protection fund appropriate attend vote instead time current financial year member proxy need member company encashed dividend warrant requested write person cannot act proxy member exceeding registrar share transfer agent shareholder 50 fifty holding aggregate ten visit company website wwwajantapharmacom percent total share capital company check detail unclaimed dividend investor section 3 proxy form sent herewith proxy form order effective must duly completed signed deposited shareholder seeking information regard 9 registered office company less 48 hour annual report requested write company commencement meeting proxy submitted early date information kept ready behalf company society etc must supported appropriate resolutionauthority applicable support green initiative government 10 electronic copy annual report year ended 4 corporate member intending send authorised 31st march 2017 notice 38th agm representative attend meeting requested sent member whose mail id available send company certified copy board companydepository participant communication resolution authorising representative attend purpose unless member requested physical vote behalf meeting copy member registered email address physical copy annual report 5 pursuant regulation 36 listing regulation 2017 notice sent permitted secretarial standard general meeting issued mode please note annual report notice institute company secretary india detail 38th agm also posted website www director seeking reappointment annual general ajantapharmacom download copy annual meeting agm form part notice report shall provided shareholder agm required register member transfer book 6 respect equity share remain closed 11 voting electronic mean wednesday 28th june 2017 wednesday 5th july 2017 compliance provision section 108 day inclusive purpose agm company act 2013 rule 20 company management administration rule 2014 7 order prevent fraudulent encashment dividend amended company management warrant company encourages remittance administration amendment rule 2015 dividend ecsneft dividend future would regulation 44 sebi listing obligation remitted ecsneft shareholder disclosure requirement regulation 2015 registered mandate company company pleased provide member facility bank particular registered respective depository exercise right vote resolution account respect share held demat mode proposed considered 38th agm shareholder therefore requested update electronic mean business may bank account detail transacted evoting service facility casting vote member using electronic respect share held demat mode informing voting system place venue change depository participant agm remote evoting provided national member security depository limited nsdl ii respect share held physical mode furnish ii remote evoting period commences sunday mandate company company rt 2nd july 2017 900 end tuesday 4th agent link intime india private limited bank account july 2017 500 pm period member detail dividend shall remitted company holding share either physical ecsneftnecs form dematerialized form cutoff date 176 wednesday 28th june 2017 may cast vote xii institutional shareholder ie remote evoting remote evoting module shall individual huf nri etc required disabled nsdl voting thereafter vote send scanned copy pdfjpg format resolution cast member member relevant board resolution shall allowed change subsequently authority letter etc together attested specimen signature duly authorized iii instruction evoting signatoryies authorized case member receives email nsdl vote scrutinizer email member whose email id registered scrutinizerajantapharmacom companydepository participantss copy marked evotingnsdlcoin open email open pdf file viz apl b case member receives physical copy remote evotingpdf client id notice agm member whose email id folio password said pdf file registered companydepository contains user id passwordpin participantss requesting physical copy remote evoting please note password initial password initial password provided attendance slip agm note shareholder already registered even e voting event number nsdl evoting receive user id ___________ pdf file aplremote evotingpdf passwordpin _________ ii launch internet browser typing following ii please follow step sr ii sr url httpswwwevotingnsdlcom xii cast vote iii click shareholder login iv case query may refer frequently asked question faq shareholder remote iv put user id password click login evoting user manual shareholder available downloads section wwwevotingnsdlcom call v password change menu appears change toll free 1800222990 passwordpin new password choice minimum 8 digit v already registered nsdl remote evoting character combination thereof note use existing user id passwordpin new password strongly recommended casting vote share password person take utmost care keep note shareholder forgot user detail password confidential password use forgot user detailspassword physical user reset password option available vi home page evoting open click wwwevotingnsdlcom evoting active voting cycle case shareholder holding share demat select electronic voting event number vii mode user id combination dp id client id even ajanta pharma limited case shareholder holding share physical viii ready evoting cast mode userid combination even vote page open folio ix cast vote selecting appropriate vi also update mobile number email id option click submit also user profile detail folio may used confirm prompted sending future communication upon confirmation message vote x vii voting right member shall proportion cast successfully displayed share paid equity share capital company cutoff date wednesday voted resolution xi 28th june 2017 person whose name recorded allowed modify vote register member register 177 beneficial owner maintained depository chairman person authorized cutoff date shall entitled avail writing shall countersign facility remote evoting well voting declare result voting forthwith agm person ceased member company cutoff date result declared alongwith report xii entitled remote evoting voting meeting scrutinizer shall placed website person becomes member company company wwwajantapharmacom dispatch notice holding share website nsdl immediately declaration cutoff date may obtain login id password result chairman person authorized sending request evotingnsdlcoin writing result shall also immediately company however already registered forwarded bse limited nse mumbai nsdl evoting use existing user id passwordpin casting vote pursuant section 72 act member holding 12 share physical form advised file nomination viii member may participate agm even prescribed form sh13 company share exercising right vote remote evoting transfer agent respect share held electronic shall allowed vote agm demat form member may please contact respective depository participant ix mr alwyn dsouza practicing company secretary mumbai membership 5559 certificate 13 register director key managerial personnel practice 5137 appointed shareholding maintained section 170 scrutinizer providing facility member act register contract arrangement company scrutinize voting remote director interested section 189 evoting process fair transparent manner act available inspection agm x chairman shall agm end discussion 14 route map showing direction reach venue resolution voting held allow 38th agm given end notice per voting assistance scrutinizer use requirement secretarial standards2 general ballot paper member present meeting agm cast vote availing remote evoting facility order board director xi scrutinizer shall conclusion voting general meeting first count vote cast gaurang shah meeting thereafter unblock vote cast avp legal remote evoting presence least 3rd may 2017 company secretary two witness employment company shall make later three day regd office conclusion agm consolidated scrutinizer ajanta house charkop report total vote cast favour kandivali west mumbai 400067 178 explanatory statement respect special business accompanying notice pursuant section 1021 company act 2013 item 6 board recommends resolution item 6 accompanying notice approval member pursuance section 148 company act 2013 company rule 14 company audit auditor rule 2014 board shall appoint cost accountant practice none director andor key managerial personnel auditing cost record company appointment shall company relative concerned interested recommendation audit committee financial otherwise resolution set item 6 shall also recommend remuneration cost auditor remuneration recommended audit committee shall order board director considered approved board director ratified shareholder gaurang shah recommendation audit committee board avp legal meeting held 3rd may 2017 considered approved 3rd may 2017 company secretary appointment m sevekari khare associate cost accountant cost audit cost record maintained regd office company remuneration 350 lac plus service tax ajanta house charkop applicable reimbursement actual travel kandivali west mumbai 400067 pocket expense year ending 31st march 2018 subject ratification member route map venue agm address aspee auditorium laxminarayan mandir complex marve road next nutan school malad west mumbai maharashtra 400064 map legend aspee auditorium malad station new link road way highway way distance malad station 12 km mith chowky 13 km pushpa park 19 km scan code map 179 detail director seeking appointmentreappointment thirtyeighth agm pursuant regulation 36 listing regulation clause 125 secretarial standard general meeting name director mr madhusudan b agrawal mr rajesh agrawal date birth 29031955 31031976 din 00073872 00302467 date appointment 31121979 30042013 expertise specific functional rich experience 4 decade strong business acumen proven record area excellent relationship management skill coupled accomplishment building growing extensive contact industry regulatory business every segment market business circle sustained improved ranking upto date knowledge latest happening effective leadership motivation skill indian pharma industry well global setting higher goal standard driving trend team achieve exceptional ability identifying business strongly pursues adhering instilling opportunity form gap patient company value workforce need availability getting developed promoting good governance culture across r getting timely regulatory organisation approval strategically launching product ahead competition core contributes innovative idea risk mitigation competence putting effective process excellent rapport industry leader control mechanism qualification ieducational bsc mba iiexperience year 40 20 share held company nil 12849999 relationship director brother mr purushottam b agrawal mr brother mr yogesh agrawal son key managerial personnel mannalal b agrawal uncle mr yogesh mr mannalal b agrawal agrawal mr rajesh agrawal board meeting attended five five fy 201617 directorship company 1 inspira project limited 1 ajanta pharma philippine inc 2 inspira infra aurangabad limited 2 gab investment private limited 3 louroux bio energy limited 4 ajanta pharma usa inc membership committee ajanta pharma limited ajanta pharma limited member c chairman executive committee executive committee b stakeholder relationship committee louroux bio energy limited executive committee bnomination remuneration committee inspira infra aurangabad limited executive committee c term condition wholetime director liable retire rotation wholetime director liable retire appointment rotation 180 disclaimer annual report disclosed forward looking information enable investor comprehend prospect take investment decision report statement written oral periodically make contain forward looking statement set anticipated result based management plan assumption tried wherever possible identify statement using word anticipate estimate expects project intends plan belief word similar substance connection discussion future performance cannot guarantee forward looking statement realised although believe prudent assumption achievement result subject risk uncertainty even inaccurate assumption known unknown risk uncertainty materialise underlying assumption prove inaccurate actual result could vary materially anticipated estimated projected reader keep mind undertake obligation publicly update forward looking statement whether result new information future event otherwise cin l24230mh1979plc022059 redg office ajanta house charkop kandivli west mumbai 400 067 tel 022 6606 1000 fax 022 6606 1200 website wwwajantapharmacom email investorgrievanceajantapharmacom